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Cancer is a growing healthcare problem worldwide with significant public health and 
economic burden to both developed and developing countries. According to the 
World Health Organization, cancer is the second leading cause of death globally, with 
an estimated 20 million new cancer cases and 10 million cancer deaths in 2020. The 
International Agency for Cancer Research (IARC) estimates that globally one in five 
people will develop cancer in their lifetime. Low- and middle-income countries have 
been disproportionately affected by the rise of cancer incidence and account for 
approximately 70% of global cancer deaths. At the same time, substantial innovations 
in screening, diagnosis, and treatment of cancer have improved patient outcomes; 
global age-standardized cancer death rates showed a 17% decline from 1990 to 2016.
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Cancer care has evolved to become highly specialized and increasingly complex 
not only pertaining to care setup and delivery, but also diagnostics and therapeutics. 
In addition, the influx of novel therapies such as targeted therapy, biologics, cellular 
and gene therapies, the need for advanced support systems such as advanced pathol-
ogy, radiology, and radiation therapy, and the requirement for integrated multidisci-
plinary delivery of care had contributed to the progressive increase in the costs of 
cancer care both direct expenditures related to infrastructure and provision of care 
from a societal perspective, as well as indirect costs due to loss of productivity at an 
individual level. Presently, many hospitals and cancer centers may not have a well- 
established and integrated setup for comprehensive and cost-effective oncology care.
The objective of this book is to provide guidance to hospitals, institutions, and 
health authorities worldwide to develop a comprehensive cancer care plan; and to 
assist cancer centers with upgrading their existing infrastructure, practice standards, 
policies, and procedures in line with contemporary and highest international stan-
dards for cancer care delivery, in a sustainable and cost-effective manner.
Each chapter tackles an aspect felt by the editors to be critical in the design of 
such centers especially as these are developed in low- to middle-income countries. 
The contents of this book are applicable at a global level and do cover broad aspects 
related to the overall organizational structure of a comprehensive cancer center, 
including inpatient and outpatient services, pharmacy and laboratory requirements, 
radiation therapy, psychosocial support and palliative care, among others. The book 
also covers staff training, quality and data management, and overall administration 
including finance and strategic planning. One chapter is specifically dedicated to 
cancer management for a center with restricted resources.
Inequality and disparities in healthcare between higher and lower resource set-
tings is well known. The authors and the editors hope that this book will help bridge 
some of the inequalities and that a more comprehensive cancer center will lead to 
better outcomes for cancer patients. The information provided by the book shall serve 
as a backbone to assist centers obtain necessary resources to provide the best possible 
cancer care. We are pleased to be able to offer this book to the community and look 
forward to developing more best practices as we go forward in tackling these diseases.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter's Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
M. Aljurf et al.
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According to the World Health Organization (WHO), cancer is the second leading 
cause of death globally, accounting for approximately 9.6 million deaths [1]. The 
WHO recommends that each nation has a national cancer control program (NCCP) 
to reduce the incidence of cancer and deaths related to cancer, as well as to improve 
the quality of life of cancer patients [2]. Comprehensive cancer centers form the 
backbone of a NCCP and are charged with developing innovative approaches to 
cancer prevention, diagnosis, and treatment [3]. This is accomplished through basic 
and clinical research, the provision of patient care, the training of new clinicians and 
scientists, and community outreach and education. Most comprehensive cancer cen-
ters are affiliated with university medical centers, but their cancer care initiatives 
may involve partnering outside the institution with other comprehensive cancer cen-
ters, community leaders, or members of industry [3]. When affiliated with a univer-
sity medical center, cancer center executives must work in concert with their 
counterparts at the hospital, patient practice, medical school, and allied health sci-
ence leaders resulting in an overlapping, often complicated reporting structure. 
Comprehensive cancer centers and the departments in the center receive funding for 
their services from various sources, including national and local grants, institutional 
funds, private donations, and industry [4].
The structure of a comprehensive cancer center arises from the mission of the 
center and the framework required to support this mission. The overarching 
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mission of a comprehensive cancer center is to reduce the incidence of cancer and 
increase the quality of life and survival rates in patients with malignancies. There 
are three primary areas of cancer care: research, clinical care, and education that 
coalesce to meet this goal. Multiple interconnected departments are required to 
meet the objectives of the cancer center. Department heads include physicians, 
scientists, or administrators, depending on the focus of the department. The 
department leaders report to the comprehensive cancer center director, who is 
assisted by deputy directors and hospital advisory boards. The comprehensive 
cancer center director is typically an accomplished individual trained in a specific 
area of cancer research, but who has a vision for the broad research and clinical 
base required of the cancer center. The cancer center director has a multitude of 
responsibilities, including setting departmental goals, coordinating efforts 
between departments, hiring and retaining scientific staff, obtaining national, 
state, and philanthropic funding, creating new programs, and monitoring the busi-
ness aspects of the center.
 Structure of a Comprehensive Cancer Center Based 
on Mission
 Research
 Basic Laboratory Research
Basic laboratory research generates the knowledge that forms the basis for applied 
science. This type of research focuses on the mechanistic understanding of bio-
chemical, biologic, physiologic, and pharmacologic processes as they relate to 
cancer and cancer treatments [5]. Tools used in this type of research include labo-
ratory techniques such as flow cytometry analysis, bioimaging, spectroscopy, and 
gene sequencing. Laboratory experiments with human cell lines or animal models 
may also be utilized in this type of research. Basic laboratory research requires 
trained scientists, laboratory space and equipment, storage facilities for cell sam-
ples and cell lines, and areas for the humane care and housing of research animals. 
In most comprehensive cancer centers, a centralized source of core services and 
equipment exists, which is accessible to all scientists. Gene expression analysis 
and next- generation sequencing are examples of services provided by a compre-
hensive cancer center’s core laboratory facility. Training of future generations of 
scientists is also a key function of laboratory scientists. Students in MD/PhD pro-
grams, clinical fellows requiring research experience, and postdoctoral scientists 
are examples of the many individuals trained in basic science in comprehensive 
cancer centers. The basic science division is composed of subspecialty areas such 
as immunology, cancer biology, or microbiology. Directors of these areas report to 
a director of basic science who in turn reports to the comprehensive cancer center 
director or deputy director.
D. Grosso et al.
5
 Clinical Research in Human Subjects
Patients with cancer require multidisciplinary care to achieve optimal outcomes. 
Therefore, clinicians with expertise in medical, surgical, and radiation oncology 
participate in the direct care of patients with oncologic diagnoses and perform 
research in their specialty areas with the goal of improving cancer care. Examples 
of clinical research initiatives include those testing cancer prevention strategies [6], 
analyses of medication efficacy, trials comparing the benefits of various treatment 
modalities, and analyses of risk based on tumor genetic signature. Cancer research 
trials may be observational, analyzing cause and effect relationships, or interven-
tional with the goal of evaluating the impact of a specific treatment [7]. Investigators 
in comprehensive cancer centers may participate with other institutions in national 
or international networks to analyze the outcomes of large numbers of combined 
patients providing more power to detect meaningful trends. Clinical research 
involves human subjects and, therefore, this type of research approach requires sys-
tems to be in place within the comprehensive cancer center to protect the safety, 
welfare, and rights of human research subjects.
 Translational Research
Translational research is the integration of basic laboratory research with patient- 
and population-based research [8]. In this area, clinical research and basic research 
are complementary to each other with both areas contributing to a specific outcome. 
Ideally, translational research applies newly developed basic research understand-
ings and applies them to early phase clinical research. This is a multistep, bidirec-
tional process in which optimal treatments are refined over time by incremental 
discovery in both the clinical and laboratory settings. The ability to translate scien-
tific data generated by the cancer center into actionable improvement in cancer care 
is central to the mission of the comprehensive cancer center. Therefore, a specific 
department of translational research exists in most cancer centers. Initiatives that 
foster working relationships between bench scientists and clinicians, such as scien-
tific meetings, data sharing sessions, and availability of funding for multidisci-
plinary research, assist in the development of transitional research. Clinical trials, 
such as first-in-man or phase I studies, are developed by basic scientists and clini-
cians and are conducted within the comprehensive cancer center. The director of 
translational research reports directly to the comprehensive cancer center director or 
deputy director.
 Population Health Research
The goal of population health science is to optimize health outcomes in specific 
populations. This type of research assesses trends in cancer incidence, identifies 
disparities in health care and suggests corrective actions, and examines cancer 
2 Building a Comprehensive Cancer Center: Overall Structure
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prevention, incidence, and treatment based on gender, race, or ethnicity, geographic 
location, or income. In doing so, population health scientists study community char-
acteristics to inform the development of cancer care initiatives. In many comprehen-
sive cancer centers, community outreach via education programs and free health 
services are offered through the population health department. The Framingham 
study is an early, important example of population health science which linked ciga-
rette smoking, poor diet, and lack of exercise to the development of cardiovascular 
disease [9]. A more recent analysis of prostate cancer screening recommended dif-
ferent screening guidelines for African American versus Caucasian men, as African 
American men have a higher incidence and rate of death of prostate cancer than 
their Caucasian counterparts [10]. Population health scientists are in key positions 
to examine local health issues and can have direct, positive impacts on the health of 
their communities. The director of population health reports directly to the cancer 
center director or deputy director.
 Protection of Human Subjects
 Institutional Review Boards
The primary group responsible for the oversight of clinical research in human sub-
jects is the Institutional Review Board (IRB) that reviews, approves, and monitors 
the conduct of clinical trials. Physicians, nurses, pharmacists, administrators, and 
community members can all serve on an IRB. The IRB reviews informed consent 
documents, investigator brochures, and provides guidance to investigators. The IRB 
also serves a critical role in monitoring the compliance of researchers to the condi-
tions set forth in their clinical trials as well as adherence to IRB regulations for 
patient safety, sponsor-investigator relationships, reporting of adverse events, and 
adherence to national guidelines. IRBs follow guidelines set forth by national regu-
latory institutions. In the United States, IRBs follow good clinical practice and clini-
cal trial guidelines set forth by the Food and Drug Administration and assure that 
researchers are trained in the basic principles of human research [11]. Most IRBs 
are part of the academic medical center that is affiliated with the comprehensive 
cancer center, but commercial and free-standing IRBs exist as well.
 Clinical Research Organizations
Comprehensive cancer centers may utilize either in-house or contracted organiza-
tions to assist in the conduct of clinical trials. These clinical research organizations 
(CROs) assist the investigator in maintaining good clinical practices in the conduct 
of the clinical trial [12]. A CRO can provide a diverse array of services that include 
clinical and regulatory support of clinical trials. Examples of clinical services 
include procurement and shipping of clinical samples and supplies, development of 
D. Grosso et al.
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case report forms, data capture of trial outcomes, adverse event monitoring, record-
ing and reporting, trial pre-screening, and assistance with patient education and 
consent. Regulatory support includes developing standard operating procedures for 
compliance monitoring, audits to assess for compliance to trial procedures, and sup-
port for changing and updating clinical trial documents. Regulatory staff addition-
ally facilitate communication between the sponsors and investigators of clinical 
trials and assist with the registration of clinical trials and clinical trial results to 
public and national databases. The department head managing an in-house CRO or 
who contracts with hired CROs reports to the comprehensive cancer center director 
or deputy director.
 Other Key Programs Supporting Cancer Research
The goal of comprehensive cancer centers is to apply resources to projects that are 
scientifically rigorous, are likely to advance cancer prevention, care, and quality of 
life, and have the potential for benefitting the largest amount of people. Towards that 
end, committees that evaluate the scientific merit, the financial feasibility, and the 
appropriateness of proposed research projects to the identified research needs of the 
population are required. Other supportive programs include an Office of Biostatistics 
to assist in formulating research plans as well as analyzing trial outcomes. An office 
of technology transfer is important in the identification of novel ideas, assistance 
with the development and application of these ideas, as well as protection of intel-
lectual rights.
 Clinical Care of Patients with Cancer
The complexity of cancer diagnostics, treatment, and follow-up requires care across 
multiple disciplines [13]. Surgeons, interventional radiologists, and clinical practi-
tioners are utilized to obtain tissue for pathological analysis. Accurate cancer diag-
nosis and prognostication depends upon the availability of pathologists trained in 
the analysis of cancer cells and accompanying genetic and molecular profiling. 
Radiology services are required for cancer staging and surveillance. Clinicians 
experienced in the treatment and administration of chemotherapy, oncology-based 
pharmacists, radiation oncologists, and surgeons specializing in oncology are 
required for the administration of treatment and the monitoring of response. The 
framework for this treatment includes inpatient and outpatient treatment areas, sup-
port staff, insurance, budgetary and billing staff, housekeeping, supply chain man-
agement resources, and equipment. In free-standing comprehensive cancer centers, 
directors of these areas report to the cancer center director. However, in comprehen-
sive cancer centers affiliated with university medical centers, services are shared 
across all disciplines, although oncology-dedicated subdivisions within these 
2 Building a Comprehensive Cancer Center: Overall Structure
8
departments exist. Cancer-specific specialty services within various specialties, 
such as cardiology, renal, and pulmonary, have been developed for more optimal 
management of organ-specific toxicities related to cancer treatment. Clinicians pro-
viding cancer care in university medical center settings may have dual reporting 
relationships to both the comprehensive cancer center director and to hospital or 
university-based leadership.
 Quality Monitoring in Cancer Care
Cancer care is a highly complex, high-risk, discipline characterized by rapid devel-
opment of new therapies. To provide the safest and most effective care, comprehen-
sive cancer centers must establish systems to assess and monitor the quality and 
safety of care. There are multiple components of a quality program, including the 
development of standardized processes to deliver care, monitoring adherence to 
established guidelines for care, assessment of compliance with established guide-
lines, and the development of procedures to improve care. Examples include the use 
of evidence-based clinical pathways when ordering chemotherapy [14], monitoring 
adherence to quality indicators, such as those developed by the Agency for 
Healthcare Research and Quality (AHRQ), and medical record auditing to monitor 
compliance to national best practice standards, such as those set forth by the 
Foundation for the Accreditation of Cellular Therapy (FACT) [15], in stem cell 
transplant programs. Because quality initiatives are integrated into every depart-
ment in the cancer center, there is typically an executive level position in the cancer 
center overseeing all aspects of the quality program. This executive reports directly 
to the cancer center director or deputy director.
 Improving the Quality of Life of Cancer Patients: 
Support Services
 Social Work
Social work is a mandatory discipline in every comprehensive cancer center sup-
porting every aspect of a patient’s cancer care experience. Social workers provide a 
wide array of patient services, including patient and family counseling and recogni-
tion of distress [16], assistance in finding financial reimbursement for medications 
and housing, end-of-life counseling and assistance with end-of-life issues [17]. 
Social workers have a broad array of responsibilities that may range from assistance 
in obtaining wigs, development of education programs for patients and families, or 
even coordinating fundraising services for patients and their families in the com-
munity. From the standpoint of continuity of care, social workers provide key infor-
mation regarding the ability to obtain medications and information regarding health 
D. Grosso et al.
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insurance issues as the patients move from inpatient to outpatient settings. Social 
workers increase the quality of cancer care by serving as a nonclinical sup-
port system.
 Palliative Care
Palliative care is another aspect of cancer care that has the goal of increasing the 
patient’s quality of life. Palliative care specialists are physicians or advanced prac-
tice providers who address the needs of patients with life-threatening illnesses. The 
aim of palliative care providers is to manage symptoms and side effects of cancer 
care [18]. This may encompass direct interventions to treat pain, anxiety, or neu-
ropathy related to cancer treatments. Palliative care specialists also address spiri-
tual, social, and psychological issues with patients. In some cancer centers, 
oncology-specific psychiatrists are part of the palliative care team. The palliative 
care team, in conjunction with clinicians and social workers, also may serve as end- 
of- life counselors. Palliative care specialists work in a variety of settings and are 
often available for acute issues in the inpatient and outpatient settings.
 Navigation
Patients undergoing cancer care attempt to negotiate the complex health care system 
at a time of physical and psychological stress. Many cancer centers employ naviga-
tors to guide patients through the healthcare continuum. Navigators provide direct 
assistance to patients in making appointments, transferring records between offices, 
distributing directions to testing sites, coordinating family meetings, and providing 
a consistent contact for patients throughout cancer treatment. Navigators are also 
useful in providing consumer feedback to the cancer center to help improve ser-
vices. Navigators have been shown to increase satisfaction and survival [19]. Most 
comprehensive cancer centers have some type of navigator services to support con-
sistency and quality of care of patients with cancer. Registered nurses or specially 
trained lay people may serve as navigators in the comprehensive cancer center.
 Survivorship
Survivorship refers to the physical, psychological, psychosocial, economic, and 
spiritual well-being of patients who have survived a cancer diagnosis [20]. 
Posttreatment survivorship goals include the transition back to a primary care pro-
vider for the majority of medical care, reintegration into the workforce, and return 
to family and social functions. This period of time in patient recovery may be 
marked by considerable anxiety related to both internal and external forces. 
Individuals recovered from cancer therapy have physical and mental challenges 
such as limited activity due to neuropathy, deconditioning, or osteoporosis, 
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decreased self-confidence, or even fear of infection or relapse. Work supervisors 
may have concerns regarding the ability of returning employees to be fully produc-
tive. Family members, friends, and coworkers may have altered perceptions of can-
cer survivors resulting in relationship strain. Time missed from school or 
employment delays scholastic or career progression adding to frustration, stress, 
and anxiety. Comprehensive cancer centers support lifestyle reintegration through 
direct counseling and education from the clinical team, educational classes in the 
community sponsored by social workers, and the sponsorship of initiatives such as 
the buddy program, cancer survivor scholarships, beauty and support days, and job 
counselling.
 Education
Comprehensive cancer centers are not only central to the education of future scien-
tists and health care providers, but also take part in the development and continuing 
education of employees, patients, and the public via community outreach programs. 
When affiliated with a university medical center, cancer centers participate in the 
education of medical students, house staff, laboratory-based future scientists, and 
students from across all health science disciplines. Care of patients with cancer and 
cancer research is intertwined with academic faculty support and career progression 
resulting in ongoing research in cancer specialty areas. Grand rounds programs with 
internal or external speakers educate staff and students to new scientific discovery. 
Cancer centers also form partnerships with community leaders, government agen-
cies, and industry to develop community outreach programs to improve health lit-
eracy, develop early detection programs, and raise money for cancer research.
Comprehensive cancer centers are highly complex institutions responsible for 
the advancement of cancer research, clinical care, and education. A multitude of 
personnel with varying areas of expertise are responsible for the integration of all 
the critical cancer center activities described in this chapter. Therefore, a highly 
organized and functional framework is necessary to avoid overlap and address all 
aspects of the cancer center’s mission. Figure 2.1 displays the basic organization 
chart of a university-affiliated comprehensive cancer center.
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Chapter 3
The Inpatient Unit in a Cancer Center
Mohamed A. Kharfan-Dabaja
 Introduction
Treatment of cancer has evolved significantly over the past four decades, moving 
away from traditional chemotherapies, with or without radiation therapy, to smarter 
targeted therapies [1–3]. As many of these novel treatments became available in oral 
formulations, or as short intravenous infusions or through the subcutaneous route, 
this has allowed moving several regimens to be administered in the outpatient set-
ting. This is the case for a significant number of cancer treatment regimens for dis-
eases, such as chronic lymphocytic (CLL) and chronic myelogenous (CML) 
leukemias, for which the current standard therapies are administered orally [4, 5]; 
and for various solid neoplasms, namely, lung, breast, colon, and prostate cancer, 
among others, for which contemporary regimens lend themselves for administration 
in outpatient infusion centers. The increase in health care cost has also played an 
important role on supporting shifting cancer care to the outpatient setting [6].
Yet, a significant number of patients still require treatment in the inpatient set-
ting, owing to the nature of the treatment, duration, and frequency, or to the level of 
supportive care required to administer such treatments, among others. Presently, the 
majority of cases treated in the inpatient setting include induction and consolidation 
therapies for acute leukemias, myeloid (AML) or lymphoid (ALL), and certain bio-
therapies [7, 8]. This also applies to more complex procedures like hematopoietic 
cell transplantation (HCT), particularly allogeneic HCT (allo-HCT), and chimeric 
antigen receptor T-cell therapy (CAR T) [9–13]. In the case of autologous HCT 
(auto-HCT), some regimens used for lymphomas are preferentially prescribed for 
administration in the inpatient setting, while using high-dose melphalan for 
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multiple myeloma is commonly offered in the outpatient setting. Furthermore, some 
cancer patients may need to be hospitalized for management of their symptoms, 
such as intractable pain or treatment of infection(s) requiring frequent antimicrobial 
dosing, or for nutritional support; and/or many other complications that might have 
resulted from cancer treatment. In many inpatient units at cancer centers, private 
rooms are also available for patients who need palliative or hospice care.
Apart from specialized trained physicians and nurses, the number of inpatient 
team services has expanded significantly to meet the complex needs of patients and 
their families. Pharmacists are resourceful to help understand, guide, and manage 
the potential side effects of new therapies and to educate patients to better under-
stand cancer treatment and potential benefits and complications. The pharmacy 
team, in coordination with physicians, nurses, and clinical research coordinators, 
also plays a crucial role in safeguarding the well-being of patients who are partici-
pating in clinical trials evaluating safety and efficacy of new drugs. Oncology social 
workers and case managers have also become an integral part of inpatient teams 
helping provide psychosocial support, and assist with short- or long- term place-
ment, whenever warranted, and to coordinate discharge needs by planning and iden-
tifying needed resources for a smooth transition to the outpatient setting. Certified 
nutritionists, dieticians, and physical and occupational therapists are also available 
to assist with clinical interventions. During cancer treatment, it is also important to 
recognize the importance of addressing the patients’ spiritual needs.
There is not a universal model for how an inpatient unit should be built and 
developed. This would certainly depend on several aspects including financial 
resources, population density, and societal factors, among others. Below, we attempt 
to describe the main components of an inpatient cancer treatment unit. We divide 
them into the human factor and other factors.
 The Human Factor
Successful operation of an inpatient unit is certainly dependent on a complex and 
well-orchestrated multidisciplinary approach to cancer care. The inpatient unit also 
provides an opportunity to educate future generation of physicians, advanced practice 
providers, and nurses in various specialties and subspecialties, particularly hematol-
ogy, medical and surgical oncology, infectious diseases, and psychiatry, among others.
The model most commonly applied in teaching hospitals comprises an inpatient 
attending physician that is responsible for leading and coordinating the care of 
patients. The team also includes trainees, generally hematology and/or medical 
oncology fellows and internal medicine residents, medical students, advanced prac-
tice providers, namely, physician assistants and advanced registered nurse practitio-
ners, nurses, a pharmacist, a social worker, and a case manager. Nutritionists and 
physical and occupational therapists are also called upon to participate in patient 
care based on indicated needs. In more complex procedures like hematopoietic cell 
transplantation, there is ample participation of subspecialties such as infectious 
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diseases owing to the increased risks of opportunistic infections in the setting of 
profound immune suppression. For patients receiving CAR T-cell therapy, there is 
active participation from specialties such as neuro-oncology owing to potential- 
associated neurotoxicity and intensive care unit specialists. Other specialties may 
also end up participating in the care of CAR T-cell recipients if they develop organ 
failure; for example, nephrologists in the case of renal failure and cardiology in the 
case of cardiac dysfunction, among others. In the nonacademic community setting, 
similar multidisciplinary services are also available; and some community-based 
cancer centers also provide educational and training opportunities.
Nurses play an important role in the inpatient oncology setting as they are directly 
involved in the care of patients and generally the first to become aware of any change 
in a patient’s clinical condition [14]. Patients’ perceptions of excellence in health-
care are strongly associated with nursing care [15]. There is not an established stan-
dard pertaining to a nurse-to-patient ratio in an oncology inpatient unit; and staffing 
needs depends on various factors including, but not limited to, level of acuity, vol-
ume of patients in the unit, and nursing skills in the case of complex procedures such 
as allo-HCT or CAR T-cell therapy. Thorough assessment of these patients is crucial 
to ensure optimal care and timely intervention whenever needed. For instance, oral 
mucositis and gastrointestinal toxicities are commonly seen when patients are pre-
scribed high doses of chemotherapy as it could be the case of certain induction regi-
mens for AML or ALL; or conditioning regimens for autologous HCT (auto-HCT) 
or allo-HCT which may also involve radiotherapy, resulting in serious malnutrition. 
Nurses would generally be the first to become aware of such findings and alert the 
rest of the team to consult nutritionists to help incorporate enteral or parenteral strat-
egies to optimize patient’s nutritional status. Several studies have reported adverse 
outcomes and nurse burnout with higher patients-to-nurse ratios [16, 17]. A recently 
published meta-analytical study showed considerable risk of burnout, emotional 
exhaustion, and depersonalization in nursing professionals in oncology services [18].
 Other Factors
 Floor Design
Inpatient cancer units are designed to provide the safest and most efficient care for 
patients. Generally, the floor layout is designed to position nurses in close proximity 
to the patients’ beds to be able to respond more promptly to patient’s needs. A work 
station is located right outside the door or inside the room (Fig. 3.1). This design is 
meant to improve efficiency and reduce the time spent away from patient care. In 
some facilities, central monitors are available to display important vital signs, such 
as monitoring of heart rate and blood pressure in patients who may be receiving 
certain types of chemotherapies, biological or experimental therapies. Yet, applica-
bility of this design in underdeveloped countries may be challenging due to finan-
cial limitations or due to lack of technology.
3 The Inpatient Unit in a Cancer Center
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 Environmental
The complex inpatient cancer center environment demands special consideration to 
ensure a healthy indoor air quality to protect patients against hospital-acquired 
infections [19, 20]. Sources of air pollution within the hospital include chemicals 
and microbial air pollutants from various sources [21]. Properly designed systems 
and optimal operations are essential to control and mitigate potential sources of pol-
lutants such as air filtration, differential pressure control, directional airflow control, 
and ultraviolet germicidal irradiation disinfection, among others [22].
 Rooms
The majority of cancer centers in the United States would provide a private room to 
a cancer patient in need of inpatient care. Naturally, a private room would offer a 
more restful and healing environment. Nevertheless, a private room is a necessity 
for those patients who require contact or respiratory isolation. In the case of patients 
undergoing a HCT or CAR-T therapy, these procedures are better administered in 
the setting of a private hospital room owing to the high risk of serious infections in 
the setting of profound cytopenias and immune suppression. With the advent of 
electronic health records, nowadays rooms are equipped with a work station inside 
the room (Fig. 3.1) for both convenience and efficacy.
 Positive Pressure Rooms
Positively pressurized rooms are generally considered the cleanest environments in 
a hospital. A room is pressurized so that it is positive with respect to adjacent areas. 
It is designed in such a way to protect severely immunocompromised patients from 
Fig. 3.1 Inpatient hospital room in a cancer floor, Mayo Clinic, Jacksonville, FL, USA. (Used 
with permission of Mayo Foundation for Medical Education and Research, all rights reserved)
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possible airborne pathogens present in adjacent areas. Positively pressurized rooms 
also commonly use high-efficiency particulate air (HEPA) filters at the supply ter-
minals to guarantee the highest air quality to the patient. These types of rooms are 
generally found in Blood and Marrow Transplant units.
 Negative Pressure Rooms
Conversely, negatively pressurized rooms used for airborne infection isolation are 
engineered to prevent airborne microbial contaminants from flowing to other areas. 
These rooms are generally reserved for patients who develop infections like tuber-
culosis because the organism can spread in the air from the patient to members of 
the healthcare team. The room typically is served by a dedicated exhaust fan, and 
some facilities also use UV radiation for disinfecting purposes.
 Discussion
We described the main components of an inpatient unit in a cancer center. The ulti-
mate goal must be to provide a safe environment for cancer patients and to facilitate 
delivery of care in an efficient manner. As healthcare expenditure continues to rise, 
it is important to ensure long-term sustainability by minimizing as much as possible 
operating costs.
Despite all advances, there are continuous challenges pertaining to further 
improving safety in the inpatient cancer setting. These include, but are not limited 
to, prevention of falls, nosocomial infections, and medication errors. Establishing 
interdisciplinary working groups which involve all healthcare participants and 
incorporate new technologies would certainly prove essential to further improve the 
safety and quality of care for patients with cancer.
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Haematology and oncology departments have historically required inpatient ward 
beds for a large number of their treatments. There are many reasons for this, includ-
ing the administration of complex and lengthy intravenous regimens and significant 
treatment-related toxicities such as emetogenicity, mucositis and infections. Over 
the last 20 years, however, there has been a move for selected patients to be man-
aged in the outpatient setting, for both chemotherapy regimens and hematopoietic 
stem cell transplants (HSCTs). This has been done both during treatment and in the 
monitoring period following immediately afterwards. The outpatient environment 
ranges from the oncology office, outpatient hospital department, accommodation- 
based treatment facilities including hotels, to even the patients’ own homes.
This change has mostly been driven by several factors:
 1. Increasing pressure on the capacity of inpatient facilities and rationalization of 
inpatient beds
 2. Avoidance of unnecessary hospitalization
 3. Improvement in cost-efficiency
 4. Improvement of patient experience [1]
Several other additional factors have aided in the transition of cancer care to the 
outpatient setting. The availability of mobile infusion devices for chemotherapy, 
good supportive care and medications, as well as the development of targeted cancer 
therapies are just a few. In the United States, the push towards outpatient care was 
also aided by non-medical factors such as regulatory and economic ones  – the 
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Medicare Prescription Drug Improvement and Modernization Act of 2003 changing 
the calculus of infusion therapy reimbursements.
Outpatient care in haematology-oncology centres provide many benefits, 
including:
 1. Reducing the inpatient clinical load and alleviating pressure on constrained 
healthcare resources in order to optimize care delivery to high-acuity patients.
 2. Giving patients freedom from the hospital environment, providing families time 
together and allowing a degree of normality to remain. The ability to stay out of 
a hospital setting in a smaller, more comforting and familiar environment is 
often linked with higher patient satisfaction [2]. In addition, it also allows 
patients and caregivers to take back some control and become active members of 
the treatment team.
 3. Survivorship programs – transitioning to primary care providers so oncologists 
can spend more time with newly diagnosed patients
 4. Cost-effectiveness: Ambulatory care is recognized as a cost-saving initiative. 
Savings can be found in bed days [3] and staffing expenditure. A study at 
University College London Hospital [1] estimated that nurse staffing for their 
ambulatory care service cost approximately a third of that of the inpatient equiv-
alent. It is important to emphasize that the amount of cost efficacy is heavily 
dependent on local regulations and reimbursement policies.
A multidisciplinary approach is crucial to the successful delivery of outpatient 
haematology and oncology care. A team of clinicians, pharmacists and nurses are 
just a few of many different disciplines crucial to the smooth running of an outpa-
tient service. Ancillary services can also be offered in an outpatient setting, includ-
ing nutrition and dietetics, physical therapy, psychological care as well as transitory 
services. Efforts should be made at planning level to coordinate seamless care in the 
ambulatory setting, focusing on synergy, access, synchronization and patient 
satisfaction.
 Clinicians
Clinicians are crucial in identifying patients that may be appropriate for outpatient 
cancer care, as well as leveraging on their therapeutic relationship with the patient 
to encourage and educate them [4]. The primary oncologist plays a key role in coor-
dinating and utilizing the various services that are available at each unique center.
Cancer is a complex condition that requires close cooperation with not just the 
primary oncologist, but several other disciplines as well. These typically include 
surgical specialties, radiation oncologists, infectious disease physicians and cardi-
ologists. It is increasingly recognized that cancer patients have unique needs and 
disease profiles. With patients surviving longer and receiving increased numbers of 
lines of treatment, the types of complications experienced are also increasing. The 
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role of multi-specialty clinics involving clinicians from various specialties is gain-
ing in popularity as it can reduce the number of clinic visits a patient requires and 
also harmonizes care between the various disciplines.
 Nursing and the Role of Advanced Practice Providers 
and Nurse Coordinators
It is impossible to overstate the role of nursing in an ambulatory cancer center. 
Oncology nurses are key to successful oncology care as they spend the most time 
with patients, playing the role of caregiver, educator, advocate and care coordinator. 
With the projected increase in oncology patient encounters expected to outpace that 
of anticipated resources, the ASCO Workforce Advisory Group has recommended 
improved integration of advanced practice providers (APPs) into the oncology 
workforce [5].
APPs can make significant contributions throughout a patient’s journey with can-
cer – from detection and diagnosis, through treatment, survivorship, surveillance 
and even end-of-life care [6]. Training to become a Nurse Practitioner (NP) helps 
develop the individual’s scientific foundation, leadership, quality improvement 
competencies, practice inquiry skills, technology and information literacy, policy 
competencies, health delivery system competencies, ethics competencies and inde-
pendent practice competencies [7].
Besides the role of APPs, nurses also play an important role in their function as 
oncology nurse coordinators. As mentioned previously, cancer care is often com-
plex and involves several moving parts that are centred around the patient. Key ele-
ments of a nurse coordinator’s role involve emotional support, guidance to patients, 
and coordination of the multifaceted aspects of the patient’s care [8].
 Pharmacists, Drug Administration and Preparation
Pharmacists are essential to the running of any cancer center. Their role encom-
passes checking of prescriptions, drug preparation, and patient education. They play 
a major role in ensuring safe, effective and cost-effective drug therapy [9].
The availability of ambulatory delivery devices and hydration pumps is one of 
the key factors facilitating the move of so much inpatient clinical care to the ambu-
latory setting. These have enabled the ambulatory delivery of drugs such as ifos-
famide and post-hydration for methotrexate regimens that were previously only 
administered on inpatient wards. The use of infusion pumps has enabled the ambu-
latory administration of regimens containing chemotherapy drugs typically given 
by continuous infusion (e.g. cisplatin in ESHAP) on an intermittent schedule (e.g. 
twice daily dosing), or those requiring continuous hydration fluid (e.g. ifosfamide or 
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high-dose methotrexate-containing regimens). Several drugs previously adminis-
tered intravenously were converted to oral administration to further facilitate outpa-
tient administration. Specific examples include oral folinic acid and sodium 
bicarbonate for high-dose methotrexate regimens and oral mesna for 
oxazophosphorine- containing regimens, as well as antiemetics.
Optimal routes of outpatient drug administration need to be constantly evaluated 
to reduce chair times and ease of administration. Increasingly, several therapies are 
released in oral formulations, or may be able to be administered subcutaneously 
(e.g. CD20 monoclonal antibodies Rituximab for treatment of B cell lymphoma) 
rather than through prolonged intravenous infusions. This helps in optimizing chair 
usage and time spent for the patient.
Strategies that have been utilized to minimize wastage of chemotherapy 
drugs include
 1. Prepacked medications
 2. Dose banding
 3. Same day chemotherapy
Many drugs either use a flat dose or have traditionally been based on calculations 
of the patient’s body surface area (BSA). The use of BSA or other weight-based 
calculations for dosing of chemotherapy drugs have been controversial and may not 
be correlated with efficacy or toxicity. The advantages of dose banding and pre- 
packaging for more commonly used chemotherapy medications with longer drug 
stability can greatly reduce the time and manpower needed in the cancer center 
pharmacy to prepare them. A list of chemotherapy drugs that can be pre-packaged 
should be available in each outpatient pharmacy and referenced in the planning and 
organization of the centre’s processes [10].
 Supportive Care for Chemotherapy or 
HSCT-Related Complications
Delivery of good supportive care for haematology-oncology patients and stem cell 
transplant recipients is vital in ambulatory care. Nursing and medical staff running 
ambulatory care centres must be equipped with the knowledge and experience in the 
management of chemotherapy complication. Improved antiemetic regimens now 
allow patients to avoid nausea and vomiting that require admission for intravenous 
hydration and antiemetics. Outpatient monitoring following chemotherapy during 
the neutropenic phase has been shown to be safe for many regimens, including for 
highly intensive protocols such as consolidation chemotherapy for acute leukae-
mias. HSCTs have also been given in either a mixed inpatient–outpatient setting, or 
entirely outpatient. The largest series of autografts reported have been Melphalan 
autografts for myeloma [11] and BEAM (Carmustine, Etoposide, Cytarabine and 
Melphalan) autografts for lymphoma [12], although many others have performed 
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HSCT with reduced intensity conditioning or non-myeloablative regimens in outpa-
tient settings as well [13].
Transfusion of blood products is also a common therapy that is administered in 
outpatient centres. An on-site blood transfusion service is most desirable for this 
purpose, although in the absence of one, this service can still be offered in collabo-
ration with the blood transfusion service in closest proximity provided the appropri-
ate safety and quality assurance measures are put in place.
 Ancillary and Community Services
It is beneficial to an outpatient cancer center to provide ancillary services, although 
this will be dependent on the needs of the patient population each center serves. 
These services include physical therapy, nutrition and dietetics, and psychological 
services, amongst many others. A significant proportion of cancer patients can be 
malnourished and physically deconditioned from their illness [14], and can benefit 
greatly from having on-site services that address these needs. It is also estimated 
that about 32% of cancer patients are diagnosed with at least one mental disorder 
[15], supporting the need for psycho-oncology services.
In addition to on-site services, partnerships with local primary care providers and 
the setting up of satellite centres can also be explored. As an example, patients who 
require routine blood transfusions may be able to have this administered in a pri-
mary care or satellite center closer in proximity to their place of residence, rather 
than at the main cancer center. The same goes for procedures such as the flushing of 
lines, as well as blood tests. Medication delivery services could be explored for 
stable patients who do not require frequent physician reviews as this will also allow 
patients to maintain a normal life outside without spending too much time in a 
crowded clinic.
 Planning for Outpatient Chemotherapy and Drug Delivery
Various models of delivering outpatient chemotherapy have been explored. The 
optimal model harmonizing physician appointments, blood tests, nursing services 
and chemotherapy administration needs to be unique to every center and the com-
munity it serves. For example, patients treated at a cancer center located in a busy 
urban community with well-connected infrastructure and transport will have differ-
ent needs compared to those being treated in a regional center that may be more 
suitable for stable patients on maintenance therapies and do not require higher lev-
els of nursing care.
The organization of an outpatient chemotherapy center does not only involve the 
administration of the chemotherapy drug, but also the process  – involving 
4 Outpatient Care
26
consultations, blood tests and drug preparation, and the resources – both human and 
technical. An example of a patient pathway for a chemotherapy session is illustrated 
in Fig. 4.1. However, it is important to note that not every patient follows the same 
pathway – for example, some patients require blood tests prior to chemotherapy 
while some do not. Liang et al. (2015) [16] have described three categories: (i) OC – 
Oncologist appointment and Chemotherapy, (ii) O – Oncologist appointment only, 
(iii) C – Chemotherapy only. Further refinement has been suggested by Lame et al. 
(2016) [10] by the addition of a further distinction – whether the patient requires 
blood tests, B – resulting in six categories of OC, BOC, O, BO, C, BC. Resources 
then need to be allocated to these categories, including but not limited to, nurses, 
phlebotomists, pharmacists, examination rooms and chemotherapy suites.
The backbone of outpatient chemotherapy administration is largely similar 
across most centres, although variations in its organization are common and unique 
to each center. Lame et al. (2016) [10] has outlined options for organizational vari-
ants in outpatient chemotherapy pertaining to the chronological order various 
aspects of the chemotherapy process is performed (Table  4.1) [10]. Whichever 
model a center chooses to adopt, it is imperative that the focus remains on maximiz-
ing resources and minimizing wastage, while optimizing patient care and enhancing 
the patient experience.
For example, Lau et al. (2014) [17] showed that patients preferred chemotherapy 
on the same day as their oncology outpatient appointments. However, not all che-
motherapy regimens can be administered as such due to factors such as drug prepa-
ration time, or duration of administration. Soh et  al. (2015) [18] attempted to 
circumvent this through pre-packaging of chemotherapy to improve patient waiting 
times for chemotherapy. However, experience in the Netherlands Cancer Institute 






































Fig. 4.1 Patient pathway for outpatient chemotherapy with patient categories and resources. 
(Lamé et al. [10])
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eventually deemed unfit for treatment [19]. The potential for drug wastage and 
accompanying financial costs for such a strategy cannot be underestimated, further 
emphasizing the need to strike a fine balance between resource planning and patient 
experience.
It is important for centres to continuously collect data and regularly review orga-
nizational policies. Lean healthcare practices should be encouraged, and advances 
in technology should be evaluated to further this aim [20]. As an example, mathe-
matical modelling can improve scheduling [16], and the use of technology like radio 
frequency identification (RFID) can optimize chair use and the number of patients 
served [21].
Table 4.1 Options for outpatient chemotherapy delivery
Options Advantages Risks
Blood test Chemo day 
in-house
Streamlined process Patients wait




Reduced waiting time on 
chemo day
Patients must come two days in 
a row
In external lab 
on previous day
Reduced waiting time on 
chemo day
Poor hospital-lab coordination 
leads to a lost advantage and is 
time consumingFreed hospital lab capacity 




Chemo day Certainty on patient status: 
no wasted drugs
Patients wait
Sensitivity to equipment 
failures
Previous day Drugs ready on patients’ 
arrival if consultation is still 
on chemo day
Wasted drugs
Mixt Reduced waiting times Patients with expensive drugs 
wait
Less wasted drugs than 
100% on previous day
Still some wasted drugs
Oncologist 
consultation
Chemo day Patients come only once No early confirmation on 
patient status: patients wait 
drug preparation
Previous day Less waiting time because 
drugs can be prepared in 
advance
Patients have to come two days 
in a row




Functional Pooled resources: 
optimized utilization
Less possibility for patient- 
nurse connections
Primary Better patient-nurse 
connection
Lost productivity if the nurse’s 




 Economical Advantages of Outpatient Care
The financial benefits of running an outpatient cancer center is heavily dependent on 
local regulations and funding. The benefits and shortfalls will be heterogenous 
across many states and countries so local regulations need to be carefully examined 
and approached appropriately. If possible, cooperation with local public officials 
should be sought to make outpatient care an attractive option for all the other non- 
financial benefits outlined in this chapter.
 Clinical Trials
Great advances have been made in haematology-oncology in the past few decades, 
and increased understanding of the immunology and biology of cancer has led to the 
development of many therapeutics. Clinical trials are important in assessing the 
safety and efficacy of any treatment and form a cornerstone of cancer care. 
Consideration should be given to the setting up of an outpatient clinical trial center 
that is geared for the running of phase 1 or phase 2 trials. These services can aid 
with the recruitment of patients and monitoring of parameters such as pharmacoki-
netic/pharmacodynamic studies. They can either form part of the outpatient clinic, 
or set up as an independent unit, depending on the size of the center.
 Telemedicine
Telemedicine utilizes telecommunication technology to deliver healthcare services, 
including consults and education. It is also a tool that allows for multidisciplinary 
discussion, including telepathology. Communities that benefit the most from the 
utilization of telemedicine are those in areas physically distant from the center in 
which they normally receive care. Telemedicine has been tested in multiple areas of 
medicine (not limited to oncological care) and has demonstrated high levels of sat-
isfaction in both patients and physicians [22]. Several studies have also demon-
strated improved cost efficacy with telemedicine [23]. Telemedicine can be used to 
complement traditional methods of patient care, from expanding access to specialist 
support, to education and patient support [24].
It should be stressed that telemedicine is not just using mobile apps like 
FaceTime™ or Zoom™ to engage with a patient, even if patients may request for 
consults to be conducted in this manner for the sake of convenience. It is imperative 
that whichever telemedicine platform is utilized (whether a program developed in- 
house or a commercial one), due care is taken to protect patient and data confiden-
tiality and security. Telemedicine services can be approached in two main 
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ways  – synchronous or asynchronous formats. The former involves real-time 
engagement between the patient and his physician utilizing interactive video tech-
nology. The latter involves a “store-forward” approach where clinical data elements 
such as imaging, lab results, and video recordings can be stored to be interpreted at 
a later time [22]. Measures need to be put in place for a successful telemedicine 
service in order to achieve patient outcomes and satisfaction that is at least equiva-
lent to in-person consultation.
Apart from conducting consultations with patients, telemedicine can be utilized 
in other ways to augment the patient care experience, for both patients and health-
care providers alike. The increased development of wearables that can aid in remote 
monitoring of patients’ vital signs may allow patients to be monitored at home for 
signs and symptoms of treatment-related complications such as fever [24]. Patient 
examination, with the exception of palpation, can also be performed with the right 
training and tools. Wound care, symptom management and even palliative care can 
also be administered using portable technology that can increase patient access to 
these services [22].
Telepathology is also an emerging technology that allows pathologists to 
remotely view microscopic images without being physically coupled to a micro-
scope. The most discernible benefit thus far appears to be the accessibility to trained 
cytopathologists who are involved in rapid on-site evaluation (ROSE) of tissue 
obtained from minimally invasive procedures where the tissue sufficiency is integral 
to accurate diagnosis. Traditionally, pathologists or cytotechnologists are required 
to be on-site where the procedures are being performed. This can tie up valuable 
manpower for an extended period of time especially if it is a particular challenging 
case. The use of synchronous, real-time telepathology services will enable more 
procedurists to have access to ROSE and improve the diagnostic yield of tissue 
obtained [22].
It is extremely important that the local regulations and infrastructure are support-
ive of telemedicine alternatives. Before embarking on a telemedicine program, cen-
tres should craft their program aiming to maximize the quality of patient care whilst 
minimizing the risks of liability for healthcare programs. Considerations include:
 1. Adequate training of the healthcare team and patient
 2. Indemnity/insurance coverage for telemedicine
 3. Whether the quality of information acquired during the teleconsult is adequate to 
formulate a diagnosis or treatment plan
 4. Potential limitations to assessment of the patient, such as
 (a) Inability of the medical team to perform a physical examination
 (b) Lack of visual and other cues compared to an in-person consultation
 (c) Technological limitations (e.g. transmission delay, potential for data 
breach) [25]
Limitations that are relevant to the treatment of the patient should be openly 
disclosed and discussed so that patients understand the risks before agreeing to 
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receiving care through telemedicine. Should care providers feel that adequate 
assessment of the patient via telemedicine is not possible, they should always rec-
ommend that the patient be seen in person at a clinic or Emergency Department [25].
As with any consult, adequate documentation and patient privacy remain of 
utmost importance and should not be neglected. The healthcare team should also be 
aware that such consults can also be easily recorded by patients even if in-program 
recording functions are turned off. Regardless of an individual’s view on such sur-
reptitious recordings, healthcare providers should be cognizant of the fact that these 
can be used as admissible evidence in future civil claims or disciplinary proceed-
ings. It is prudent that the healthcare team continues to conduct themselves profes-
sionally on the assumption that every encounter is being recorded [25].
Technology has the potential to improve the patient experience and free up 
healthcare manpower to better optimize patient care. This can herald better multi-
disciplinary patient care, cost savings, increased patient access to treatment, clinical 
trials and education. With the appropriate focus on physician training, reimburse-
ment and infrastructure development while addressing deficits inherent in the digi-
tal divide, telemedicine can be a powerful in the future of outpatient cancer care [23].
 Outpatient Cancer Care in a Pandemic
The COVID19 Pandemic that began in early 2020 greatly impacted healthcare 
worldwide, not just cancer care. Apart from the obvious strain on healthcare 
resources, it has also had a significant impact on global economies and international 
travel. The COVID19 pandemic is not the first such disaster the world has faced, 
and will not be the last.
Considerations for cancer care that need to be undertaken in a pandemic are 
unique and aimed at addressing the negative effects it has on cancer treatment and 
research. Cancer patients and HSCT recipients are an especially vulnerable popula-
tion who are at higher risks of complications from any pandemic illness and should 
take extra safety precautions. A retrospective analysis of 355 patients who died of 
COVID19 in Italy showed that 20% had active cancer [26]. Healthcare resource 
scarcity due to the influx of non-cancer patients into the healthcare system also 
disrupts the routine treatment of cancer and HSCT [27]. Serious and disruptive 
effects are also wrought upon the conduct of haematology and oncology clinical 
trials with reduction in recruitment, and delay in drug development timelines [28].
It is imperative during such pandemics that healthcare teams address the follow-
ing issues:
 1. Which specific populations are most at risk
 2. Decisions for initiation or continuation of treatment, with careful balancing of 
risk/benefit
 3. Cancer patient prioritization by anticipated outcomes [28]
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Specific to the COVID19 pandemic, measures undertaken in the outpatient set-
ting include:
 1. Follow-up appointments by phone or telemedicine where possible
 2. Prioritize oral or subcutaneous routes of drug delivery over infusional routes
 3. Perform blood tests out of hospital
 4. Home delivery of medications and administration of infusional medications at 
home if possible
 5. Critical triaging of second opinions [28]
 6. Cryopreservation of donor stem cells or arranging alternative sources (e.g. cord 
blood) for HSCT
While every pandemic and wide-scale disaster will present its own unique chal-
lenges, it is important for haematology and oncology units to be as well prepared as 
possible for such eventualities through the gleaning of knowledge from prior expe-
riences. The COVID19 pandemic of 2020 has shown how disastrous and deadly the 
lack of preparation can be for any healthcare system, cancer care notwithstanding.
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Cancer remains a major public health problem worldwide. In the United States, 
cancer represents the second leading cause of death [1]. Availability of more effec-
tive supportive therapies, namely, new generation of antimicrobials, antiemetics, 
and hematopoietic growth factors, among others, coupled with emergence of novel 
antineoplastic agents, have facilitated administration of cancer treatments outside 
the hospital setting [2–4]. Moreover, a significant number of new targeted therapies 
for various cancers are more amenable to being offered in the outpatient infusion 
center setting owing to a better toxicity profile [5, 6]. Another factor driving 
increased utilization of infusion centers include a lower healthcare cost when com-
pared to the inpatient hospital setting. For instance, receiving a cancer treatment in 
a hospital will definitely cost more than if it were administered in an infusion center 
for the same medication at the same dose and frequency. This is also the case for 
other supportive therapies.
Cancer treatments typically require multiple visits. The logistics can be exhaust-
ing for patients and their caregivers who are already under a lot of stress including 
physical, emotional, and financial strain, among others. There are times when visi-
tors may be restricted at the discretion of nursing staff. Receiving a treatment in an 
infusion center is definitely more convenient than going to a hospital, considering 
the increased hassle and complexities associated with the latter. Infusion centers are 
purposely designed to provide a calm environment for people receiving chemo-
therapy and other types of infusions, hence resulting in an improved psychological 
well-being. Yet, presently the role of the infusion center transcends beyond 
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antineoplastic treatment administration. Below, we highlight the main services pro-
vided by infusion centers.
 Infusion Center Area
Generally, infusion areas comprise a mix of beds and recliner chairs which are 
assigned based on the needs of the patient and the type of treatment that they will be 
receiving. Other services include on-site cable television, computers, and Wi-Fi 
access. Also, with the advent of electronic health records the contemporary design 
of infusion center rooms incorporate a computer working station for added conve-
nience and efficiency (Fig. 5.1). Infusion centers provide a multitude of services 
including but not limited to:
 (a) Administration of blood products
 (b) Intravenous biotherapies
 (c) Chemotherapies: intravenous or subcutaneous
 (d) Antimicrobial therapies
 (e) Intravenous fluid including electrolytes replacement
 (f) Other therapies
 (i) Bisphosphonates or similar therapies for bone protection
 (ii) Intravenous iron replacement therapy
 (g) Nurse educators and library resources
Infusion centers allow providers to help patients better manage and control their 
disease and associated symptoms by providing a continuity of care throughout their 
medical need. By enhancing continuity of care, it improves patient compliance.
Fig. 5.1 Outpatient infusion center, Mayo Clinic, Jacksonville, FL, USA. (Used with permission 
of Mayo Foundation for Medical Education and Research, all rights reserved)
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Infusion centers, in academic hospitals and even community-based setting, 
which are actively participating in research, do offer experimental therapy(ies) 
which encompass new drugs, or use existing drugs prescribed in new ways or on 
new diseases, among others. All medical and nursing staff are generally trained in 
oncology and clinical trial patient care. Clinical lab facilities are usually present on- 
site for proper specimen management. Most clinical trials, particularly phase 1 and 
2 studies would also require presence of advanced cardiovascular life support certi-
fied personnel and equipment; for example, a defibrillator on-site in case patients 
develop untoward side effects to experimental therapies being administered. 
Pharmacists are also available on-site for the purpose of preparing and compound-
ing antineoplastic agents; and to help determine the possibility of drug–drug inter-
actions or to closely monitor administration of experimental therapies as part of 
clinical trials.
 Staff
The team in a cancer center infusion facility consists of medical oncologists/hema-
tologists, advanced practice providers, and certified oncology nurses who are avail-
able to help support your treatment needs in a safe manner. Other services that are 
available according to specific patients’ needs include:
 (a) Social workers
 (b) Case managers
 (c) Nutrition therapists/dietary counselors
 (d) Health and wellness counselors
 (e) Administrative staff to assist with insurance-related issues or referrals to other 
clinical services.
 Other On-Site Services
Clinical labs: Presence of on-site clinical labs provides added convenience to the 
patient and allows administration of prescribed therapies in a more timely fashion. 
While the capabilities and level of sophistication varies among centers, these labs, 
at the minimum, should be able to offer a complete blood count with a differential 
and a comprehensive metabolic panel. In cancer centers that perform complex pro-
cedures like allogeneic hematopoietic cell transplantation (allo-HCT), these on-site 
labs may also have capabilities to measure blood titers of immune suppressants, 
among others.
Diagnostic imaging: In large cancer centers, patients are able to have basic diag-
nostic imaging in close proximity to the infusion center, generally within the same 
building. The level of complexity of diagnostic services provided varies among cen-
5 The Infusion Center
38
ters, but generally standard radiologic testing such as chest X-ray are generally 
readily available. It is important to keep in mind that there is no universal model for 
what diagnostic imaging services must be available in close proximity of an infu-
sion center, and it would certainly depend on available financial resources and archi-
tectural design, among others.
Disease-specific support services: Owing to the different type of treatments 
offered at an infusion center, various support services are available. This includes 
but is not limited to physicians, nurses, and advanced practice providers specialized 
in various specialties such as infectious diseases, hematology, and medical oncol-
ogy, among others. Also, for those patients receiving their first cycle of therapy, a lot 
of education about the potential side effect(s) of newly prescribed antineoplastic 
agents or potential drug–drug interactions are provided by nurses and/or specialized 
pharmacists. Disease-specific educational materials such as booklets are regularly 
available on-site to be shared with patients and caregivers.
 Infusion Centers: Convenience and Potential Healthcare 
Cost Savings
Availability of infusion centers in the outpatient setting provides a smoother transi-
tion of care from the inpatient to the outpatient setting in patients who had com-
pleted induction antineoplastic therapies for diseases like acute myeloid leukemia, 
or complex procedures such as HCT, both autologous (auto-HCT) or allo-HCT, and 
other cellular therapies, namely, chimeric antigen receptor T (CAR T)-cell therapy 
in the hospital setting. Generally, patients who undergo these procedures are 
required to continue to be followed closely for few weeks in the case of auto-HCT 
and CAR T-cell therapy, or for longer time (typically, approx. 2–3 months) in allo- 
HCT recipients [7–9]. These patients are required to stay in the vicinity of the can-
cer center for close surveillance and needed clinical management. Among the 
clinical services provided to these patients include administration of intravenous 
fluids and electrolytes, antimicrobials, transfusion of blood products and certain 
antineoplastic therapies. Although there are no established standards for hours of 
operations, in some cases infusion centers provide extended hours and weekend 
day access.
The cost of health care is rising at an unsustainable rate in the United States, and 
it is expected to continue to rise because of population changes and the high cost of 
novel anti-cancer therapies, among other reasons [10, 11]. Availability of outpatient 
cancer infusion centers has the potential to reduce readmission rates to the inpatient 
hospital setting [12]. This is possible by providing services like transfusion of blood 
products, intravenous fluids, antimicrobials, and others, which traditionally need to 
be administered in the hospital. This results in a twofold benefit of not only 
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preventing readmissions to the hospital, which is a national policy priority, but also 
providing aforementioned services at a lower cost.
 Remaining Challenges
Cancer care is complex both logistically and operationally. Financial aspects related 
to the practice of oncology could be challenging owing to the very expensive cost of 
cancer drugs and the need to secure prior authorizations from third-party payers for 
certain therapies. This requirement can be at times problematic and could poten-
tially affect the overall delivery of efficient and timely care. Also, during the 
COVID-19 pandemic caused by SARS-CoV-2, individual patient’s decision needed 
to be made which could have resulted in delaying administration of chemotherapy. 
This has certainly been a learning lesson, and different oncology societies have 
developed guidelines on cancer care which will certainly help being better prepared 
for similar future events [13, 14].
 Discussion
We described the major components required for successful operation of a cancer 
infusion center. The ultimate goals of a successful infusion center are to offer a 
patient-centered experience that improves the overall quality of delivered care at a 
sustainable cost. Beyond comfort and convenience, infusion centers are helpful in 
providing continuity of care, adherence to prescribed therapies, and administration 
of supportive therapies whenever indicated. This could have a beneficial effect on 
reducing readmissions to the hospital and improve patient satisfaction.
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Chapter 6




Cancer is a significant cause of morbidity and mortality. As per multiple cancer 
registries, the incidence of cancer is increasing worldwide. The highest increase is 
observed among low- and middle-income countries [1]. Radiotherapy is a crucial 
and cost-effective component of cancer care and can be utilized in the definitive, 
adjuvant, and palliative settings. Radiation therapy has been shown to increase over-
all survival in many types of locally advanced cancers. Around half of all cancer 
patients will receive radiation treatment at some point during their course of treat-
ment [2, 3].
A radiotherapy facility is an integral component of a multidisciplinary cancer 
center. Along with surgical intervention and chemotherapy, radiotherapy is crucial 
and needed in designing a cancer care facility. Once the decision to establish a 
radiotherapy facility has been made, careful strategic planning is needed to ensure 
alignment with the cancer center’s overall mission and goals concerning available 
resources. Recruitment of skilled clinicians and personnel is critical to ensure safe 
and high-quality patient care. Coordination and monitoring of the planning and 
timelines are critical to a successful project, especially when resources are limited. 
The professional team required to design, construct, and commission a radiotherapy 
facility needs to be in a multidisciplinary sitting from various background [4].
This chapter presents an overview of radiotherapy’s value in treating the most 
common clinically indicated malignancies worldwide. We aim to present a proposal 
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to assess the radiotherapy facility’s clinical, infrastructure, and resources need while 
establishing a new radiotherapy facility.
 Population Description
Determining the need for radiation therapy requires in-depth knowledge of the pop-
ulation demographics, cancer incidence, and national disease burden estimates with 
precise projections for the future [5]. Establishing cancer registries is essential for 
estimating the community’s clinical needs, developing clinical pathways, and 
implementing research programs. Further forecasts regarding anticipated radiother-
apy capacity and use (number of radiation courses and fractions per course for each 
cancer type, as well as the amount of potential retreatment) should also be estimated 
[6]. These steps are unique for each nation and country. In the countries where these 
variables are not measured, the International Agency for Research on Cancer 
(IARC) provides the best estimate of crude incidence, Table 6.1 and Fig. 6.1.
 Needs Assessment
The target population is subdivided into various tumor sites. According to multiple 
cancer registries, most treated cases will include breast, prostate, lung, and colorec-
tal cancers. Data from Australia [7] indicates that a curative radiotherapy course 
Table 6.1 World Cancer Statistics per International Agency for Research on Cancer, World Health 
Organization 2018
Summary statistic 2018
Males Females Both sexes
Population 3,850,719,284 3,782,099,828 7,632,819,272
Number of new cancer cases 9,456,418 8,622,539 18,078,957
Age-standardized incidence rate (world) 218.6 182.6 197.9
Risk of developing cancer before the age of 75 
years (%)
22.4 18.3 20.2
Number of cancer deaths 5,385,640 4,169,387 9,555,027
Age-standardized mortality rate (world) 122.7 83.1 101.1
Risk of dying from cancer before the age of 75 
years (%)
12.7 8.7 10.6
5-year prevalent cases 21,014,830 22,826,472 43,841,302
Top 5 most frequent cancers excluding 




Stomach Cervix uteri Prostate
Liver Thyroid Stomach
M. Aldehaim and J. Phan
43
requires an average of 22 fractions and a palliative course 4 fractions; thus, the total 
average would be 18 fractions per the first course. The average linear accelerator 
(linac) treats four to five patients per hour, so the total linac utilization will depend 
on the total number of hours per day that the machine is active.
In the developed world, most breast cancer (approximately 95%) cases present at 
potentially curative early stage or locally advanced cases. Evidence of treating breast 
cases with hypofractionation is well established [8] and widely utilized worldwide.
Similarly, for prostate cancer, due to screening, the majority of cases will present 
at an early stage (low-risk disease). Treatment options for low-risk prostate cancer 
include active surveillance (standard of care), radical prostatectomy, external beam 
radiotherapy, or brachytherapy. It is estimated that 60% of these cases will receive 
external beam radiation treatment, either definitively or in the early salvage setting, 
during their disease trajectories. The majority of cases are treated with conventional 
fractionation (although early salvage radiation usually requires a lower radiation dos-
age) [9]. Hypofractionation is increasingly an attractive option and often delivered in 
20 fractions [10] or fewer. Recently, there is growing evidence of ultra- hypofractionation 
with seven or fewer fractions that have been utilized in many cancer centers [11].
Lung cancers can be categorized into non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC), which require different radiotherapy treatment pro-
tocols. For NSCLC, stages 1 and 2 comprise 30% of presenting cases, and some of 
them (medically inoperable) will be treated with curative intent Stereotactic Body 
Radiotherapy (SBRT). It is estimated that a small percentage will receive SBRT with 
five or fewer fractions for peripherally located tumors and eight to ten fractions for 
centrally located one [12]. Approximately, 45% of NSCLC cases present at stage III 
and are treated with concurrent chemoradiation [13]. For SCLC, which comprises 
Lung
2 093 876 (11.6%)
Breast
2 088 849 (11.6%)
Colorectum
1 849 518 (10.2%)
Prostate
1 276 106 (7.1%)
Stomach
1 033 701 (5.7%)
Other cancers
9 736 907 (53.9%)
Total: 18 078 957
Fig. 6.1 Number of new cancer cases in 2018 by sites, both sexes, all ages. (Source: International 
Agency for Research on Cancer, World Health Organization 2018)
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~15% of all lung cancer cases, both limited and extensive stage presentations are 
considered. For limited-stage SCLC (33% of cases), the radiation treatment is tho-
racic radiation with 30 fractions twice daily with at least 6 h apart [14] to follow with 
prophylactic cranial radiation in 10 fractions [15]. For extensive-stage SCLC (66% 
of cases), the standard treatment is a systemic therapy, and the responder will require 
consolidative thoracic radiation with [16] +/− prophylactic cranial radiation [17].
In the category of colorectal cancers, radiotherapy has a more limited role except 
for rectal cancers, where radiation treatment is often utilized. Rectal cancers com-
prise of ~28% of colorectal cancers, and ~20% of rectal cancers are metastatic at 
presentation. The remaining 80% is often treated with long-course chemoradiation 
[18], which is typical in the neoadjuvant and adjuvant setting. Another alternative is 
short-course radiotherapy, with five fractions in selected cases.
For endometrial cancer, most cases present at an early stage and need observa-
tion or vault brachytherapy in an adjuvant setting. However, assuming at most, 30% 
of endometrial cancers will require external beam radiation. This includes medi-
cally inoperable and adjuvant treatment cases treated with 25 fractions [19]. 
Approximately 60% of cervical cancers present between stage IB2 and stage IVA 
and require external beam radiation as part of treatment. The most common pre-
scription is 25 fractions [20]. Approximately 40% of esophageal cancers present at 
a curable stage, requiring on average concurrent chemoradiation [21].
Palliative cases constitute a significant radiation oncology workload component, 
and up to 50% of all oncology cases may receive palliative intent treatment. This 
includes new patients presenting with the metastatic and non-curable disease, and 
previously treated patients who have developed a non-curable recurrence. The major-
ity of palliative intent treatments constitute radiotherapy for bone metastases, brain 
metastases, and spinal cord compression. For bone metastases, the most common pre-
scription is single or a few fractions. For spinal cord compression, the most common 
prescription is ten or fewer fractions. For brain metastases, the main treatment options 
include fractionated whole-brain radiation or stereotactic radiosurgery (SRS) with 
single fraction doses ranging from 15 to 24 Gy depending on the target’s size [22].
Head and neck cancers and sarcomas typically require the services of surgical 
oncologists with highly specialized training. There is existing evidence that sup-
ports that the outcomes for head and neck cancers [23], sarcomas [24], and bladder 
cancers [25] are significantly better in tertiary high-volume centers with specialized 
care in these areas. Similarly, pediatric oncology is highly subspecialized and 
requires input and management from multiple disciplines.
 Brachytherapy
This section focuses on the use of brachytherapy to treat prostate, endometrial, and 
cervical cancers. For prostate cancer, brachytherapy can be used as monotherapy for 
low-risk and intermediate-risk patients, or in combination with external beam radia-
tion therapy (EBRT) as a form of dose escalation for selected intermediate-risk and 
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high-risk patients. Brachytherapy with either permanent implants (low dose rate 
[LDR]) or temporary implants (high dose rate [HDR]) has become an integral com-
ponent of radiation therapy with excellent oncological outcome [26]. There is well- 
established evidence suggesting that low and intermediate-risk prostate cancer 
patients who are treated with brachytherapy have superior outcomes compared to 
EBRT in terms of better biochemical failure-free survival (e.g., PROCARS Database 
where 7974 prostate cancer patients managed at four Canadian institutions 
1994–2010 Fig.  6.2) [27]. This evidence supports the increased utilization of 
brachytherapy treatment.
The general rationale for using brachytherapy is as follows:
 1. Dose escalation is required to maximize cancer control.
 2. Brachytherapy enables increased dose delivery to the target and sparing of adja-
cent healthy tissues.
 3. The low a/β ratio of prostate cancer provides a radiobiological rationale for HDR 
brachytherapy.
 4. There is a substantial body of clinical evidence to support the use of prostate 
brachytherapy.
Many cancer centers plan to use only HDR brachytherapy instead of permanent 
implants LDR as there is a dosimetric and practical rationale for this. Because dose 
optimization with HDR brachytherapy is performed after placement of catheters, 
HDR enables more consistent target coverage and excellent dose uniformity, resulting 
in a lower dose to the urethra and rectum when compared to permanent seed implants 
[28]. Currently, there is no clinical evidence to suggest that HDR brachytherapy is 
inferior to LDR brachytherapy. Thus, offering HDR brachytherapy alone is a cost-
effective solution without compromising clinical efficacy when resources are limited.
It is estimated that ~13–15% of total prostate cancer patients will eventually 
receive brachytherapy (LDR or HDR) alone or combined with EBRT. The sug-
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Fig. 6.2 Kaplan-Meier curves comparing propensity score-matched patients receiving external beam 
radiation therapy (EBRT) versus brachytherapy (BT) for intermediate-risk patients. (Smith et al. [27])
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We estimate that a high number of patients will be diagnosed with endometrial 
cancer. The majority of these cancers are seen in postmenopausal women, with a 
median age of 60 years. The majority of them will be early stage disease and require 
surgical intervention with a total abdominal hysterectomy and bilateral salpingo- 
oophorectomy (TAH-BSO). We estimate that at most we will treat one-third with 
vaginal vault brachytherapy either alone or in combination with external beam radi-
ation therapy. Each patient will require two to three fractions of treatment. Patients 
are routinely booked for three insertions to allow the additional dose to be given if 
there is an incomplete response after two insertions.
There are three sets of vaginal vault applicators depending on size (small, 
medium, and large). Most utilize cylindrical applicators (various diameters 
(20–40 mm) and lengths (2.5–10 cm)) with a dome cylinder at the top and with one 
central channel or two to three channels in different configurations. The suggested 
dose and fractionation schemes are detailed in Table 6.3.
It is well established that HDR brachytherapy is an essential component of cervi-
cal cancer management. It has been estimated that 70% of these patients will be 
candidates for HDR brachytherapy. There is growing evidence that better oncologi-
cal outcomes can be achieved with the utilization of MRI guidance. As per the 
consensus of the Brachytherapy in Cervical Cancer Expert Working Group 
(BCCEWG) Panel of the Cancer Care Ontario (CCO) meeting in 2009 [29], MRI 
was strongly recommended for delineation of target volumes and planning. The 
meeting concluded that CT provided acceptable but significantly inferior soft-tissue 
delineation and, in many cases, could not accurately delineate the target volumes. 
As per BCCEWG, cervical Brachytherapy also requires that it should only be done 
at centers with direct access to appropriate gynecological expertise for multidisci-
plinary patient assessment. The suggested dose and fractionation schemes are 
detailed in Table 6.4.
Table 6.2 Suggested dose and fractionation for HDR brachytherapy in prostate cancer
Single fraction boost 
(before EBRT) HDR monotherapy Focal salvage
Dose 
fractionation
15 Gy/1 F 19 Gy/1 F (worse 
outcome)












Adjuvant with EBRT 45 Gy/25 5.5 Gy to 0.5 cm 2
Sole adjuvant 0 7 Gy to 0.5 cm 3






Recurrence following previous 
RT
0 7 Gy to 0.5 cm 3
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 Equipment
This section describes the required equipment for delivering both external beam 
radiation and brachytherapy. A radiotherapy center aiming at treating an average of 
1000 patients/year need to be equipped with at least a single-photon energy unit, a 
brachytherapy afterloader (ideally for high dose-rate brachytherapy), a full range of 
applicators, a simulator, preferably a CT simulator, a computerized treatment plan-
ning system (TPS), patient immobilization devices, and a beam measurement and 
quality assurance (QA) equipment [30].
 External Beam Radiotherapy
For a resource-limited area, the decision to use a cobalt-60 unit or a linear accelera-
tor (linac) for radiotherapy depends on various factors. The use of linacs in develop-
ing countries is increasing [31]. With good infrastructure and reliable power supply, 
a linac is preferred, although curative and effective radiation treatments are possible 
with a cobalt-60 unit. Linacs can generate electron treatment beams that can be used 
to treat skin cancers. However, linacs require more frequent quality assurance that 
needs to be carried out by a medical physicist.
Most newer facilities are equipped with high-energy linacs with intensity- 
modulated radiation therapy (IMRT), volumetric arc therapy (VMAT), and image- 
guided radiation therapy (IGRT) capabilities. This will require a careful review of 
deliverables, functionality, technical specifications, and cost of all commercially 
available linacs. It is crucial to evaluate the quality of the manufacturer’s service and 
technical support that they will provide.
Linacs will have different energies, with 6 MV photon beams and 15–18 MV 
photon beams as the more commonly used energies. There is no anticipated need for 
25 MV capability because the uniformity produced by 18 MV photons over targets 
is generally deemed sufficient while yielding less neutron production and, therefore, 
requiring less shielding. Further, some manufacturers no longer provide a 25 MV 
photon beam as a standard option. Installing a linac with 25 MV photons will only 
increase the price of the unit with no anticipated great benefit for the clinic. 
Stereotactic radiation and ablative treatments can be performed on the linac, Gamma 
Table 6.4 Suggested dose and fractionation for brachytherapy prescription for cervical cancer
Scenario External beam dose









Alternative prescription for patients 
requiring fewer HDR fractions
45 Gy/25 + parametrial 
boost
8 Gy to point 
A
3
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Knife, or Cyberknife systems. There will be a need for a CT simulation unit which 
can be shared between the external beam radiation and brachytherapy programs.
 Brachytherapy
There will be a need for a dedicated HDR brachytherapy suite with a treatment 
room and control area. The brachytherapy treatment room contains a mini operating 
theatre equipped with the following:
• A Remote afterloader
• An in-room radiation detector and check source
• Audiovisual communication systems
• A securely locked door and door interlock
• A multiple-position patient procedure table
• A mobile ultrasound machine for guidance
• Emergency crash cart and recovery equipment
• Survey meter
• An anesthesia area with patient monitoring equipment
• An operating room procedure light
• A sink and scrub area
• Emergency shut-off buttons
Both Co-60 and Ir-192 are commonly used as sources in HDR brachytherapy; 
however, Ir-192 is usually selected as the radiation source to be used for the remote 
afterloader system due to lower photon energy and advantages it offers with regard 
to radiation protection. For example, the use of Ir-192 results in the amount of con-
crete required to be cut in half compared to Co-60.
An adjacent control area will allow for safe monitoring of the brachytherapy 
procedure and patient. Cameras will be needed for patient observation. Intercom 
facilities between the treatment room and control area are required to permit direct 
communication with the patient during the treatment. There will be dedicated com-
puters and planning workstation in the control room.
Recovery area [32, 33]
• One anesthesiologist need to be present in the facility until such time that the last 
surgical patient of the day is deemed fully conscious.
• A fully qualified registered two nurses need to be present in the room. They must 
know and be in charge of the equipment, critical supplies, personnel assign-
ments, and duties.
• Two fully equipped recovery beds. There should be curtains or screens to allow 
privacy.
• Space allocated per bed/trolley should be at least 9 m2. There must be easy access 
to the patient’s head.
• Adequate space to allow the transport of patients and movement of personnel. A 
continuous oxygen delivery system must be in place.
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• All necessary medical equipment from monitoring, suction, and resuscitation 
equipment must be available.
• The emergency power source must be available, which will provide adequate 
lighting essential area lighting, and have the capacity to operate all necessary 
equipment.
 Commissioning
Once the equipment is acquired from vendors, it will be subject to acceptance test-
ing where tests and measurements will be performed to ensure that the equipment 
of software meets the specifications set by the manufacturer. The manufacturer will 
indicate the acceptance testing protocol, and the testing process will be jointly car-
ried out by the installation technicians and medical physicists. Each facility needs to 
have the necessary equipment for acceptance testing, which might include: a 3D 
water phantom scanner, ion chambers, electrometer X-ray films, and film laser 
scanner. The American Association of Physicists in Medicine (AAPM) makes avail-
able useful task group reports (TG-35, TG-40, and TG-43) that provide detailed 
information about linacs safety and quality assurance.
 Room Shielding
Design of the radiation treatment room shielding incorporated consideration of As 
Low As Reasonably Achievable (ALARA) principles, International Atomic Energy 
Agency (IAEA) Safety Standard Series, National Council on Radiation Protection 
and Measurements (NCRP), and American Association of Physicists in Medicine 
(AAPM) corresponding reports and the requirements set by different Safety 
Commissions, which mandates the maximum allowed limits of radiation exposure 
to occupants adjacent to the treatment rooms. These limits depend on whether or not 
those occupants would be considered nuclear energy workers (e.g., radiation thera-
pists) or members of the public (e.g., patient family members, administrative staff). 
Important factors influencing the room shielding requirements and, therefore, cor-
responding cost include but are not limited to the expected workload of the unit 
(output in dose (Gy) per year), maximum expected dose rates per fraction, conven-
tional or specialized treatment protocols, and associated fractionation (e.g., stereo-
tactic body radiation therapy (SBRT)) and a number of palliative fractions and 
expected dose.
Careful selection of treatment room placement can help save cost by aligning the 
rooms such that walls requiring more shielding are shared (e.g., primary walls) and 
preventing most walls from being adjacent to public areas (e.g., by having the bun-
kers underground where some walls are lined by the earth and having treatment 
areas aligned such that most do not border a public waiting area).
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 Radiotherapy Staffing
The core professional team in radiotherapy consists of radiation oncologists, radia-
tion therapists, dosimetrists, and medical physicists supported by nursing, adminis-
tration, and various medical officers.
 Personnel
To best serve the population, and based on the proposed size of the facility with 
linacs and brachytherapy unit, we can anticipate the need for radiation oncologists 
(ROs). According to the Cancer Care Ontario (CCO), the number of ROs required 
at any radiation center is consistent regardless of the size of the center and is 1.8–2 
ROs per linac. Many community radiation centers operated within that framework. 
To run the linacs and an additional brachytherapy unit, we propose using a factor of 
two ROs per linac. A 0.5 Full-Time Equivalent (FTE) anesthesiologist is required 
for Brachytherapy, and 1 FTE medical oncologist for concurrent chemoradiation.
Based on the proposed number of concurrent clinics, we also anticipate the need 
for a number of dedicated nurses. Those would be used to see patients coming for 
clinic appointments, for radiation review clinic, for the brachytherapy unit, to take 
calls from patients and other healthcare providers, to run the chemotherapy suite, 
and float nurses. There will be a need for clinic coordinators to help with patient 
flow. The facility will need radiation therapists to help run the facility. Generally, 
four therapists are needed per linac. Two would be required to run the CT sim and 
two more for the brachytherapy suite. An additional dosimetrist would be dedicated 
to radiation planning.
Other support staff required would include administrative assistants for the ROs, 
administrative assistants to check patients in for CT sim or radiation treatments, and 
janitorial staff.
 Quality Assurance
The responsibility for quality assurance and safety falls on every individual working 
at the radiotherapy facility, including radiation therapists, physicists, and radiation 
oncologists. In this section, some of the planned quality assurance activities for 
radiation oncologists and physicists will be discussed.
Physics: Equipment-specific quality assurance will be performed on all treatment 
equipment and software. Regular and continuous QA testing for equipment will be 
necessary to ensure safe and correct functioning. A written equipment quality con-
trol program must specify the required policies and procedures:
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 1. Parameters to be tested or the tests to be performed
 2. Instruments to be used to perform the tests
 3. Test setup (geometry, etc.)
 4. Frequency of the tests
 5. Individuals responsible for testing
 6. Expected results or values
 7. Tolerance level
 8. Action to be taken when tolerance is exceeded
QA procedures for treatment machines will be performed on a daily, monthly, 
and annual basis using the guidelines and recommendations specified in the TG-45 
report “AAPM code of practice for radiotherapy accelerators: Report of AAPM 
Radiation Therapy Task Group No. 45”. The radiation therapists will perform daily 
machine QA, whereas the monthly and annual QA procedures will be the responsi-
bility of the physicists. QA will mandate compliance with the specific requirements 
for remote afterloading units of the HDR brachytherapy unit.
Physicists will also be responsible for “chart checks” before delivery of 20% of 
the total dose, where a review of the prescription and treatment plan will be per-
formed along with an independent MU calculation. There will also be a weekly 
physics chart check to ensure that the treatment is delivered as intended.
Oncologists: Oncologists will participate in weekly tumor board conferences 
where there will be input from surgeons and medical oncologists, and other medical 
doctors for the management of difficult or challenging cases. Usually, each site will 
require two oncologists’ practice in that specific area, so that peer review of plans 
can be performed. Each section will have dedicated weekly quality assurance 
rounds where this process can take place. Usually, the quality assurance rounds will 
require the presence of at least two oncologists, one physicist, and two radiation 
therapists.
 Timeline
A typical timeline of approximately a few years from the time of approval to the 
time when patients can first be treated is reasonable. The proposed timeline would 
break down as follows:
 1. Commissioning design, engineering firms, architectural plans (6–12 months)
 2. Facility and bunker construction (1–2 years)
 3. Install linacs, CT, brachytherapy equipment (6–12 months)
 4. Get clinic space up and running (3–6 months)
 5. Training for ROs, physicists, planners (3–6 months)
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 Budget
The anticipated life span of technology is 10 years. The brachytherapy suite costs 
are estimated in Table 6.5.
In terms of personnel, the estimated salaries are drawn from the literature from 
Europe and converted to dollars [34]. Note that base salaries are included for radia-
tion oncologists and not the fee for service aspect. The staffing costs are estimated 
in Table 6.6.
 Conclusion
Establishing a new radiotherapy facility is a complicated and costly process that 
required careful planning, understanding of the local disease burden, infrastructure, 
and multimodality expertise. Each step has many obstacles and challenges. The 
people, time, and money commitment can be substantial but rewarding and reduce 
cancer patients’ suffering.
Table 6.5 Estimation of the cost of brachytherapy suite (please note as these values might vary 
significantly depending on regions)
Parameter Low end High end
HDR device $250K $350K
Applicator $50K $100K




Planning system $150K $200K
Construction $50K $70K
Table 6.6 Staffing costs for the proposed radiation therapy facility (please note as these values 
might vary significantly depending on regions)
Staff Cost per FTE ($)
Radiation oncologists 180,000
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Cancer is a leading cause of death worldwide, accounting for nearly 10 million 
deaths in 2020 [1]. This is due to many risk factors such as aging society, alcohol 
abuse, smoking, obesity, and lack of physical activity [2]. It is essential to deliver 
high-quality nursing care, from prevention and screening to end-of-life care. As 
research and scientific discoveries are incorporated into cancer treatment, nurses 
working in the oncology field should be well educated and be prepared to play an 
integral role in delivering complex treatment regimens and targeted cellular thera-
pies. Therefore, focusing on specialized oncology nursing practice through advanced 
education will ensure successful care delivery.
By utilizing established standards and competencies to provide oncology nursing 
care, nurses will improve their knowledge and skill set. Nurses new to oncology, as 
well as experienced nurses from other specialties, should receive the required com-
petencies to provide high-quality care to cancer patients. According to the Institute 
of Medicine [3], these include leadership, health policy, system improvement, 
research and evidence-based practice, teamwork and collaboration, community and 
public health, geriatrics, and oncology. Documentation supporting the development 
and validation of nursing competency is frequently required of accreditation agen-
cies, including the American College of Surgeons and The Joint Commission, as 
part of the accreditation and reaccreditation process [4].
Any oncology setting should have policies to document any additional qualifica-
tions of specialized staff providing care to the cancer patient, especially regarding 
chemotherapy administration and documentation. The 2016 updated American 
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Society of Clinical Oncology/Oncology Nursing Society (ONS) chemotherapy 
administration safety standards recommend a minimum expectation for ordering, 
preparing, and administering chemotherapy [5]. There should be a comprehensive 
program for initial and ongoing oncology education requirements for all staff and a 
dedicated time frame for onboarding all new hires within the institution.
Oncology nursing continues to progress and can differ significantly across cul-
tures. Currently, oncology nurses work in diverse settings such as hospitals, private 
physician clinics, outpatient infusions, radiation centers, home health agencies, and 
community settings, supporting many oncology disciplines. The oncology nurse’s 
roles vary from a community focus of screening, detection, and prevention to a 
more intensive care focus such as blood and marrow transplantation. Regardless of 
the setting, nurses working in cancer care are responsible for focusing on patient 
assessment, management of symptoms, education, coordination, and support-
ive care.
According to the World Health Organization (WHO), there is a shortage of 7.2 
million healthcare workers concerning health needs, whereas the report by the 
“Third Global Forum on Human Resources for Health” estimates that by 2035, the 
nursing deficit will reach 12.9 million [6]. With the growing shortages of health care 
professionals skilled in providing cancer care, the focus should be on providing 
oncology-specific training and competencies. Nursing staff shortages affect the 
quality or quantity of healthcare and decrease nurses’ motivation regarding compre-
hensive care provision or care based on scientific principles [7]. This may lead to 
work overload, burnout, and increased nursing turnover. It is imperative to assess 
each clinical area’s nursing unit structure and staffing needs and develop a nursing 
care model focused on evidence-based patient-centered care.
 Oncology Inpatient Clinical Service Unit
Oncology nurses play a vital role in delivering high-quality care to patients hospital-
ized with a cancer diagnosis. The oncology care nurse needs to develop a collabora-
tive relationship with the physician to deliver exceptional comprehensive patient 
care. Depending on the type of clinical service unit (CSU) being established or 
maintained, the nurse–patient ratio must be assessed initially and again over time. 
By benchmarking with other institutions, identifying an appropriate ratio and skill 
mix can be validated for the individual unit type. Because of the increased acuity 
and workload on an oncology inpatient unit, registered nurses (RN) are a critical 
component of the healthcare delivery model. However, due to the limited number of 
RNs in many countries around the world, it is suggested each institution assesses the 
individual characteristics of their nurses, their work environments, and their patient 
population [8] to ensure the appropriate skill mix has been identified. For example, 
the inpatient blood and marrow transplant unit would use a primary model with 
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highly trained nurses and a lower nurse–patient ratio due to the complexity of care 
being delivered. In contrast, a medical oncology unit may have a higher nurse–
patient ratio but utilize non-licensed personnel to assist with care. Based on the 
clinical unit’s care and scope, one must consider what their staff may require to 
meet patient needs.
With the administration of antineoplastic agents occurring mostly on inpatient 
units, a global standard is recommended to ensure safe handling and administration 
for the care nurses by following the Oncology Nursing Society (ONS) guidelines. 
Nurses working in cancer care are responsible for education before start of treat-
ment, safe drug handling; two-person independent verification of chemotherapy 
with the calculation of drug dosage based on body surface area, insertion of intrave-
nous lines or accessing central venous devices; and continuous intense monitoring 
to identify early recognition of oncologic emergencies. Nurses specifically working 
in radiation oncology require an additional skill set. During basic nurse training, 
many nurses do not have the opportunity to participate in any radiation-related 
courses. To prevent nurses from exposure, it is necessary to provide the healthcare 
nurse with the appropriate knowledge of radioactive contamination. The nurse will 
also be responsible for symptom management assessment of skin rashes and com-
munication of any toxicities identified.
 Ambulatory Setting
Although an inpatient care delivery model can be transitioned to an ambulatory model 
easily, an assessment is imperative to understand the model’s cost- effectiveness and 
efficiency while supporting high-quality care and positive patient outcomes. With the 
increased number of complex oncology patients transitioning to ambulatory care, 
highly skilled nurses’ requirements are as crucial as in the inpatient setting. Choosing 
the correct nursing care delivery model will need to include patient-centered care 
while considering the increased complexity of nursing care requirements, monitoring 
quality metrics and patient outcomes, and implementing cost-containment measures 
such as drug costs. No standard staffing model or nurse- to- patient ratio exists for 
ambulatory infusion or chemotherapy treatment and radiation centers [9].
With this fast-paced setting, including the rapid turnover of patients, experienced 
nurses may be preferred. Ambulatory settings should consider many variables when 
creating a staffing model, for example, the physical location assessment: freestand-
ing clinic versus attached to the hospital, types of service provided, hours of opera-
tion, patient population mix, and care needs. Acuity-based models should not be 
based solely on the patient’s time in the treatment center and consider the complex 
care being administered. Implementing supportive protocols such as electrolytes, 
blood supplementation, and fever workups allow nurses’ autonomy and immediate 
care delivery with minimal delay.
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 Oncology Role Outside of the Clinical Setting
With cancer care transitioning to the ambulatory setting, patients and caregivers 
have to manage symptoms and side effects of treatment in their home. Many of 
these patients travel from afar to receive cancer therapy. The nurse should serve as 
the first line of communication. From the referral process to end-of-life care, the 
patient and or/family should be able to contact an oncology nurse by phone during 
their entire continuum of care. By developing a triage support system, the patient 
will have consistent communication with their health care team, allow for emotional 
support, and identify any emergencies. A nursing care triage model can support 
various settings, including ambulatory clinics and outpatient infusion areas, sup-
porting increased patient satisfaction and positive patient outcomes. For example, 
for a patient calling with a fever, an evidence-based protocol with a physician order 
set embedded would reduce the time to receive antibiotics and potentially decrease 
a patient’s length of stay in the hospital. It is also essential to assess hours of opera-
tion and a need for 24-hour access.
With global technology increasing and patients traveling from afar, is there an 
opportunity, when able, to leverage telehealth for remote symptom management. 
For some remote geographic areas, telecommunication technology may allow 
nurses a vehicle to provide nursing care to patients in alternative care sites such as 
patient homes, shelters, and nursing homes. Nurses can provide numerous services 
in these areas, such as patient education, coordination of care, arranging appoint-
ments, and symptom management with physician resource support. Utilizing tele-
health and other types of remote technology, nursing can help eliminate barriers, 
time, and distance a patient may experience living in remote areas and assess as part 
of the care delivery model.
 Survivorship/Palliative Care and Hospice
As cancer survivors grow, nurses often play a pivotal role during the survivorship 
plan of care. Once a patient’s treatment regimen is completed, patients are often at 
a loss of managing their long-term side effects, emotional distress, and economic 
burden lacking the knowledge they can reach out to address these concerns. By 
providing specialized training for long-term oncology care, nurses can deliver guid-
ance, education, and appropriate referrals to address various issues. These real-life 
situations can help the cancer care community develop optimal care algorithms and 
identify the interprofessional team members for survivorship care delivery [10]. 
Depending on how far the patient may travel for cancer survivorship care, a tele-
health platform may benefit a particular institution.
Palliative care is necessary to support comprehensive cancer care. As the trend in 
healthcare moves from a fee-for-service model to a patient-centered, value-based 
model, the expectation is that an increase will occur in the integration of palliative 
J. Frith and N. J. Chao
61
care into comprehensive oncology care [11]. Nurses have learned to incorporate 
caregiver goals into the plan of care. A cancer diagnosis often results in distress in 
the physical, psychosocial, spiritual, and emotional domains of care. Today, pallia-
tive care nursing focuses on care delivery to individual patients and families, within 
specific disease populations, and palliative care issues within health care and soci-
ety as a whole entity. Proper training is essential to have the knowledge and skillset 
to address the numerous facets of cancer. The Hospice and Palliative Nursing 
Certification (CHPN) was developed in 1994 to support additional education and 
guidance in this field of nursing. Once the care nurse has a few years of experience, 
certification is recommended to support continued education in this field.
With the increased aging population in developed countries worldwide, patients 
may choose to have end-of-life care in various settings such as a hospital, outpatient 
facilities, or at home. Both new and seasoned oncology nurses need to be comfort-
able providing end-of-life nursing care. Training programs exist, End-of-Life 
Nursing Education Consortium (ELNEC), focusing on nursing education to deliver 
optimal end-of-life care to patients and their families [12]. Burnout is a significant 
concern for the oncology nurse delivering end-of-life care. To support resilience and 
sustain the workforce, oncology nurses need strategies on how to support these 
complex patients, their families, and themselves to be successful in delivering high- 
quality end-of-life care.
In conclusion, the care nurse plays a vital role in delivering oncology care, 
including administering multiple and complex treatment regimens. The coordina-
tion encompasses direct patient care, documentation in the medical record, partici-
pation in therapy, symptom management, organization of referrals to other 
healthcare providers, family and patient education, and diagnosis, therapy, and fol-
low- up. Providing continuous education and competencies to the care nurse, imple-
menting evidence-based practice, and identifying the appropriate nursing care 
delivery model will support quality care delivery in these complex environments.
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Chapter 8
Laboratory/Pathology Services and Blood 
Bank
Kathryn M. Fleming, Matthias Klammer, and Mickey B. C. Koh
Comprehensive cancer care (CCC) brings together clinical services, research and 
education for the benefit of cancer patients. The main input of laboratories and 
pathology services to CCC service is rapid access to high-quality diagnostics, which 
will be much of the focus of this chapter. In addition, the support of laboratories 
toward education, research and development is also essential to attain the status of 
world-class CCC, and this is reflected in the definition given by the National Cancer 
Institute [1].
Pivotal to all high-quality cancer care is the ability to achieve accurate and 
detailed diagnosis so as to enable prognostication and treatment strategies. This 
has increasingly moved from morphological and descriptive diagnostic tech-
niques to a molecular landscape where tumour genomes are interrogated for their 
tumour signatures. All of this sits within the purview of pathology and its 
laboratories.
The other essential role played by the laboratory/pathology services is the sup-
port of patients undergoing treatment and follow-up: delivery of safe blood, a stem 
cell processing lab, rapid analysis of blood samples, identification of infectious 
agents amongst a host of other functions.
World-leading CCC centres are not only international reference centres for 
patient care, their genomics research and access to large volume clinical material 
and data aim to embed personalised medicine as part of patient care, likely in inves-
tigational clinical trials [2–4]. The ability of laboratory and pathology services to 
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obtain, analyse and integrate ever-increasing amounts of complex information helps 
the modern cancer multidisciplinary team (MDT) to achieve this goal.
We have subdivided this chapter into the broad headings of what we consider to 
be the fundamental roles of pathology and laboratory service in the CCC as follows:
 1. Laboratory and pathology support for screening programs and arriving at a can-
cer diagnosis
 2. Laboratory and pathology support for maintaining quality supportive care 
throughout cancer treatment
 3. Specific pathology support for running stem cell transplant/cellular therapy pro-
grams and pathology support for running cancer clinical trials and research.
Relevant to all aspects of laboratory and pathology services in CCC is the 
requirement for accreditation or external review and control. Accreditation is 
public recognition by a healthcare body of the achievement of standards by a 
healthcare organization, demonstrated through an independent external peer 
assessment of that organization’s level of performance in relation to the stan-
dards. Accreditation standards may be regional or national, or they may be inter-
national and aim to define quality standards and achieve uniformity in a health 
system [5]. Whatever laboratory or pathology service you provide, this process is 
being used worldwide to ensure that results from labs are comparable, clinically 
useful and safe.
A CCC centre would be expected to drive the development of local, national or 
international evidence-based guidelines in an area of cancer care. The ability of a 
CCC centre’s laboratory and pathology service to access high-quality data, with 
high throughput of patient cases and samples would be best suited to this function. 
This is reflected in major world CCC centres’ laboratory involvement in national 
and international guidelines seen today, for example,
• Comprehensive Cancer Center Ulm, Ulm, Germany  – input into European 
Society of Medical Oncology (ESMO) guidelines in chronic myeloid leukaemia, 
chronic lymphocytic leukaemia and acute myeloid leukaemia [6–8].
• INCLIVA, University of Valencia, Spain – input into several ESMO guidelines 
including metastatic colorectal cancer, anal cancer, hereditary GI cancers, hepa-
tocellular cancer [9–12].
• Dana-Farber Cancer Institute, Boston, MA, US  – into ESMO guidelines for 
advanced breast cancer, but also many American Society of Clinical Oncology 
guidelines [13, 14].
Information management, maintaining of databases and storage of laboratory/ 
pathology data, as well as management of laboratory research data are also major 
considerations but will be not covered in this chapter. Most CCC centres have 
invested heavily and developed systems capable of dealing with vast data 
quantities.
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 Laboratory and Pathology Support for Screening Programs 
and Arriving at a Cancer Diagnosis
The input of laboratory/pathology services into the modern cancer MDT or “tumour 
board” contributes to the formation of a full “integrated” cancer diagnostic report. 
An integrated report at its most basic, from a lab/path perspective, needs cellular 
pathology and histopathology. However, CCC centres add immunohistochemistry, 
cytogenetics, molecular, genomic analysis and immunophenotyping (particularly in 
haemato-oncology) as key components of the integrated report, given that many 
diagnoses will not be complete or therapeutic options will not be fully explored 
without these techniques [15].
An MDT or “tumour board” will need to integrate all of the above information 
with clinical and radiological data, and it is in part the responsibility of laboratory 
and pathology services to achieve this. It is crucially this “integration” process that 
is the hallmark of CCC, and then “translating” the integrated report into excellent 
care and facilitating patient-centred research. Support and personal attendance of 
senior scientists, laboratory staff and pathologists is increasingly vital to the modern 
cancer MDT.
In addition to individual patient care, population-based cancer screening pro-
grams that may be linked to CCC centres will also depend on laboratory and pathol-
ogy support from cervical pap smear cytology to faecal occult testing to supporting 
research-based programs like UK-based 100,000 Genomes Project [16].
Cellular pathology and histopathology will require the capability for specimen 
fixation, embedding into paraffin, tissue slicing, and staining. The pathologists 
reporting of samples at CCC centres will frequently require subspecialty expertise 
or access to such expertise via international networks, especially for rare cancers. In 
many cases, this is facilitated by telepathology which may include sharing of 
selected static images, whole-slide scanning, dynamic non-robotic telemicroscopy, 
and dynamic robotic tele-microscopy. Selected static image sharing can be as sim-
ple as a microscope, digital camera, and Internet connection and has been success-
fully used in Butaro Cancer Center of Excellence in Rwanda, where a static-image 
telepathology system was established after a training period for field selection, in 
collaboration with the Dana-Farber/Brigham and Women’s Cancer Center [17, 18].
Immunohistochemistry (IHC) now provides important diagnostic and prognostic 
information as well as guiding therapeutic options for cancer care. IHC, the applica-
tion of antibody stains with a chromogenic or fluorescent readout to identify tumour 
markers, their quantity and location and interpretation of significance is nowadays 
ubiquitous. An important choice to be made is whether to carry out IHC on formalin- 
fixed, paraffin-embedded samples or on fresh frozen samples. Paraffin embedding 
offers superior tissue/cell morphology, but antigenicity is potentially compromised 
by the fixation required for paraffin-embedded samples. A CCC would require 
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access to facilities capable of freezing samples, storing samples and access to many 
antibody panels that often need refrigerated storage themselves [19, 20].
Cytogenetic studies, the study of chromosomal structure, or karyotyping was 
first utilised in cancer diagnostics in the 1960s with the discovery of the Philadelphia 
chromosome. Classical karyotyping or banding techniques (G-, Q-, R- banding) 
nowadays is a limited, but useful genome-wide screening tool. However, it requires 
a high mitotic index of cells, good chromosomal morphology and is time- consuming. 
The drive for rapid results and the ability to analyse preserved samples in interphase 
has pushed molecular cytogenetic techniques such as fluorescence in situ hybridisa-
tion (FISH), multicolour-FISH (M-FISH and SKY) and competitive genome 
hybridization (CGH) into the forefront of modern cancer diagnostics. The ability of 
the CCC centre to bridge basic research to clinical practice using these techniques 
has expanded rapidly in recent years. Access to reliable and specific marker probes 
and increasingly automated methods would help to facilitate expansion of testing 
capabilities in what has traditionally been a highly labour-intensive technique.
Molecular cytogenetic analysis is particularly useful in haematological and soft 
tissue tumours albeit historically less used in solid tumours due to a scarcity of spe-
cific associated cytogenetic abnormalities and difficulty in processing the sample 
for analysis. As more and more targetable tumour markers are identified, FISH stud-
ies are increasingly useful to identify upfront whether patients can be offered tar-
geted treatment. Some examples of solid tumour FISH use are: differential diagnosis 
between teratoid/rhabdoid and medulloblastoma/primitive neuroectodermal 
tumours and dual colour FISH for HER-2 in breast cancer as a prognostic marker 
and predictor or therapy response [21].
Genetic analysis of tumour and patient DNA in modern cancer care has been 
revolutionized with the recent advances of next-generation sequencing (NGS), 
hybridization capture targeted multigene panels and computational data analysis 
[22]. Discussing the various genome analysis techniques, their implementation and 
practical aspects are beyond the scope of this chapter; however, there are important 
principles to consider. Technical challenges related to the quantity and quality of 
tumour sample will have a direct impact on your ability to use genetic studies related 
to your laboratory’s knowledge and equipment. Sample preparation methodologies 
are crucial to maximising the chance of obtaining useful information from what 
may be a small, poor quality and formalin-fixed biopsy sample.
Most centres now run tumour-specific multi-gene panels which are “trade-off” 
between slow turnaround, labour-intensive genome-wide screening approaches and 
potentially low-yield single mutation screening with Sanger sequencing. A myeloid 
gene panel for suspected Acute Myeloid Leukaemia, for example, could contain 
>20 genes which are of high specificity and sensitivity for the disease and may 
directly alter prognosis and treatment options, for example, IDH mutations [23]. 
The decision as to the depth, breadth and methodology used in multi-gene panels 
will be very much centre-dependent, taking into consideration the throughput, turn-
around time, equipment, cost and skill set of your centre. Hereditary cancer 
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syndromes are a field of CCC that has greatly benefited from massively parallel 
sequencing, as most known familial cancer syndromes are represented by several 
distinct genes that may cause similar clinical manifestation. The ability to scrutinize 
many known or potential disease-causing mutations is very powerful [22]. For 
instance, in Lynch syndrome or Hereditary non-polyposis colorectal cancer  – a 
screen might involve NGS to identify MLH1, MSH2, MSH6, PMS2, or EPCAM 
mutations, then PCR-based microsatellite instability testing [24].
The post-genomic era has created vast quantities of data for CCC, which in most 
centres has spawned a “cancer genomics MDT”, a genomics review board (as in the 
UK) or “molecular tumour board” (as in US institutions like Brigham and Women’s 
Hospital) [25, 26]. The genetic complexity of cancer, the relevance of mutational 
changes and the application of multiple NGS-based assays create a challenge in the 
interpretation and clinical application of this data. Increasingly, this makes it neces-
sary for pathologists and molecular scientists to be core and essential members of 
the multidisciplinary team in deliberating the final clinical recommendation based 
on multiple complex test results [27, 28].
Other molecular studies for diagnosis and disease monitoring, such as tumour 
markers, immunological studies such as protein electrophoresis and high- 
performance liquid chromatography (HPLC) are discussed in the section “Laboratory 
and Pathology support for maintaining quality supportive cancer care”.
Immunophenotyping using flow cytometry (FCM) is extensively used in haemato- 
oncology but can also be ancillary to the diagnosis of metastatic adenocarcinoma 
and malignant mesothelioma in effusions. The limitations in haematological cell 
morphological analysis are vastly compensated for by this technique; it can be per-
formed in a matter of hours and provides key information for the diagnosis, classi-
fication and monitoring of many haematological malignancies. Single-cell 
suspensions of solid tumours and circulating tumour cells are being used and are 
likely to be of increasing clinical use as more research is developed. Panels of FCM 
markers are also used in the assessment of neuroblastomas, primitive neuroectoder-
mal tumours, Wilms’ tumour, rhabdomyosarcomas and germ cell tumours [29]. 
FCM can not only provide analytic data, but also be used as a cell sorting method to 
enrich cell populations for genetic studies. With the use of multi-colour FCM, labo-
ratory scientists and clinicians will both need to have an understanding of the diag-
nostic relevance and interpretation of results. It is of key importance that clinician 
and scientist are sharing information.
It is also important to mention that, although we have discussed cytogenetic, 
genetic and immunophenotypic analyses in the “diagnosis” section, all are of 
immense value in disease monitoring and monitoring of treatment response. With 
the concept of minimal/measurable residual disease (MRD) and the emerging 
knowledge that tumour genetic evolution can influence relapse and treatment failure 
risk, there is an increasing challenge to pathologists, geneticists and laboratory ser-
vices to standardise procedures, increase testing capacity and engage with clinicians 
throughout the patient’s treatment.
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 Laboratory and Pathology Support for Maintaining Quality 
Supportive Cancer Care
Microbiological services are essential in a CCC centre, as immunocompromised 
patients undergoing chemotherapy/immunotherapy often are highly vulnerable to 
infection. This includes suspected infections that may be rare or atypical, antimicro-
bial resistance monitoring, monitoring of therapeutic drug levels (e.g. gentamicin, 
vancomycin, voriconazole, ganciclovir) and translating microbiological research 
results into practice in cancer patients.
Prevention of infectious disease, such as screening of blood-borne virus expo-
sure prior to chemotherapy, will require serological study facilities, screening for 
Healthcare Associated Infections (HAI) potential, for example, MSRA and swab-
bing may also be required in large healthcare facilities. The treatment of infectious 
disease during chemotherapy will require the capability for blood and fluid bacterial 
and mycological culture, viral PCR capabilities (e.g. respiratory virus swab PCR) 
and senior microbiology input to interpret results and advise on therapy options.
Biochemistry and haematology laboratory services with capabilities specific to 
cancer care are vital in CCC. Coagulation studies, automated cell counting technol-
ogy and manual differential cell counting in blood and marrow samples, provided in 
haematology laboratory services are both diagnostic in their own capacity (for hae-
matological malignancy and bone marrow infiltration of other solid tumours) as 
well as supportive for all aspects of CCC. They allow monitoring myelosuppression 
during chemotherapy/radiotherapy, monitoring response to infectious disease, 
determining safety for cancer-related procedures (e.g. coagulation assays prior to 
surgical resection), as well as the facility to deal with complex problems of haemo-
stasis in cancer patients (e.g. complex venous thrombo-embolism, anti-Xa monitor-
ing, acquired haemophilia, etc).
Biochemistry support for CCC at its core entails electrolyte monitoring, surro-
gates for organ function or damage, for example, U&E, LFTs, BNP, protein-based 
and immunological assays for disease monitoring used in solid and liquid tumours, 
for example, prostate-specific antigen (PSA), cancer antigen 125 (CA-125), carci-
noembryonic antigen (CEA) and serum protein electrophoresis, serum free light 
chain analysis and HPLC (the latter specifically for diagnosis of phaeochromocy-
toma, neuroblastoma and carcinoid syndrome) [30, 31].
Blood bank and transfusion support: This includes the acquisition, storage and 
appropriate use of blood products. The laboratory infrastructure required for the 
storage of blood products and the information technology support used in electronic 
cross-matching, product storage tracking and monitoring fridge performance is con-
siderable, but necessary in large cancer centres particularly in those specializing in 
haemato-oncology. Laboratory support needs to be provided to clinicians to guide 
the appropriate use of blood products and to provide appropriate protocols for emer-
gency situations, such as massive haemorrhage. Laboratory support is required for 
the detection of complex auto-, allo- and drug-induced antibody presentations in the 
multiply transfused or treated patient (e.g. Daratumumab) and  management/
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investigation of transfusion reactions or product refractoriness. Access to irradiated 
blood products is crucial for many cancer patients for prevention of transfusion- 
associated Graft vs Host Disease as well as access to HLA/HPA-matched products 
in platelet refractory cases.
 Pathology Support for Running Stem Cell Transplant/
Cellular Therapies
Haematopoietic stem cell transplantation (HSCT) and cellular therapies (CAR-T) 
require many unique laboratory facilities. Broadly, we have subdivided these into:
 1. Biochemistry, microbiology and histopathology services
 2. Histocompatibility and immunogenetics (H&I)
 3. Apheresis and cell management
 4. Chimerism studies
 1. Monitoring of drug levels specific to stem cell transplantation monitoring such 
as ciclosporin and tacrolimus. Due to the highly immunosuppressive nature of 
stem cell transplantation, more intensive microbiological screening and monitor-
ing is required, such as regular CMV, EBV, and adenovirus viraemia screening 
(preferably by PCR testing), pre-transplant serology HIV, HTLV, viral hepatitis, 
syphilis, toxoplasmosis and other mandatory tests for communicable diseases. 
Histopathologists with expertise in identifying graft-versus-host disease (GvHD) 
from biopsy samples are required to support a haematopoietic stem cell trans-
plant service. HSCT and CAR-T centres must have a 24-hour on-site blood 
bank, haematology and biochemistry laboratory services and access to stem cell 
collection and processing facilities.
 2. Apheresis is the most commonly used technique for stem cell collection requir-
ing staff with both clinical and laboratory training in the use of this procedure. 
CCCs will need access to facilities for storage and cryopreservation of haemato-
poietic cells from a variety of sources. Close coordination with apheresis units is 
required to ensure adequate CD34+ cell doses from stem cell collections. 
Furthermore, HSCT centres require the preparation of T cell therapeutic (TC-T) 
aliquots (formerly called donor lymphocytes infusions or DLI) in measured CD3 
doses. Quality assurance methodologies by validated procedures will be neces-
sary such as the use of microbiological tests to assure the suitability of donors 
and the safety of products. The use of flow-cytometric and/or tissue culture assay 
systems to demonstrate progenitor viability and process suitability is mandatory 
[32–34].
 3. Histocompatibility & Immunogenetics (H&I) services in support of cancer care 
are mostly involved with HLA typing and antibody screening which is manda-
tory for all allogeneic transplant centres. However, H&I is also important for 
other ancillary services with respect to cancer such as screening for 
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 heparin- induced thrombocytopenia, HLA-polymorphism testing (for lapatinib-
induced DILI in breast cancer) and the diagnosis of platelets refractoriness 
(using PIFT and MAIPA studies). In recent years, accredited H&I laboratory 
facilities perform timely DNA-based intermediate and high-resolution HLA typ-
ing via a form of sequence specific priming, or NGS. The H&I lab will allow 
clinician access to bone marrow registries to facilitate access to matched unre-
lated donors and cord blood registries [32, 35].
 4. Recent advances and understanding in cellular immunotherapy as a major thera-
peutic pillar in cancer treatment, especially, haemato-oncology has increased the 
reliance on and interdependency of the stem cell processing laboratory and more 
advanced Good Manufacturing Practices (cGMP) cell therapy facilities, often 
under the management of pathology. This will require expert staff individuals 
trained in the manufacture of complex cell therapy therapeutic products [35]. 
The area of chimeric antigen receptor T-cell therapy (CAR-T) is an example of 
this with numerous worldwide clinical trials and with the cell therapy laboratory 
requiring access to apheresis, bespoke CAR-T manufacture requiring viral vec-
tors, genetic modification, packaging, systems for T cell expansion and vapour 
liquid phase nitrogen storage [44].
 Pathology Support for Running Cancer Clinical Trials 
and Research
Laboratories and pathology services are integral to the running of clinical trials and 
biomedical cancer research. Development and discovery of genetic/biomarkers of 
disease (or disease classification and prognostic stratification), drug development, 
nanotechnology, cellular therapy development, gene therapy are a few broad exam-
ples. Education and training of academics, clinicians and laboratory staff is at the 
forefront of comprehensive cancer care, and this includes both standard-of-care 
clinical practice and investigational clinical trials supported by ethical guidance at 
national and international level (e.g. FDA Good Laboratory practice (US), EU clini-
cal trials, Good Clinical Practice, the Declaration of Helsinki and the Human Tissue 
Act (UK)) [36].
From a laboratory perspective, apart from the above-mentioned facilities (high- 
quality diagnostic techniques, monitoring of biochemistry and haematology lab 
support), clinical drug trials may need the facilities to synthesize and purify new 
compounds, assess drug pharmacokinetics and pharmacodynamics in cell, animal 
or human subject samples. Laboratory involvement can be from drug discovery and 
development right through to post-market safety monitoring.
Biobanks, with respect to cancer care, are the storage of large numbers of bio-
logical samples for use in research – ranging from tumour tissue samples, genetic 
material and drug levels or biomarkers from serum, saliva, stool, etc. Biobanks are 
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often utilized by major CCC research centres, giving research teams rapid access to 
vast quantities of samples spanning a long time period [37–40]. Although biobanks 
are often disease-oriented, for example lung cancer, they may be population-based 
to determine susceptibility of disease development.
Laboratory support in biobanking will require secure, well-maintained, long- 
term cryogenic storage facilities (with temperature control documentation and 
backup systems in case of power failure), and sample tracking capabilities. 
Traceability is critical and the strict adherence to protocols ensuring appropriate 
patient informed consent. Standard operating procedures for laboratory sample han-
dling and processing are also highly desirable for reproducibility and data reliabil-
ity. Such biobanking facilities are often required to comply with stringent operating 
policies and meticulous laboratory support in order to gain a human tissue act 
license [41]. To this end, many international groups have written “best practice 
guidelines” for example, International Society for Biological and Environmental 
Repositories (ISBER) and NCI Best Practices for Biospecimen Resources. They 
have also tried to address the ethical concerns that often surround biobanks such as 
ownership of specimens and the extent as to which specimen donor can consent to 
all forms of future research [42, 43]..
In conclusion, pathology and its laboratories are central in supporting every facet 
of cancer care in a CCC center, from diagnosis, biobanking, patient support during 
treatment, research, therapeutic drug manufacture and development. The ability to 
support all of this will always need to be balanced against time and costs. As such, 
any strategic planning for the setting up of a CCC center should allow for careful 
deliberation and meticulous planning on the scope and breadth of pathology ser-
vices to be set up.
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Healthcare is experiencing significant challenges in recent years. The aging popula-
tion and increasing prevalence of chronic diseases have led to increase in demand 
and complexity of medication regimens requiring major changes in the way cancer 
care is delivered. In addition, care providers face a consumer and patient base that 
is better informed and educated, technologically savvier with ready access to infor-
mation through social networking and the Internet of things. Compounding these 
are rising healthcare costs, lack of hospital and long-term care beds, and healthcare 
manpower shortages.
In the face of a healthcare environment that is constantly changing, pharmacy in 
a comprehensive cancer center needs to be cognizant of new and emerging models 
of care that are integrated and patient-centered, attentive to cutting-edge research, 
cancer treatment, and different approaches to managing the entire spectrum of 
oncological care. To support the functions of a comprehensive cancer center, phar-
macy services need to focus on delivering care that is timely and convenient, afford-
able, financially sustainable, and quality assured.
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The prerequisites to transformation from a brick-and-mortar pharmacy model to 
a progressive pharmacy is guided by the perspectives of (1) investing in people to 
attract and retain the best, (2) investing in place to build a future-ready facility, (3) 
investing in process to create greater value for patients, and producing safe and 
quality products.
The COVID-19 pandemic has brought numerous challenges to the healthcare 
system. At the same time, it serves as a timely reminder of the importance of pan-
demic preparedness, not only to support safe and quality use of medicine but ensur-
ing the availability of medicines for patients where and when they need it, as well 
as the safety and ability of staff to continue to function and respond to disruptions 
while ensuring the continuity of care for patients.
 Investing in People
At the heart of transformation and provision for comprehensive care is a competent 
healthcare workforce. Pharmacists, as medication experts, are accountable and 
responsible for promoting safe and effective medication use. As complex cancer 
care issues continue to demand a multidisciplinary approach, oncology-trained 
pharmacist is a vital member of the collaborative care team to improve treatment 
outcomes. The pharmacy department manpower planning needs to move in tandem 
with prevailing and future cancer care model. It is imperative that the plan takes into 
consideration a transdisciplinary, shared decision-making practice model as phar-
macists expand scope of practice.
Key considerations important to attract and retain a competent pharmacy work-
force (pharmacists and pharmacy support staff) include the following:
 (a) A career structure for progression and advancement framework
Enhancing professional development and competency of existing pharmacy 
workforce and attracting high potential recruit is a win-win for both employees 
and employers. In addition to clinical practice track, inclusion of researcher and 
educator tracks will aid in developing a pool of pharmacists with matrix career 
tracks such as clinician-researcher and clinician-educator.
 (b) A competency framework to complement the implementation of proposed career 
pathways
Taking reference from national, professional and regulatory bodies, the com-
petency framework enables pharmacy workforce to reflect on their practice, 
identify needs for continuous professional development and acquires new com-
petencies to advance their practice systematically.
A common enabler for workforce transformation in addition to training and 
development includes but not limited to identifying meaning and purpose, staff 
engagement, building trust, communication and creating opportunities.
 (c) Manpower and workforce optimization for effective number and skill mix to 
deliver comprehensive and safe cancer care
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When planning, it is important to consider activity level, service demand and 
variation, patient acuity, staffing norms, staff experience, organisational service 
and quality indicators and consistency with published best practices.
Pharmacy technicians form an important part of the pharmacy support work-
force. The roles of pharmacy technicians have shifted from picking, packing, 
dispensing and inventory to support niche areas like medication review, medi-
cation administration, information technology support (automation, data ana-
lytics), clinical trial drug management and tele-pharmacy. A competency 
framework from entry to advanced practice would be instrumental to provide a 
structured approach towards development of this workforce in terms of prac-
tice, clinical and task specialization.
 (d) Staff benefits and recognitions
This can come in the form of training grants and scholarships to fund for 
further studies and residency training, or competitive staff remuneration pack-
age that recognizes high potential and performing individuals.
 Investing in Place
Oncology pharmacy services in a comprehensive cancer facility go above and 
beyond needs to build a future-ready facility. Proper space planning for a pharmacy 
facility can ensure configurable space when the need arises. COVID-19 pandemic 
has brought about the creative use of space amidst social distancing requirements. 
Wherever possible, space reconfigurability, mapping of patient journey, equipment 
and material flow and processes must be well thought out to ensure workplace con-
tinues to support job to be carried out in the most efficient manner.
Key considerations for a future-ready pharmacy in a comprehensive cancer cen-
ter include the following:
 (a) Adopting technology
Harnessing new technology such as automation, robotic, and RFID tech-
nologies to ensure a highly efficient and accurate medication dispensing pro-
cess has enabled pharmacy workforce to deliver more valued direct patient care 
activities. The use of automation and robotics requires careful planning, ensur-
ing workflow marries the capabilities of robotics to seek the best outcome of 
safety and efficiency for the pharmacy. With the increasing complexity in medi-
cation regimes, and array of decision-making tools available, it is crucial to 
ensure that these tools fit into the overall information technology workflow so 
that these systems fulfill the purported benefits.
The use of artificial intelligence (AI) can inform patient load and flow, 
thereby allowing workforce planning and optimization. On the clinical front, 
use of AI to predict patient response or adverse reactions to a drug is not a far- 
off reality. Pharmacies must be ready to embrace the wealth of data and turn 
them into meaningful information to inform practice.
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 (b) Good Manufacturing Practice (GMP)
Sterile compounding is an integral component of a cancer center pharmacy. 
Quality assurance and control is paramount to ensure that cancer patients 
receive the right drug in the right dose, at the right time and with right vehicle 
and container. GMP in the pharmacy laboratory accords patients and providers 
of sterile compounded products a seal of quality assurance. Fatal incidents have 
been reported worldwide (e.g. lack of vigilant decision-making process and 
anticipatory models with programs to prevent errors, disaster and crisis in the 
New England Compounding Centre leading to fatalities from meningitis from 
tainted sterile products) [1]. The hub-and-spoke model for sterile compounding 
in Singapore leveraged on the principles of quality assurance and efficiency to 
provide the nation with cost-effective and quality sterile products [2]. It is of 
tactical importance that a comprehensive cancer center pharmacy laboratory 
becomes a GMP-certified hub.
 (c) Business continuity planning (BCP)
Identifying risks that has high impact on the business operations is the initial 
step in formulating the BCP plan. Critical operations and functions that need to 
be continued are then identified and prioritized [3] . Communicating the plan to 
key stakeholders is important. A BCP plan once developed and implemented 
needs to be maintained. Constant drills and refinement should be in place to 
keep up with the changes in practice.
 Investing in Process and New Models of Care
Processes bring people and place together. The aim of achieving optimum process 
in pharmacy is to deliver seamless integration of pharmacy services into the patient’s 
cancer journey. Pharmacy needs to lead in the medication management process. 
Organizations with foresight, agility, and resilience recognize the need to continu-
ally improve their processes to meet the needs of the changing healthcare landscape 
and their patients. Research forms the backbone of a comprehensive cancer center. 
Pharmacy involvement in the new models of care needs to embrace bench to bed-
side research, including novel therapies (drugs, biologics, and medical devices) and 
survivorship. The latter is of increasing focus as screening and treatment modalities 
sees shifting demographics and increased cure options.
Key considerations in process management and improvement include:
 (a) Medication use and procurement
A good medication management system supports appropriate and judicious 
use of drugs. Rapid reviews using health technology assessment methodologies 
are useful tools for presenting evidence-based reviews and expert opinion for 
decision making. Drug utilization evaluation that assesses the appropriateness of 
drug use can provide timely feedback and presents evidence for rectification.
L. Chew and M. C. M. Thum
79
To help facilitate the safe, effective, and timely administration of innovative 
therapies to cancer patients, it will be important for pharmacy to collaborate 
with clinicians, researchers, educators, and administrators to develop policy 
and procedure pertaining to approval for access, evidence-based guidance, 
work instructions, and educational materials for these therapeutics.
Procurement becomes more complicated as cancer care becomes increas-
ingly more individualized and complex with precision medicine and novel 
treatments, including but not limited to CAR T-cell therapy, novel immuno-
therapies, and gene targeting approaches.
Similarly, for access to generic drugs and biosimilars, pharmaceutical pro-
curement expertise is needed to ensure timely and relevant input into procure-
ment of generic drugs and biosimilar choices. Fulfilment of contracts, 
negotiation, and lock-in of preferential drug pricing are other important func-
tions of procurement.
 (b) Medication supply
From the ordering to administration of medications, numerous processes are 
involved before medication is supplied. These processes must be engineered 
and constantly reviewed to ensure effective communication between all parties 
involved. Strict standards should be set for ordering, preparing, dispensing, 
administration, handling, and storage of chemotherapy to ensure all important 
elements are addressed [4].
Presently, home delivery of oral chemotherapy drugs presents an attractive 
option for patients’ convenience, avoids overcrowding in pharmacies, and facil-
itates round-the-clock access. Patients can wait in the comfort of their homes/
offices where the medications will be delivered. Other supply alternatives 
include express pickup at designated dispensing sites and secure lockers for 
patients who do not want home delivery option.
 (c) Administration
There has been increasing focus on delivering care that is centered on the 
needs and preferences of patients, administered in the most clinically appropri-
ate and convenient settings for patients. Home and community administration 
of chemotherapy have been made possible with the availability of subcutaneous 
dosage forms and smart ambulatory infusion devices. A clear set of service 
guidance and criteria involving multi-stakeholders, including but not limited to 
clinicians, nursing, clinic operation and business office, need to be established 
for pharmacy to support the care model.
 (d) Monitoring
With mobile applications that supports tele-consult, patient-reported out-
comes and patient-reported experience, oncology pharmacists can help patients 
to achieve better medication adherence and monitoring of adverse effects aris-
ing from treatment. Research looking at mobile application-based monitoring 
and intervention, and factors that affect oral chemotherapy adherence, can help 
to improve medication use process for cancer patients [5].
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 (e) Community partnership for cancer education and survivorship
Pharmacy can support patient and caregiver engagement through develop-
ment of online patient information leaflets, patient counselling, medication 
therapy management clinics, tele-pharmacy, and public education seminars.
According to the National Cancer Institute, survivorship starts from the time 
of diagnosis to the end of life, focusing on the health and well-being of a person 
with cancer including the physical, mental, emotional, social and financial 
effects of cancer [6]. Pharmacy can support survivorship initiatives through 
patient education, pharmacy and nurse-led survivorship programs or clinics, as 
well as partnering with community pharmacies to support the physical effects 
of cancer such as nutrition, prosthesis, stoma and dressing supplies.
 (f) Resource optimization
Pharmacy must work within allocated resources to achieve desired out-
comes. Through utilization of visual stream mapping and data analytics to 
guide day-to-day activities and its variation, for example in chemotherapy 
scheduling, staff rostering, and medication fulfilment, pharmacy will have the 
capability to balance and optimize available resources with service demand.
 (g) Quality improvement
Continuous quality improvement must be embedded into the culture of a 
future-proof pharmacy. Process improvements can range from small changes in 
workflow to improve efficiency, to impacting patients’ experience in the cancer 
care journey. Embracing the concept of Kaizen is a good start. It involves apply-
ing ‘process-oriented thinking’, ‘plan-do-study-check-act’ and ‘standardize- 
do- check-act cycles’ approaches, speaking with data, embracing quality-first 
and focusing on the customer [7]. New processes are also subjected to failure 
mode effect analysis to identify risk and develop mitigation strategies. Investing 
in process improvement requires a proactive and concerted effort by staff at all 
levels. It is important to raise issues promptly and seek timely support for 
resolution.
 Building a Sustainable Pharmacy
From terrorist attacks and cyber threats to hurricane, riots, and pandemic, disrupters 
abound. Technological disrupters such as the Internet, social media, and AI are also 
changing the fabric of society. While future events may not take same form, they 
will require a deliberate effort from organization to navigate with agility and 
effectively.
Key considerations in building a sustainable pharmacy include:
 (a) Self-sustainability
The pandemic has highlighted the importance of diverse supply chains. 
Establishing emergency drug formularies and resolving drug shortages has 
become a priority in these times. Strong collaborations with the governmental 
L. Chew and M. C. M. Thum
81
agencies and establishing networks to ensure adequacy of essential medications 
must complement rational stockpiling and stock rotation to achieve national 
drug supply objectives. Methods of drug savings through centralized com-
pounding can and should be explored.
Pharmacy ought to support different models of care and work together with 
other care providers to provide remote pharmacy services through telemedicine 
and home delivery when the need arises. Empowering patients for self-care and 
flagging issues to pharmacists and healthcare professionals allows patients to 
be more involved in their own care, allowing healthcare professionals’ limited 
resources to be used in the most value-added tasks.
Staff well-being, as well as education and training, plays an important role 
towards self-sustenance. Staff must now cope with disruptions brought about 
by technological advances as well as new working norms brought about by 
pandemic. Mental health and staff well-being are thus integral factors to build a 
sustainable workforce. The pandemic has also changed the delivery of educa-
tion, and training and new modalities must be explored to ensure staff are 
upskilled and remain relevant and always ready.
Societal changes and demographic shifts necessitate the adoption of technol-
ogy, including mobile applications, AI-enabled medication support, robotics, 
and automation, to sustain pharmacy services and delivery of pharmaceutical 
care in peace time and during disruption.
 (b) Environmental sustainability
Interventions for a greener pharmacy include the adoption of a wide array of 
environmentally friendly activities ranging from facility to practice. Energy- 
saving ventilation, water, and lighting practices should be encouraged in the 
facility. The energy consumption of equipment and automation should form 
part of the evaluation criteria in the procurement process. Proactive scheduling 
of replacement of older equipment with newer and energy-saving ones should 
form part of the equipment management process. Pharmacy must strive to 
encourage recycling, reduce the use of paper through adoption of electronic 
systems, and decrease reliance on plastics. This will save running costs in the 
long term and decrease the carbon footprint from these day-to-day activities.
On the practice front, interventions include reducing imprudent prescribing, 
which can result in stockpiling, improper storage, and irresponsible disposal 
with the consequences of poisonings, pollution, and wasted healthcare resources 
[8]. Patient education becomes important to prevent adherence problems aris-
ing from lack of understanding of drugs and their side effects and thus wastage 
of medications. Stockpiling of medications at home should be discouraged 
through medication reviews and counselling.
Patient education on proper medication disposal, in particular, cancer and 
targeted therapies, should be part of the patient journey. Pain medications like 
fentanyl patches can also lead to issues of drug abuse and harm through inad-
vertent exposure if not disposed properly. Pharmacists are in the prime position 
to provide advice on the proper handling and disposal of these medications as 
well as to provide support for proper disposal.
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 (c) Financial sustainability
It is challenging to achieve the right balance across the key priorities of effi-
ciency, safety, quality, accessibility and affordability. To achieve efficiency, 
safety and quality, pharmacy needs to invest more resources and inject technol-
ogy in the overall medication management and use. To make accessible innova-
tive and novel therapeutics to patients, pharmacy needs to have sufficient drug 
budget to procure, while affordability remains questionable depending on who 
is paying for the costs of treatments. Therefore, an important consideration that 
underpins these priorities is financial sustainability.
Health technology assessment is an important capability to have, grow and 
apply in pharmacy, so that new treatments, technologies, and drugs can be eval-
uated, and judicious decision can be made for availability and access. Given the 
rapid medical advances, this can help to avoid unnecessary expenditure on new 
and unproven, or less effective treatment.
 Conclusion
Pharmacy in a comprehensive cancer center must be geared to provide comprehen-
sive pharmacy services to a diverse population of cancer patients. The pharmacy 
workforce consisting of oncology specialty trained pharmacists, generalist pharma-
cists, pharmacy technicians, administrators, and other support personnel is compe-
tent and committed to clinical excellence, continuous process improvement, and 
innovation in pharmacy practice.
Investment in a modernized pharmacy will lead to improve safety, efficiency, and 
effectiveness in medication management, distribution, handling of hazardous drugs, 
and advancement in practice model.
Given the likely increase in demand for cancer care, new therapeutics and the 
complexity of cancer treatment, it is apparent that high-quality care for cancer patients 
will require an end-to-end medication use process that is robust and cost- effective, 
while also helping patients access pharmaceutical care when and where is needed.
Building to last should be the long-term strategic view for a sustainable phar-
macy practice model. The need to be nimble and responsive to changes, recognize 
the need to be innovative and develop new solutions, being eco-conscious and pru-
dence in spending are key ingredients toward better, faster, safer, and enduring phar-
macy for the patients we serve.
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The capacity to develop a comprehensive cancer center varies with available 
resources such as human capital (providers, nurses, staff), facilities and equipment, 
and most importantly financial funding. The availability of such resources will dic-
tate the services that can be provided. Sources of funding vary widely and can 
include national and subnational government funding; private user payments, either 
through health insurance or out of pocket, revenue-generating practices such as 
retail and parking, and philanthropic support from external donors. Strategic plan-
ning allows for a proactive approach in determining what populations can be served, 
what services can be delivered, the funding needs to grow the center, and develop-
ing and directing a short- and long-term business plan for expansion, implementa-
tion, and sustainability.
The long-term financial health of a cancer center ultimately determines its ability 
to effectively deliver quality cancer care services. Thus, another key component in 
strategic planning is the ability to understand the market intelligence and the ability 
to change as market conditions change. Changes in market conditions include changes 
in governmental funding; changes in private payer policies and practices; pricing 
changes for medical supplies, equipment, and personnel; and even scientific develop-
ment and the subsequent delivery of new cancer treatments. The impact of such 
changes needs to then be evaluated within the context of the socio-demographics and 
health needs of the patient population that the cancer center is looking to serve. 
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Effective planning and understanding of the culminating effect of these various fac-
tors will enable a cancer center to grow strategically in a manner that is fiscally 
responsible and positions it well for sustainability.
 Space and Facilities Planning and Program Development
Strategic planning eventually transforms into program development and the opera-
tional execution of such plans to enable safe, quality, and efficient patient care. 
Administrative personnel are often responsible for the design of physical spaces as 
well as design of workflows and processes to move patients through the various 
steps in their care. If the strategic planning team can identify the volume of the 
patient population that needs to be served, then the administrative team can plan the 
type and number of resources needed to provide comprehensive cancer care:
• Number of inpatient beds
• Number of outpatient exam rooms
• Number of surgical suites
• Number of infusion chairs for outpatient treatment
• Number of radiation therapy machines
• Number of imaging machines
• Number of lab draw stations
• Number of waiting room chairs
• Number of parking spaces
• Time it takes for lab results
• Time it takes for chemotherapy to be prepared
• Time it takes for an inpatient bed to be turned
• Time it takes for an outpatient exam room to be turned
• Time it takes for a patient to enter/exit the cancer center (cycle time)
Coupled with human resource planning, such space planning is necessary to 
ensure that your cancer center facility is designed and built to efficiently manage the 
patient demand.
 Financial Management
All cancer centers need administrative support and competent financial systems to 
monitor and manage revenues and expenses of the centers. Centers need competent 
financial and accounting systems that measure the collective productivity of the cen-
ter – the units of service being administered, the number of patient visits, etc., and 
the relationship of expenses to incoming revenue for the delivery of such services.
Healthy revenue management and enhancement is maintained by instituting and 
improving policies and processes to assure all clinical services are billed accurately 
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and timely, and that collections are pursued promptly and accurately. Retrospective 
analysis of charge capture, denial reasons, and reimbursement patterns can result in 
recommended actions to optimize the revenue return. Such action could include 
developing guidelines, providing feedback, and educating providers and staff on bill-
ing processes and practices that accurately reflect the level of service being delivered 
and that maximize the financial return for such service or even the movement or ser-
vices to a lower cost setting or delivery of new services that may have more long-term 
reduction in health-care expense – all of which is also a factor of strategic planning.
 Budgeting
Administrative support is also needed for the management of expenses – budgeting 
of personnel and non-personnel expenses for operating purposes and how they 
relate to anticipated patient volumes and revenue expectations. Capital budgets are 
needed for the planning of financial reserves for the larger capital purchases such as 
equipment, furniture, and maintenance, acquisition, or construction of facilities.
There may be instances where the patient revenue stream from private payers, 
governmental payers, or self-pay patients does not cover all the expenses necessary 
to deliver the needed health-care services. If such is the case, then alternative sources 
of revenue should be sought such as grants or philanthropic support from financial 
donors or even a form of subsidization from the larger institution or health system. 
In all cases, obtaining of such financial support typically requires the development 
of a business plan that explains to the investor(s) the mission of the cancer center, 
the long-term goal it aims to accomplish, and the level of investment and support 
needed to carry out such mission. Effective management of sponsored funds and 
philanthropic support require an additional level of accountability in complying and 
adhering the spending as per the conditions of the sponsor or donor.
 Performance Management
A growing concern today is the overall cost of health care. There are changes occur-
ring today to improve the “value” of health care begging to ask the question of “am I 
getting the best quality care at the best price?” A comprehensive cancer center needs 
an administrative infrastructure to measure the overall performance of the center – in 
quality and outcomes, patient volumes, patient satisfaction, workforce satisfaction, 
and financial performance. It is important to be able to measure quality outcomes in 
both acute and long-term setting. Acute quality measures for cancer hospitals typically 
include infection rates, length of stay, readmission rates, and mortality rates. Acute 
quality measures in the ambulatory setting are a bit more limited and are typically 
measured more by operational measures such as patient satisfaction (were the needs of 
the patient met?) and cycle time (measure of throughput for time the patient spends at 
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cancer center and its various services). Overall, the healthcare industry is moving 
towards improved measures that measure overall health over the patient’s care con-
tinuum vs measuring episodic moments such as outpatient visits and hospital stays on 
an individual basis. This level of value-based care will require enhanced collaborations 
across various specialties beyond hematology/oncology to address the adverse health 
impacts that may come with the delivery of cancer treatments (cardio or neuro toxici-
ties, for instance) as well as primary care in the survivorship setting, and marriage and 
family therapy to address the psychosocial and mental health impacts that come with 
cancer care. In this ever- changing market, administrative support is needed to be able 
to report on such performance outcomes so that centers can gauge their effectiveness 
and efficiency in the delivery of care and make internal adjustments as needed.
 Regulatory and Accreditation Standards
Yet another component of performance management is the evaluation of the health-
care provider’s ability to provide safe and effective care of the highest quality and 
value per the standards of regulatory and accreditation agencies. Specially trained 
administrative support with regulatory knowledge is needed in a comprehensive can-
cer center to ensure compliance to regulatory and accreditation standards that are 
required for the provision of clinical services. Such accreditations can range from 
overall delivery, quality, and environment of health care – in the USA for instance, the 
Joint Commission on Accreditation of Healthcare Organizations (JCAHO) is respon-
sible for the accreditation of all healthcare organizations. However, cancer services 
may also require more specialized accreditations for services such as chemotherapy, 
radiation therapy, clinical laboratories, and transplantation and cellular therapy.
 Human Resources Management
• Refining and developing the administrative structure that provides the necessary 
level of support services for the sustainable growth and success of the center
• Understanding and appropriately implementing the varied policies and proce-
dures for providers and staff
• Generally overseeing personnel actions for providers and staff such as recruit-
ment, selecting and hiring, training, performance management, promotions, suc-
cession planning, and terminations
 Access Services
A core administrative service of any comprehensive cancer center is the access 
function – the intake or management of new patients into the cancer center via self- 
referrals or physician referrals. Referrals can come in from a variety of 
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sources – telephone, fax, or internal via the electronic medical record system. Key 
administrative components of an access team include:
• Utilization of scheduling questionnaires/algorithms to appropriately tri-
age patient
• Insurance verification
• Medical record collection
• Referral management (inbound and outbound)
 Scheduling Questionnaires
Scheduling questionnaires ought to be developed to guide the scheduler through a 
series of questions designed to assign the patient to the right provider at the right 
time for an appropriate diagnosis. For example:
 1. What is the reason for your call or visit? Is this a new diagnosis, existing diagno-
sis, a relapse or refractory diagnosis, a second opinion, or establishment of long- 
term follow-up care?
 2. For solid tumors, do you need to see a medical oncologist, surgical oncologist, 
radiation oncologist, or all three?
 3. For blood cancers, do you need to see a hematologist/oncologist or do you need 
to see a stem cell transplant specialist?
The patient or referring physician’s office personnel may not always fully under-
stand what services they are in need of given their unfamiliarity with the disease. In 
such cases, scheduling questionnaires can help guide schedulers through the appro-
priate questions to determine what services may be needed next. For example, does 
the patient have a definitive diagnosis from a pathology record? If not, has the 
patient been scheduled for a surgical biopsy to obtain a specimen for pathology to 
analyze and diagnose? Based on the information gathered, the scheduler utilizes the 
scheduling questionnaire and a diagnosis algorithm to assign them to an appropri-
ate oncologist for that condition. Given the rapid and escalating potential of a can-
cer diagnosis, every effort should be made to have a patient seen timely; a goal of 
many comprehensive cancer centers is to offer patients an appointment in as soon 
as 72 hours or 7 days or less is another common goal. Some more chronic condi-
tions can wait to be seen a bit further out, that is, a few weeks out. The challenge 
there is managing the anxiety that often comes with a patient waiting to understand 
their new condition and eager to learn what is next. Some cancer access teams uti-
lize a nurse or patient navigator to help review the patient’s medical records to 
ensure if they can in fact wait to be seen, but a nurse in such role can help a patient 
waiting to be seen understand their condition and help them navigate what is often 




 Insurance Verification and Medical Record Collection
Depending on the financial clearance policies of your cancer center, protocols may 
need to be established to ensure that new patients have a financial plan to pay for their 
cancer services, whether that be through self-pay or through insurance. Uninsured or 
underinsured patients may need another mitigation strategy such as referral to another 
center that accepts their insurance, financial assistance from the center, or assistance 
in applying for governmental or foundational support for their care. Though not com-
mon, there could also be the scenario of a patient needing immediate emergency or 
urgent care – in such cases, the goal is to provide the appropriate clinical services to 
stabilize the patient while other financial options continue to be explored.
Assuming the patient meets the financial and medical clearance to be seen by the 
oncology team, various medical records are collected from the referring provider 
office and other medical offices that may have participated in the patient’s care over 
the years. The goal of such record collection is to ensure that the oncologist has as 
much comprehensive clinical information. Medical records that may or may not 
need to be collected in advance of the patient visit include:
• Physician notes
• History and physical




• Imaging results (CT/MRI/PET/US)
• Screening results (mammography, colonoscopy, PAP smear)
• Chemotherapy flow sheets (hospital and clinic)




Comprehensive cancer centers are becoming increasingly aware that access services 
are maturing from just scheduling to more enhanced referral management. Referral 
management is defined as the process by which patients are transitioned to the next 
step in their care. Normally, referral management takes place when a condition changes 
for the patient, thus necessitating a referral to a specialist but there are various cases in 
which care may also be appropriate to transition out or be shared, for example:
• Patients who are in remission and can be transitioned to a survivorship program 
or care with their primary care physician
• Patients who can receive part of most of their oncologic care closer to home
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• Patients with complex conditions who may require various specialties in addition 
to hematology/oncology, that is, cardiology, neurology, rheumatology, 
endocrinology
The plan for when to make those transitions of care is planned by the oncologist, but 
a strong, clerical administrative group is essential in making these transitions back and 
forth across various care settings – it can often be a high-volume, busy function requir-
ing the ability to multi-task and be organized in managing the various patients being 
referring in and out. This necessitates a key customer service ingredient – relationship 
management – the cancer center’s access and scheduling teams are often the first and 
the lifeline connecting the various medical offices, and thus it is critical to ensure 
smooth and efficient processes so as not to delay care. As more options present for 
cancer care, a strong referral base may choose to refer their patients elsewhere when 
cancer centers have processes and policies that make it difficult for patients to access.
 Conclusion
In summary, a solid administrative infrastructure is necessary for a comprehensive 
cancer center to efficiently and effectively deliver cancer care. From intake/access 
functions to high-level strategic planning for the future, such administrative func-
tions are needed to keep the cancer center solvent and well positioned to meet the 
needs of our cancer patients.
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Chapter 11




As the number of cancer survivors continues to increase due to a rising cancer inci-
dence, better treatment, and early detection, there is a growing need for comprehen-
sive psychosocial and supportive care at comprehensive cancer centers. Based on 
cancer incidence and survival statistics in the United States, the number of cancer 
survivors will increase to 20 million by 2026 [1]. Supportive care services not only 
benefit patients who are cured or have achieved long-term remission, but also those 
living with metastatic disease. However, despite current guidelines on survivorship 
care, many recommendations have not been uniformly implemented across cancer 
centers. For example, in a survey conducted by the American Psychological 
Oncology Society [APOS], approximately half of the clinical cancer centers did not 
offer routine psychosocial screening for new cancer patients [2]. The Institute of 
Medicine [IOM] has also framed several key recommendations to ensure that can-
cer survivors are not lost in transition after completing active treatment [3]. Hence, 
strategically addressing both psychosocial and physical effects in cancer survivors 
should be an important treatment goal that needs to be uniformly addressed by com-
prehensive cancer centers [4]. In this chapter, we will discuss the key psychosocial 
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and supportive care services that are required as a part of survivorship programs at 
comprehensive cancer centers. We will discuss the services required for managing 
common psychosocial and physical effects experienced by cancer survivors and the 
current models of survivorship care. Pharmacologic management of psychosocial 
and physical issues in cancer survivors are outside the scope of this chapter and will 
not be discussed here. Palliative care and hospice are an important component of 
comprehensive cancer care and are discussed in detail in Chap. 9. Table  11.1 
describes various domains that fall within the purview of cancer center patient sup-
port services and psychosocial care and the resources recommended for their effec-
tive management.
 Common Psychosocial and Physical Effects
 Distress and Mood Disorders
The National Comprehensive Cancer Network (NCCN) defines distress as an unpleas-
ant experience of psychological, social, spiritual, and/or physical nature that may 
hinder the ability of patients to cope effectively with cancer or its treatment [5]. 
Distress is prevalent in approximately one-third of cancer survivors and can be asso-
ciated with a reduced quality of life [6, 7]. Furthermore, patients experiencing distress 
have a lower likelihood of adhering to recommended health behaviors and surveil-
lance strategies [8]. Mood disorders, including anxiety, depression, or post- traumatic 
stress disorder [PTSD] is also prevalent among cancer survivors and warrants screen-
ing by the oncologist or primary care physician [PCP] [4]. A meta-analysis showed 
the odds ratio of PTSD in cancer survivors to be 1.66 compared to controls [9].
Screening for distress, anxiety, and depression is recommended by the NCCN 
survivorship guidelines. The NCCN distress thermometer along with other tools such 
as PHQ9 can be easily administered prior to clinic visit such that the clinician and 
appropriate support staff [e.g., social worker or financial navigator] can be notified.
 Services Required for Management
Patients who display signs of anxiety, depression, or distress on initial screening 
should be thoroughly evaluated by the oncologist regarding any physical cause 
related to cancer or anticancer therapy. Furthermore, safety evaluation, such as sui-
cidal intent, safety at home, and social isolation, should be conducted by appropriate 
personnel. Access to licensed social workers experienced in caring for cancer patients 
or a dedicated psycho-oncologist is desirable for initial evaluation prior to referring 
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Table 11.1 Various domains of services for patient support and psychosocial care within 
comprehensive cancer centers
Domain Personnel support Infrastructure support
Advance care planning Social worker Clinic space
Care coordination Care coordinators, patient 
navigators, nurse navigators
Clinic space, technology support to 
facilitate care coordination
Community outreach Care coordinators, social 
worker, patient navigator
Cancer screening, infrastructure to 
facilitate referral and access to care, 




Providers for specific services 
(e.g., art and music therapist, 
yoga instructor)
Space and equipment for services 
(e.g., yoga, art therapy, music 
therapy, acupuncture)
Fertility Gynecologist, urologist, 
reproductive endocrinologist
Mechanism for counseling and 
referral for fertility preservation
Financial support and 
navigation
Financial coordinator, care 
coordinator, social worker
Workspace, access to extramural and 
community services and grants, 
assistance for local housing
Genetic counseling Genetic counselors Clinic space
Home care services Patient navigator, social worker, 
nurse
Infrastructure to provide lab 
services, medication administration, 
and other care at home
Pain and symptom 
management
Palliative care physician/
advance practice provider and 




Clinic space, space and equipment 
for rehabilitation services, liaison 
with hospice services
Patient information and 
education
Patient navigator, nurse 
coordinator, social worker
Patient resource library, information 
technology support for patient 
education, workspace, and meeting 
rooms
Pharmacy Pharmacist Pharmacy space, supply chain to 
provide access to chemotherapeutic 
and supportive care drugs.
Psychological 
assessment and support
Social worker, psychiatrist, 
psychologist, spiritual care 
providers (e.g., chaplain)
Clinic space, technology support for 
assessments, support groups, access 
to community resources for 
psychological support, liaison with 





adult, and geriatric 
patients)
Clinical providers with 
expertise in treating specific 
patient populations
Clinic space, other support services 
geared specifically towards special 
populations
(continued)
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selected patients to psychiatry. Access to a psychiatrist who specializes in the care of 
cancer survivors is desirable. There is robust evidence for several non- pharmacological 
measures for the treatment of distress and mood disorders. Several meta-analyses 
have demonstrated beneficial effect of exercise on overall reduction in depressive 
symptoms among cancer survivors [10, 11]. Hence, providing services and transpor-
tation for a structured exercise program to selected patients can be beneficial and 
improve their quality of life. Cognitive-behavioral therapy [CBT] is effective for the 
treatment of PTSD in general population [12], and is also recommended for cancer 
survivors with PTSD [4]. Data on the efficacy of integrative medicine in improving 
the mental health of cancer survivors is limited. However, mindfulness-based stress 
reduction [MBSR] has the highest quality evidence on improving mental health in 
breast cancer survivors. A randomized controlled trial [RCT] on 322 breast cancer 
survivors showed that patients undergoing MBSR had improvement in psychological 
symptoms of anxiety, fear of recurrence, and fatigue compared to usual care, with the 
magnitude of benefit being greatest among patients with highest levels of baseline 
stress [13]. Notably, the intervention consisted of weekly 2-hour sessions for 6 weeks 
conducted by a clinical psychologist trained in MBSR, with the meditative practices 
consisting of sitting meditation, walking meditation, body scan, and gentle Hatha 
Yoga. Similar results have been replicated by other RCTs as well [14–16]. Hence, 
providing integrative and lifestyle medicine services to cancer survivors can be ben-
eficial, especially for those with distress due to fear of recurrence or persistent 
fatigue. Online or distance sessions should also be provided for patients who cannot 
attend in person due to logistical reasons. At the Cleveland Clinic’s Taussig Cancer 
Center, we provide free Yoga classes by a certified yoga instructor and a registered 
nurse. Furthermore, the Integrative and Lifestyle Medicine Institute at the Cleveland 
Clinic also provides classes on Yoga and mindfulness meditation.
 Fatigue
Fatigue in cancer survivors is defined as emotional, physical, or cognitive tiredness 
as a result of cancer or its treatment that can interfere with activities of daily living 
[4]. The putative mechanisms for cancer-related fatigue are pro-inflammatory state, 
dysregulation of hypothalamic-pituitary-adrenal axis, skeletal muscle wasting, 
Table 11.1 (continued)
Domain Personnel support Infrastructure support
Special services (e.g., 
post-laryngectomy, 
ostomy care, speech 
pathology)
Physician, advance practice 
provider, nurse, or other 
providers based on need
Clinic space, equipment, and other 
support based on specific scenario
Survivorship care Advance practice providers or 
nurses, social worker, 
specialists, patient navigator, 
care coordinator
Clinic space, resources for patient 
education, resources for generating 
and provision of survivorship care 
plan
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genetics, and psychosocial/ behavioral factors, among others [17]. A large study on 
cancer survivors from the PROFILES registry showed a high incidence of fatigue at 
39–51% among cancer survivors, depending on the tumor type [18]. Persistent 
fatigue can lead to impaired health-related quality of life [HRQoL] and a decreased 
likelihood of staying employed [4]. The NCCN guidelines recommend that oncolo-
gists should screen cancer survivors for fatigue, based on patients’ description of 
their fatigue level. Several patient-reported questionnaires such as Brief Fatigue 
Inventory [BFI] are also available that can be used for screening [19].
 Services Required for Management
The first step in the management of fatigue is to identify and treat the contributing 
factors, if any, such as pain, nausea, or dyspnea [4]. An RCT from the Netherlands 
showed superiority of nurse-led monitoring and treatment of physical symptoms 
over usual care in alleviating fatigue as well as interference of fatigue with daily 
living in cancer survivors [20]. The symptoms that were of major concern to fatigued 
patients were pain, shortness of breath, and decreased appetite.
Increasing physical activity has category 1 recommendation for the management 
of fatigue in cancer survivors [4]. A Cochrane systematic review had studied the 
impact of exercise on cancer-related fatigue, as observed in RCTs [21]. At the end 
of study intervention period, patients who were randomized to exercise intervention 
had significantly lower fatigue compared to those in the control arm, especially in 
breast and prostate cancer survivors [21]. Subsequently, another large meta-analysis 
compared exercise, psychological, and pharmaceutical treatments for the treatment 
of cancer-related fatigue [22]. Interestingly, exercise, exercise plus psychological, 
and psychological interventions all led to a statistically significant as well as clini-
cally meaningful decrease in fatigue at the end of intervention period, whereas phar-
maceutical interventions did not. The absolute mean weighted effect size was 
numerically highest with exercise intervention [22]. Referral to a physical therapist 
or an exercise specialist should be strongly considered for cancer survivors who are 
at a risk of injury, for example, survivors with bone metastasis.
Several psychosocial and behavioral interventions, such as MBSR, CBT, psycho- 
educational therapy, support groups, and journal writing, have shown promise in the 
treatment of cancer-related fatigue. A meta-analysis of RCTs on behavioral and psycho-
social interventions showed a statistically significant reduction in fatigue, depression, 
anxiety, and stress [23]. Acupuncture is also considered to be an acceptable option for 
cancer-related fatigue; however, data from RCTs have been conflicting thus far [24, 25].
 Pain
Pain is one of the most concerning symptoms that is prevalent in approximately 
one-third of cancer survivors and can lead to depression, lack of sleep, and poor 
quality of life [26]. There is a diverse etiology of pain in cancer survivors, including 
11 Psychosocial and Patient Support Services in Comprehensive Cancer Centers
98
arthralgia in breast cancer patients on aromatase inhibitors and neuropathic pain in 
patients with chemotherapy-induced peripheral neuropathy. The NCCN guidelines 
recommend periodic screening for pain in all survivors. Survivors with chronic pain 
should have easy access to pain management or palliative care specialists under a 
shared care model. The non-pharmacologic management strategies with a robust 
evidence base and the services required are summarized below.
 Services Required for Management
Several behavioral approaches have been studied for pain management in a random-
ized fashion. In breast cancer survivors with late post-treatment pain, an 8-week 
mindfulness-based cognitive intervention led to a significantly decreased pain 
intensity, nonprescription pain medication use, and improved quality of life com-
pared to usual care in an RCT [27]. Another RCT of sedative music therapy from 
Taiwan showed a significant decrease in post-intervention pain [28]. Other psycho-
social support and behavioral interventions that have been shown to be effective in 
alleviating cancer-related pain are breathing exercises, relaxation, guided imagery, 
and hypnosis [29, 30]. There is a high-level evidence for increased physical activity 
and exercise in the management of cancer-related pain. An RCT of exercise inter-
vention [including aerobic exercise and supervised strength training] in breast can-
cer survivors with aromatase inhibitor-induced arthralgia showed a significantly 
lower worst pain score, pain severity, and interference with activities of daily living 
at the end of 12-month period in the exercise arm [31]. A Yoga intervention for can-
cer survivors also showed decrease in musculoskeletal symptoms, including general 
pain, muscle ache, and physical discomfort among breast cancer survivors in an 
RCT [32].
Given pain being highly prevalent in cancer survivors, comprehensive cancer 
centers should consider provision of these services, including access to physical 
therapist or an exercise specialist, and classes for several behavioral interventions 
like mindfulness or relaxation techniques.
 Cognitive Dysfunction
Cognitive dysfunction is a well-described long-term side effect of cytotoxic chemo-
therapy and is associated with impaired functioning and quality of life [33]. An 
online survey named LIVESTRONG 2010 was conducted between June 2010 and 
March 2011 on 3108 post-treatment cancer survivors to investigate perceived cogni-
tive dysfunction and depressive symptoms [34]. Approximately one-half of respon-
dents reported current perceived cognitive dysfunction, with the highest prevalence 
among brain tumor survivors. Notably, perceived cognitive dysfunction was associ-
ated with receiving chemotherapy and self-reported depressive symptoms. The cur-
rent NCCN guidelines acknowledge the lack of effective screening tool for cognitive 
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dysfunction and recommends clinicians to use their judgement and perform appro-
priate workup in patients who self-report cognitive dysfunction. Several questions 
that can assess patients’ ability to perform activities of daily living and instrumental 
activities of daily living may help clinicians uncover subtle cognitive dysfunction.
 Services Required for Management
Apart from simple non-pharmacological interventions such as deprescribing unnec-
essary medications and instruction in self-management, robust data on efficacy of 
behavioral interventions are lacking. In a small RCT, cognitive behavioral therapy 
[CBT] was shown to improve spiritual well-being and verbal memory in breast 
cancer survivors but did not have any impact on self-reported daily cognitive com-
plaints [35]. Another small RCT of videoconference-delivered CBT in breast cancer 
survivors showed significant improvement in perceived cognitive function and neu-
ropsychological processing speed compared to controls who received supportive 
care [36]. Similar to its impact on other psychosocial and physical effects, struc-
tured exercise program offers benefit to patients with cognitive dysfunction as well, 
with a dose-response relationship observed with greater levels of physical activity 
[37]. Other services that can offer benefit to patients with cognitive dysfunction 
include cognitive training [38], relaxation, meditation [39], and Yoga [40].
 Services for Healthy Lifestyle in Cancer Survivors
Maintaining a healthy lifestyle in cancer survivors, including regular physical activ-
ity, a balanced diet, and avoiding tobacco smoking, is associated with superior out-
comes in several tumor types [41–43]. There is a robust evidence on the impact of 
physical activity in reducing the risk of cardiovascular events in cancer survivors. 
Data from the Childhood Cancer Survivors Study demonstrated the impact of exer-
cise on cardiovascular events in Hodgkin Lymphoma survivors at a median follow-
 up of approximately 12  years [44]. Furthermore, the impact of exercise was 
dose-dependent, with the risk of cardiovascular events being significantly lower 
among patients reporting ≥9 METs [metabolic equivalent hours]/week. Similar 
results were seen among patients with nonmetastatic breast cancer [45]. The current 
NCCN guidelines recommend periodic assessment of physical activity level in can-
cer survivors. A questionnaire survey of 975 cancer survivors identified several bar-
riers for physical activity, including lack of time, lack of access to an exercise 
environment, uncertainty regarding safety of exercise post-cancer treatment, physi-
cal limitations, and lack of knowledge regarding appropriate physical activities 
[46]. Hence, providing access to a formal exercise program within comprehensive 
cancer centers can be beneficial to patients and help provide an individualized exer-
cise plan to survivors. Offering behavioral strategies, including telephone counsel-
ling, print material on benefits of physical activity, and motivational interviews can 
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also be helpful in increasing physical activity among cancer survivors. Providing 
tailored print materials to cancer survivors by mail, promoting consumption of 
fruits and vegetables, reducing fat intake, and increasing exercise has been shown to 
be superior to providing standardized non-tailored materials in an RCT [47]. At 
Taussig Cancer Center, we also provide a mentoring program for cancer survivors 
called as 4th Angel Patient and Caregiver Mentoring Program, as a part of which, 
patients and their caregivers are connected with similar cancer survivors who can 
share their experiences and provide emotional and spiritual guidance.
 Survivorship Care Models
A “model” for providing survivorship care is defined as a comprehensive approach for 
follow-up care of survivors, which can be performed by the oncology team or primary 
care providers or both [48]. Designing a strategy for caring for long-term cancer survi-
vors is an integral part of most comprehensive cancer centers and has been endorsed by 
the American Society of Clinical Oncology [48]. A large systematic review has demon-
strated that cancer survivors benefit from coordinated posttreatment psychosocial, reha-
bilitative, and supportive care [48]. Table 11.2 provides guidance on various elements 
and domains of cancer survivorship care that cancer centers should strive to achieve.
Table 11.2 Various aspects of survivorship care provided by comprehensive cancer centers
Survivorship care elements
Surveillance for cancer recurrence
Monitoring for and management of medical late effects
Monitoring quality of life and management of psychological effects
Screening for secondary malignancies
Providing health education about diagnosis, exposures, and risks for potential late effects
Familial genetic cancer risk assessment
Education about diet, exercise, and healthy living
Management of financial toxicity
Care coordination with primary care physicians/advance practice providers and specialists
Models of survivorship carea
Oncology specialist care (follow-up care in oncology setting with treating oncologist)
Multidisciplinary survivorship clinic (care provided by a specialized team in a separate clinical 
area)
Disease or treatment-specific survivorship clinic (e.g., clinic specifically for blood and marrow 
transplant survivors)
General survivorship clinic (care provided by physician or advance practice provider that may 
be in a cancer center or community practice setting)
Consultative survivorship clinic (one-time visit to a physician or advance practice provider to 
address survivorship issues)
Integrated survivorship clinic (clinic embedded within a treatment focused oncology setting)
Community generalist model (survivorship care provided by primary care physician or 
advanced practice provider)
aAccording to American Society of Clinical Oncology (https://www.asco.org/practice- policy/
cancer- care- initiatives/prevention- survivorship/survivorship/survivorship- 3; accessed 09/01/2020)
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Survivorship care models are usually described by the type of survivors [tumor- 
specific versus general], care setting [separate survivorship clinic versus integrated 
model], type of clinician(s) providing survivorship care [physician-led versus nurse- 
led versus nurse practitioner-led versus shared-care model], or the purpose of the 
survivorship program [e.g., transition clinic model] [48]. The Institute of Medicine 
recommendations have identified four key domains of survivorship care: preven-
tion, surveillance, intervention, and coordination [3]. To our knowledge, there are 
three large randomized controlled trials that empirically tested different survivor-
ship care models. Wattchow et  al from Australia randomized patients with early 
stage colon cancer who had underwent curative-intent surgery followed by postsur-
gical chemotherapy to follow-up by general practitioners [primary care] or surgeons 
[secondary care] for five years, with the prescribed frequency being every three 
months for the first two years followed by every two months for the subsequent 
three years [49]. The primary outcome measures, which were measured at 12 and 
24 months, were (a) physical and mental quality of life (b) anxiety and depression, 
and (c) patient satisfaction. At both 12 and 24 months, there was not any clinically 
meaningful or statistically significant difference in the primary endpoints between 
the two care groups. Furthermore, the recurrence rate, time to recurrence detection, 
and death rate were also similar in both groups. Another Canadian study random-
ized early stage breast cancer survivors who had completed adjuvant chemotherapy 
+/− radiotherapy to follow-up by the cancer center [CC group] or their own family 
physician [FP group]. Of note, patients were allowed to receive hormonal therapy 
during the study period [50]. The primary outcome of the study was rate of 
recurrence- related serious clinical events, and the secondary outcome was health- 
related quality of life. There was no difference in the primary or secondary out-
comes in either group. The total number of breast cancer recurrences and deaths was 
similar in both groups. Notably, family physicians in this study were provided fol-
low- up guidelines, including frequency of follow-up, yearly mammogram, diagnos-
tic tests to investigate signs or symptoms of new primary cancers, and close 
surveillance for vaginal bleeding in patients on tamoxifen. Hence, based on these 
two studies, a transition clinic model of survivorship care, which focuses on transi-
tion of care from specialists to PCPs, should provide results comparable to contin-
ued survivorship care at cancer centers, as long as PCPs are provided specific 
guidance and expectations regarding long-term toxicities, late effects, and signs of 
disease recurrence. In a survey of PCPs caring for adult survivors of hematopoietic 
cell transplantation [HCT] in the United States, commonly identified barriers to 
care delivery were lack of resources to facilitate care, lack of awareness regarding 
screening/prevention guidelines in HCT survivors, lack of awareness regarding psy-
chosocial needs, inadequate time, and preference of patients to follow-up with their 
oncologists [51]. Several of these factors can be potentially addressed by providing 
education, tools for clinical decision making, and guidelines to PCPs caring for 
cancer survivors. Finally, a third RCT assessed the cost of follow-up in breast can-
cer survivors by randomizing them into four different treatment schedules [52]. The 
four schedules differed either in the frequency of visits [every third or sixth month] 
or in the intensity of diagnostic tests [on a routine basis versus specific clinical 
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grounds]. Neither increasing the visit frequency to every three months nor perform-
ing routine diagnostic examinations led to any benefit in disease-free or overall 
survival despite increasing the cost of care.
Providing patients and their PCPs with a survivorship care plan [SCP] has been 
endorsed as a key component of survivor care by the Institute of Medicine [3]. However, 
the evidence on impact of SCPs on health outcomes and health care delivery is conflict-
ing. A large systematic review including 13 randomized studies on SCPs showed 
largely negative results regarding impact on physical, psychological, and functional 
well-being, which were the most commonly assessed outcomes [53]. On the other 
hand, positive findings on proximal outcomes such as the amount of information 
received, care satisfaction, and physician implementation of recommended care was 
noted in some studies. One of the major limitations of this review was heterogeneity in 
study design. A study conducted at ten cancer centers within the NCI-funded Cancer 
Research Network in the United States showed that oncology and primary care were 
jointly responsible for the care of cancer survivors, similar to a shared-care model [54]. 
However, only two out of ten sites had a formal survivorship program in place. Issues 
with patient finances and insurance reimbursement were also a major area of concern. 
At the Cleveland Clinic Blood and Marrow Transplant department, we have established 
a formal survivorship program since 2016 [55]. Since BMT survivors have unique 
health care needs due to late effects like chronic graft versus host disease, infections, 
and second cancers, lifelong follow-up and monitoring is recommended according to 
most guidelines, which prompted us to develop the survivorship program. A shared-
care model, in which BMT physician and PCP liaise to provide ongoing care along with 
referral to other subspecialty services when needed, was thought to be the most appro-
priate for this patient population. The program consists of day 100 and 1-year survivor-
ship visit by NP, a treatment summary, and care plan developed by the NP on day 100 
and 1-year post-transplant for all non-relapsed patients, and development of educa-
tional materials. At the 1-year visit, the NP provides patients, their PCPs, and the pri-
mary BMT physician with a summary of test results and a revised care plan, which 
includes recommended screening/preventative guidelines. Hence, development of a 
successful survivorship program requires several elements, including appropriate con-
sideration of patient and disease-related factors, buy-in from department leadership, 
allocation of sufficient resources and personnel, and finally, identifying physician 
champions in different specialties which will be involved in patient care. Finally, as 
seen in a recent review [48], survivorship care models are highly institution-dependent, 
which highlights the need for further research in this area to identify optimal care models.
 Community Outreach
Finally, comprehensive cancer centers should also engage in community outreach to 
especially target high-risk population with the goal of early cancer detection to improve 
outcome. Cleveland Clinic Cancer Center offers cancer prevention, screening, education 
and navigation programs designed to meet the needs of the diverse community we serve. 
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We work with local churches, schools, and other nongovernmental organizations. Our 
partnership with Federally Qualified Health Centers (FQHC) to provide screening ser-
vices is very unique. Since there are data on delay in cancer treatment initiation among 
minorities and low-income population [56], our goal is to reduce the disparity by provid-
ing preventative education, cancer risk assessments, and recommended screening 
including mammogram, prostate exam, colonoscopy, low-dose chest CT, and oral can-
cer screening for appropriate population. If cancer is found, our Cleveland Clinic Cancer 
Center community outreach patient navigators can also help with providing cancer edu-
cation and resources, scheduling appointments, arranging transportation, navigating 
treatments, providing support during appointments, and offering financial guidance.
 Patient Support and Psychosocial Services 
in Resource-Limited Settings
Provision of patient support and psychosocial services (see Table 11.1) are an essen-
tial component of comprehensive cancer care. Although not directly related to treat-
ment of underlying cancer, they ultimately impact patient access to care and optimal 
outcomes. Cancer centers in resource-limited setting should strive to provide these 
services to patients while recognizing and prioritizing services that are most rele-
vant to their local patients and communities. For example, in areas where cancer 
care is largely subsidized by the government, there may not be much need for per-
sonnel who need to focus on financial navigation for patients. On the other hand, 
some elements comprise basic cancer care and should be considered in the planning 
phase of developing a cancer center such that personnel and infrastructure invest-
ments can be made early on. Examples of such services include social work, pallia-
tive care, and survivorship care. In several resource-limited settings, local and 
regional health care in areas other cancer may be better developed – an attempt 
should be made to identify, optimize, and share existing resources. In these settings, 
cancer care is often provided by the government and advocating with policy makers 
to emphasize the importance of psychosocial and patient support services often 
needed to ensure sufficient resources and infrastructure is assigned towards their 
development. Ultimately a needs assessment is required as a cancer center is being 
established with the plan to bring in these services early and focus on domains that 
will have the most impact on patients and local communities.
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Chapter 12




While previously a resource only found in large academic hospitals or specialized 
community-based healthcare agencies, palliative care (PC) has become an essential 
part of modern health care in the United States (US) and around the world. A status 
report in the Journal of Palliative Medicine in 2016 reported that 67% of US hospi-
tals with 50 or more total facility beds and 90% of hospitals with 300 beds or more 
reported the presence of a palliative care program [1]. The presence of inpatient PC 
programs varied regionally, with the highest percentage in the Northeast and the 
lowest in the South [1]. Outpatient access to PC has also grown, both in the clinic 
setting and in the community [2, 3]. As clinical access has grown, so has the body 
of evidence about the positive impact of PC. A wide range of data demonstrates the 
important role PC plays in care quality, patient and family satisfaction, clinician 
experience, and healthcare resource utilization [4–7]. Alignment with this “qua-
druple aim” positions PC to be a key player in future healthcare transformation and 
the movement toward value-based care [8].
The Center to Advance Palliative Care (CAPC) defines “palliative care” as spe-
cialized medical care for people living with a serious illness. The term was coined 
in 1974 by Dr. Balfour Mount, a surgical oncologist at The Royal Victoria Hospital 
of McGill University in Montreal, Canada. Mount likely created the new term to 
circumvent existing negative connotations many had with hospice. Dame Cicely 
Saunders, considered the founder of both the modern hospice movement and the 
field of PC, developed and propagated the clinical practice around her concept of 
“Total Pain.” Total Pain refers to the comprehensive, multifaceted experience of suf-
fering associated with serious illness, which Saunders further divided into four 
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domains: physical, emotional, social, and spiritual [9]. A commitment to improve 
quality of life by attending to all of these dimensions of suffering remains central to 
the practice of PC today. Consistent with this comprehensive approach, interdisci-
plinary team-based care by physicians, nurses (including advance practice nurses), 
social workers, chaplains, and complementary therapists is fundamental. PC is 
appropriate at any age and at any stage in a serious illness and is provided along 
with curative treatment. Thus, the provision of PC is based on the needs of the 
patient, not on the patient’s prognosis.
Palliative care has played a central role in the delivery of high-quality cancer care 
for some time, likely stemming from the fact that many of the early PC practitioners 
were oncologists. While specialty PC practice and training has grown to encompass 
serious illnesses of all types, PC remains heavily focused on supportive cancer care. 
The National Comprehensive Cancer Network (NCCN) guidelines direct: “institu-
tions should develop processes for integrating palliative care into cancer care, both 
as part of usual oncology care and for patients with specialty palliative care needs.” 
[10] A wide body of evidence has demonstrated PC’s impact on cancer care quality 
throughout the trajectory of cancer care in a wide variety of malignancies and care 
settings [11–14]. In addition to addressing the aim to palliate symptoms, systematic 
early integration of PC has shown to prolong survival [15]. Consistent with PC’s 
aim to facilitate individualized, patient-centered plans of care, research has demon-
strated that those who receive PC consultations have care plans aligned with their 
goals and care that costs less overall [6, 16, 17]. As a result, PC metrics have been 
incorporated into cancer-focused, value-based care approaches, like the Center for 
Medicare and Medicaid’s Advanced Alternative Payment Model, the Oncology 
Care Model (https://innovation.cms.gov/innovation- models/oncology- care).
Although specialty PC has become an integral part of high-quality cancer care, PC 
services are not ubiquitous, and access to PC is still limited in many areas and care 
settings. The reasons for limited access vary by locale and include specialty PC work-
force constraints, lack of financial support for PC staffing resources, and variable 
engagement by clinicians and healthcare leadership. Despite these challenges, many 
healthcare professionals and institutions remain committed to establishing new spe-
cialty PC service lines, a complex but worthwhile endeavor. The following sections of 
this chapter will focus on the steps and anticipated challenges in initiating and inte-
grating specialty PC within a cancer care entity. The stages have been broken into 
Planning (early and late), Launch and Integration, and Monitoring and Sustainability.
 Planning
 Early Planning
The first step in starting a new PC service line is engaging PC champions and insti-
tutional leadership. Quite often, new PC programs or service lines are created in 
response to requests, or even, demands from existing clinicians (physicians, nurses, 
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care managers). Engaging these frontline allies simultaneously as one petitions 
institutional leadership for financial support can be effective in generating support 
for the initiation of a new PC service line. Fortunately, “making the [financial] case” 
for the integration of PC in cancer care is no longer a difficult task. As described 
above, a wide variety of evidence exists to support PC’s role in supporting outcomes 
around care quality, patient/provider satisfaction, and healthcare utilization. These 
published outcomes can be complemented by analysis of local data, including:
• Clinical volumes by cancer diagnosis.
• Acute admissions and/or ED visits.
• Hospital and/or ICU length of stay (LOS).
• Hospice utilization (referral rates and LOS on hospice).
• Prevalence of moderate to severe symptoms.
• Rate of advance directive completion.
Subjective reports from patients, families, and providers about care gaps can also 
be compelling data when advocating for resource allocation to a new PC service 
line. As organizational leadership is engaged, it is essential to understand and then 
align PC service line goals with those of the larger institution.
Once conceptual alignment between organizational and PC leadership is 
achieved, early planning should also include a focused “needs assessment” to iden-
tify what the patients, families, clinicians, and institution want and need most from 
a specialty PC team. There are a wide variety of reasons to start PC programs, and 
no inaugural program can address all possible needs from the start. Building com-
prehensive PC programs across care settings takes years to decades. When starting 
a new PC program, it is important to identify focused, key aims that address high- 
priority patient care or provider practice needs. The following list represents only a 
few of the many possible “needs” for initiating a new PC service:
• Management of complex, time-consuming cancer-related pain, especially in the 
setting of increasing regulatory requirements around opioid prescribing.
• Underutilization of hospice care, including low rates referrals and/or short length 
of stay on hospice care.
• High-level psychosocial distress in patients in families around coping with the 
challenges of cancer care.
• Facilitation of conversations around care goals and preferences in patients with 
long hospital length of stay or those ideintified as “high utilizers” of healthcare 
resources.
Designing the PC service line according to the most pressing needs will increase 
the likelihood of successful achievement of shared goals. Once there is alignment 
around focused goals, shared outcome measures can be created. Clearly outlining 
the anticipated “deliverables” is an important next step in considering the design of 
a new PC service line. Typical deliverables include clinical symptom management 
(pain and non-pain symptoms), facilitation of discussions about patient care goals 
and preferences, transitions from disease-directed therapy to comfort-focused care, 
the provision of comfort focused and end-of-life care, psychosocial support, 
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spiritual support, and complementary therapies like music, art, Reiki, meditation. 
An effective PC service does not need to include all components listed here in order 
to be successful, especially at the start of the service. On the contrary, PC services 
that are built piece by piece, starting where needs and engagement are highest, are 
most likely to be successful. Teams or institutions who try to tackle every PC need, 
everywhere (outpatient, inpatient, and in the community) all at once may be quickly 
overrun by unmanageable referral volumes, unmet expectations, and strained clini-
cal teams. Depending on available resources and primary aims, goals can further be 
tailored to a specific malignancy or stage (e.g., allogeneic stem cell transplantation 
or metastatic lung cancer). The importance of the early planning stage, including 
engagement of institutional leadership and alignment around shared goals, cannot 
be underestimated. The Center to Advance Palliative Care has a robust collection of 
materials available online for members for PC program planning, design, and exe-
cution (www.CAPC.org).
 Late Planning
Once primary objectives and outcomes have been established, the next step is 
designing the PC service line, with consideration to care setting and staffing scheme. 
While staffing models may ultimately be limited by resource allocation, it is impor-
tant to design a service line that will address the primary objectives. For example, if 
the primary objective is complex pain and symptom management in patients with 
advanced solid tumors, starting an outpatient PC service with an experienced physi-
cian embedded within the outpatient oncology clinic would be an advisable first 
step. If the primary need is symptom management during an admission for an allo-
geneic stem cell transplant, then embedding a PC clinician (either physician or 
advance practice provider (APP, includes nurse practitioner or physician assistant)) 
on the transplant unit may be more appropriate. If the resources and request for PC 
are coming from hospital leadership, the needs may be centered on ICU throughput, 
hospital length of stay, or inpatient readmissions. In this case, a consultative inter-
disciplinary inpatient PC team to help facilitate conversations around care goals and 
preferences may be the right place to start. Alternatively, if the resources and 
engagement are from an institutional or community-based hospice organization 
with an aim to increase timely referrals and offer earlier service to high-risk patients 
in the community, it may make sense to start with an interdisciplinary community-
based PC team to capture referrals upon hospital discharge or via insurance claims-
based data. Table 12.1 outlines the primary PC delivery models and the associated 
target outcomes, team composition, and support needs. These PC delivery models 
can include:
• Inpatient consultation.
• Inpatient primary admitting service, with or without a designated physical space 
or unit.
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• Outpatient clinic, either embedded within a target specialty or stand-alone.
• Community-based, offering visits to patients in home and facilities, in person or 
virtually.
The decision about staffing the service with a physician or an APP depends on a 
number of factors including clinical acuity, healthcare system culture, and available 
workforce. A team that includes both a physician and an APP supports both the 
interdisciplinary practice of PC and facilitates management of higher clinical 
volumes.
Table 12.1 Palliative care delivery models
Service type Target outcomes Team clinicians Support needs
Inpatient 
consultation
Hospital-based metrics like 
hospital or ICU LOS or 
readmissions
Facilitation of discussion 
about care goals and 
preferences
Transitions from disease- 
directed plan of care to 











Consultative needs as above
Desire to “hand-off” PC 
patients from medical, 
surgical and ICU services
Physical space to attend to 
the care of actively dying 
patients
Physician



















Support for conversations 
regarding care goals and 
preferences















Facilitation of discussion 
about care goals and 
preferences
Transitions from disease- 
directed plan of care to 
comfort-focused plan of 
care
Symptom management










aThe ability to impact acute care utilization metrics depends on the design of a community-based 
PC program
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Decisions should be made early about what kind of symptoms and which patient 
populations the PC team will manage. For example, will an inpatient PC team’s 
services be available to all patients, only patients with an identifiable serious illness, 
patients in the ICU or RNF, or focused on particular diagnoses like cancer? This is 
especially important when considering pain management, which can quickly con-
sume staffing resources. Will the team manage cancer pain, pain related to serious 
illness, chronic pain, postsurgical pain, complex or refractory pain syndromes?
Once a commitment has been made about resource allocation, care delivery setting, 
and staffing scheme, it is time to plan the implementation of the PC service by estab-
lishing a timeline. Due to specialty PC workforce constraints and training needs, 
recruitment is often  the limiting step in service initiation. In the United States, it may 
take 6–24 months to recruit a fellowship-trained PC physician. APP staffing is often 
available within a much shorter time frame; however, many APP recruits do not have 
specialty PC training or experience. Therefore, a 6–12 month period for training must 
be allowed. For institutions who do not have existing PC specialists, it is advisable to 
start with an experienced or fellowship-trained PC physician. This provider will come 
equipped to deliver specialty PC from the start of their employment and may serve as 
a resource to train APP hires as the service grows. CAPC has extensive online training 
resources to support the development of the entire interdisciplinary team. PC certifica-
tion pathways (available for physicians, nurse practitioners, social workers, and chap-
lains) offer additional opportunities for professional development of the PC team.
If not already in existence (and engaged with planning the service line), an 
administrative team should be assembled after the clinical team is recruited. The 
administrative team can support service integration by identifying team space, coor-
dinating credentialing, reviewing pertinent hospital bylaws and standard operating 
procedures, and setting up meetings with potential referral sources and PC service 
champions. Furthermore, developing an integration “Steering Committee” com-
posed of the institutions’ PC champions, healthcare system leadership, and other 
key stakeholders will help facilitate a successful launch. Typical steering committee 
members include leadership, chief nursing officers, finance, marketing and com-
munications, pharmacy, spiritual care, and complementary care services.
Prior to service launch, it is important to clarify operational standards around 
service hours, evening on call and weekend coverage, the time frame within which to 
see new referrals, follow-up frequency and duration, and communication processes 
for referral sources and other bedside caregivers. Routine team workflows, such as 
clinical huddles and interdisciplinary team meetings, can then be designed to support 
these expectations and facilitate effective communication within the PC team.
 Launch and Integration
Despite the wider access to and presence of PC, many healthcare professionals and 
lay public still lack an understanding of what PC encompasses. PC is often confused 
with hospice or end-of-life care, such that physicians who refer to PC sometimes 
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have trouble articulating to patients why they are making the referral and what out-
comes to expect from the referral. Simply put, palliative care is specialized medical 
care for people living with a serious illness. The ultimate goal is to improve quality 
of life for both the patient and the family, which is often achieved through palliation 
of symptoms and enhanced communication with patients and families about their 
care preferences, goals, and plans. While end-of-life care is a critical part of PC, it 
is only a part of what PC envelops. Addressing this knowledge deficit about PC is 
essential when launching a new specialty PC service. In addition to clearly com-
municating what PC is, it is helpful to share simple, concise language (e.g., an 
“elevator speech”) for referring clinicians, healthcare leadership, and other PC 
champions to use when interacting with patients and other healthcare 
professionals.
At or just prior to service launch, one should organize meetings or schedule pre-
sentations for stakeholders, like institutional leadership, shared governance teams, 
medical and nursing staff, medical educators, and care management. These engage-
ments serve several functions by creating a forum to: (1) address the existing gaps 
in understanding about what PC is, (2) set expectations about what this new service 
line will deliver, and (3) clarify referral processes. Attendees need to leave these 
presentations understanding: (1) who may place referrals (is referral limited to phy-
sicians or can other clinicians refer?), (2) why to refer a patient (what are the clinical 
eligibility criteria?), (3) when to refer a patient (either during a hospital stay or 
along their trajectory of serious illness), and (4) how to communicate a new patient 
referral to the patient and PC team (electronic, telephone, etc.).
A successful service line launch is ultimately dependent on the development of 
meaningful relationships between the PC team and other clinicians within the care 
setting. Intentional steps to enhance visibility, like presence in clinical care areas, 
participation with hospital or clinic committees, and supporting educational or 
training efforts go a long way in helping establish the PC team. Prioritizing thought-
ful, effective communication with referring providers and other bedside clinicians 
also helps develop trust and service line success.
 Monitoring and Sustainability
Monitoring the activities of the PC service entails collecting data from a number of 
sources. An “Advisory Committee,” composed of stakeholders and high utilizers of 
the service can be a key source of information. While this committee may include 
some of the participants from the Steering Committee, it can envelop a larger scope 
to include key referral sources, such as large medical or specialty practices, ICU 
clinicians, and patient/family councils. The goal is to get real-time input from end 
users for early identification of best practices, service gaps, or emerging challenges. 
The PC team itself will be another great source of data. Scheduling regular team 
meetings with the aim of collecting experiential feedback supplements standard 
data points like clinical volumes, service outcomes, and patient/family experience 
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scores. PC team meetings also create a forum for team members to share successes 
and best practices and collaborate around challenges in care delivery.
Successful integration of the PC service is often marked by increasing referral 
volumes over time. Developing thresholds for hiring additional staff supports ongo-
ing incremental growth. Understanding the reasons for referral, the average number 
of visits per referral, and the referral sources themselves will direct what kind of 
additional staff is needed. Often, PC team bandwidth can be expanded by adding 
interdisciplinary clinicians like APPs, social workers, chaplains, and care coordina-
tors. If the service is started in one care setting (inpatient or outpatient), the next step 
for expansion may be a complementary PC service in the alternate setting. Building 
a comprehensive PC program with clinical services available in a variety of care 
settings ultimately creates a continuum of support to follow a patient across care 
transitions and throughout the trajectory of a serious illness. When considering the 
most advanced stages of a serious illness, it is important to either provide hospice 
care (or similar end-of-life care) or partner closely with a high-quality hospice orga-
nization. This will assure that patients and families receive optional care throughout 
the duration of their illness.
 Quality
The availability of PC services is essential to quality cancer care. Organizations 
such as the Multinational Agency for Supportive Care in Cancer (MASCC), 
American Society for Clinical Oncology (ASCO), the NCCN, and the American 
College of Surgeons Commission on Cancer (CoC) have issued guidelines and stan-
dards for the provision of PC services to cancer patients from early in the course of 
illness, throughout the disease course and at end of life [10, 16, 18, 19]. ASCO had 
also issued guidelines for PC in the global setting, stratified by resource availability 
[20]. This guideline outlines quality PC for patients with cancer in resource- 
constrained settings under various models of care. Consistent among all guidelines 
and standards are recommendations and/or requirements including the following:
• Interdisciplinary care is essential to identify and address physical, psychological, 
spiritual, social, and cultural aspects of care.
• PC services are ideally available on-site at a cancer center but may also be pro-
vided by referral to care partners in the community.
• PC begins at diagnosis and may be initially provided by the oncology team (pri-
mary palliative care) with availability of specialist palliative care team 
consultation.
• Quality PC should be provided in accordance with established evidence-based 
national and international guidelines.
The most robust recently updated guidelines were developed as a national con-
sensus project among 13 member organizations and are summarized in 
Table 12.2 [21].
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Table 12.2 Guidelines for quality palliative care
Domain Guideline
Structure and process of care Interdisciplinary team (IDT)
Comprehensive palliative care assessment
Palliative care plan
Continuity of palliative care
Care settings
IDT education
Coordination of care and care transitions
Emotional support to the IDT
Continuous quality improvement
Stability, sustainability, and growth
























Care of the patient nearing end of life Interdisciplinary team
Screening and assessment
Treatment before death
Treatment during the dying process and immediately 
after death
Bereavement
Ethical and legal aspects of care Global
Legal considerations
Screening and assessment
Treatment and ongoing decision-making
Table adapted from: Ferrell et al. [21]
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Palliative care programs have many resources available to help determine how to 
assess and improve quality of their care. Palliative provider education is integral to 
quality care, and palliative certification ensures a strong knowledge base for the 
interdisciplinary team, including physicians, advance practice providers, nurses, 
social workers, and chaplains. There are abundant online opportunities for ongoing 
education through the American Academy for Hospice and Palliative Medicine 
(www.AAHPM.org), the Center to Advance Palliative Care (www.capc.org), 
MASCC (https://www.mascc.org/palliative- care), and the World Health 
Organization (https://www.who.int/cancer/palliative/en/).
As a palliative program is developed, it is critical to include evaluation of the 
structure, process and outcomes of the program from the outset. This ensures that 
the best care is provided to those who need it most. Importantly, ongoing evaluation 
identifies best practices and opportunities for ongoing quality improvement initia-
tives. Recently, several national quality registries in the United States have been 
merged to become the Palliative Care Quality Collaborative and plan to establish 
the Palliative Care Quality Initiative (PCQC), a registry anticipated to open in 2021 
to capture both patient and program quality data.
Metrics specific to palliative care have been proposed by AAHPM in the 
Measuring What Matters project [22]. The top ten metrics are: comprehensive 
assessment, screening for physical symptoms, pain treatment, dyspnea screening 
and management, discussion of emotional or psychological needs, discussion of 
spiritual/religious concerns, documentation of surrogate, treatment preferences, 
care consistency with documented care preferences, and a global measure such as 
quality of life [23]. CAPC has published updated suggested quality metrics which 
is shown in Table 12.3 [24]. Key illustrations of patient quality are access to pallia-
tive care, pain assessment and management, safe opioid prescribing practices, and 
documentation of advance directives (ADs). Program quality measures may include 
patient satisfaction scores, hospital readmission rate, ICU utilization near end of 
life, and days on hospice care. Palliative programs can select areas they wish to 
prioritize based on their care delivery models.
Ongoing continuous improvement is the mainstay of quality care. In fact, a focus 
on improving quality is intrinsic to the patient-centered discipline of palliative care 
[25]. Tracking quality metrics allows for rapid recognition of areas a program can 
improve care. Quality improvement (QI) projects can then be tailored to improving 
care in a specific area such as AD completion rates or accurate, safe opioid prescrib-
ing. QI projects are best accomplished by a multidisciplinary team of engaged 
stakeholders who wish to facilitate sustainable change. Basic QI methodology 
includes identification of a problem to be addressed, measuring and defining goals, 
root cause analysis, rapid cycle plan-do-study-act interventions and plans for sus-
tainability and spread. The Institute for Healthcare Improvement Open School ini-
tiative offers free courses in QI methodology to support programs wishing to learn 
a model for improvement (www.ihi.org).
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 Research
Establishing a research framework is foundational to developing and sustaining pal-
liative care services. The concept of research begins with asking questions and dis-
covering new knowledge to help better care for our patients. Creating a database of 
patients for QI purposes at the outset allows for evaluation of quality and can also 
help identify areas for future research in symptom management, novel care delivery 
models, and palliative care education. Such a database should incorporate assess-
ments, measurements, and outcomes. Any new research protocol would need to be 
approved by an institutional review board (IRB), which may be on-site or affiliated.
Palliative care research has expanded significantly over the past decade. 
Competitive funding sources support well-designed palliative clinical trials that are 





Access Structure Availability of interdisciplinary palliative care team, with 24/7 
response of some kind in selected facility(ies)
Satisfaction Patient 
experience
Consumer assessment of health providers and systems (CAHPS)




Process Rates of patients who have an advance care plan or surrogate 
decision maker documented in the medical record or 
documentation in the medical record that an advance care plan was 
discussed but the patient did not wish or was not able to name a 
surrogate decision maker or provide an advance care plan
Clinical 
quality
Process Proportion of patients with pain screening or assessment (and/or 
with pain plan of care)
Clinical 
quality
Process Proportion of patients with functional assessment (ability to 




Process Proportion of patients with their caregiver burden formally 
assessed
Utilization Outcome Rates of avoidable hospital and/or emergency department 
utilization; risk-adjusted as appropriate
Utilization Outcome Days at home: Number of days a patient remains outside of an 
institutional care setting during a standardized time period
Utilization Process Appropriate hospice utilization (e.g., hospice referral rate or 
hospice length of stay (LOS) for those referred or proportion of 
hospice LOS less than 7 days or more than 180 days for those 
referred)
Additional details and resources are available at https://www.capc.org/defining- and- 
measuring- quality/
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published in high-impact journals and result in practice-changing outcomes. A 
prime example of this is the randomized trial of early palliative care for outpatients 
with metastatic non-small cell lung cancer [15]. Patients who received early special-
ist palliative care had better quality of life, less depressive symptoms, less aggres-
sive end-of-life care, and longer median survival that those with usual care. Now 
early palliative care for such patients is recognized as the standard of care and a best 
practice. More recent examples are the randomized trials of integration of palliative 
care into the care of patients undergoing hematopoietic stem cell transplantation 
and acute myeloid leukemia induction, affirming better quality of life and less anxi-
ety for those who received palliative care [26–28].
In order for research to have impact, findings must be shared. There are multiple 
venues to share QI and clinical trial results. AAHPM, CAPC, National Hospice and 
Palliative Care Organization (NHPCO), ASCO, and IHI have annual assemblies 
with opportunities to present posters and oral abstracts. In additional, McGill 
University in Montreal, Canada, offers a long-running International Congress on 
Palliative Care with written and oral presentations. In addition, there are many pal-
liative journals dedicated to palliative research, and cancer-specific journals such as 
Journal of Clinical Oncology (JCO), JCO Oncology Practice, JAMA Oncology, and 
others which also publish impactful palliative oncology research.
 Conclusion
Palliative care, focused on the optimization of quality of life, has become an essen-
tial part of cancer care. While the prevalence of PC has grown, access is still limited 
in a variety of care settings, institutions, and geographic locations. Developing and 
launching a specialty PC service enhances cancer care and helps address unmet 
needs related to cancer symptoms, communication about care goals and prefer-
ences, and transitions in care. Planning for the integration of a new palliative care 
service is a complex process that requires attention to thorough planning, as well as 
attentive execution and monitoring to assure delivery of sustainable, interdisciplin-
ary, and high-quality care. Cancer centers need to strategically invest in this area as 
they progress towards provision of comprehensive cancer care services to patients.
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Hematopoietic cell transplantation (HCT) is an established treatment for selected 
patients with high-risk hematologic malignancies and other malignant and non- 
malignant diseases. An estimated 50,000 transplantation procedures are performed 
worldwide annually [1]. The number of patients who need and receive HCT is 
expected to grow as transplantation becomes safer with advances in transplantation 
technology and supportive care, greater donor availability, emerging indications, 
and diffusion of this procedure to lower income and lower middle income countries. 
The increase in utilization of transplantation has been paralleled by improvement in 
outcomes, resulting in a larger number of transplant survivors who are potentially 
cured of their underlying disease [2–5]. Addressing the needs of long-term survi-
vors is, therefore, a growing aspect of transplant programs. An added dimension to 
this is the advent of cellular therapies, especially chimeric antigen receptor (CAR) 
T-cell therapies, which are also included within the domain of transplantation pro-
grams. A comprehensive center should ideally consider provision of HCT proce-
dures, both in the context of routine care and clinical trials. This chapter will review 
the foundational aspects required to establish a transplantation and cellular therapy 
program within an upcoming cancer center. The Worldwide Network for Blood and 
Marrow Transplantation (WBMT) has also published guidelines on establishing 
HCT program, with a specific focus on lower middle and lower income coun-
tries [6, 7].
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 Rationale for HCT and Cellular Therapy Program
HCT and cellular therapy are essential treatments as part of providing comprehensive 
care to cancer patients. There is a plethora of indications for transplantation, which 
mainly focus on hematologic malignancies [8, 9]. However, cancer centers will fre-
quently manage patients with nonmalignant but life-threatening conditions that may 
warrant HCT (e.g., aplastic anemia). Furthermore, indications for transplantation in 
pediatric patients also include conditions such as inherited metabolic diseases and 
hemoglobinopathies that are treated with HCT. The expansion of cellular therapies 
and the emerging role of transplantation for autoimmune diseases is another area 
where an HCT program can serve a role in providing care for patients. Furthermore, 
an HCT program can serve as a resource for external referrals to a cancer center [10]. 
Overall, there continues to be a strong demand for the advanced treatment of patients 
with hematologic malignancies using HCT and cellular therapies [11, 12].
The need to have a dedicated resource in the form of an HCT program stems 
from the complexity of the procedure and its associated risks for severe morbidity 
and mortality, experience and expertise required of the team that manages patients, 
the logistical aspects around collection and ultimately infusion of hematopoietic 
progenitor cells, and the highly regulated nature of the procedure. Quality is an 
important component of care that is provided to patients, and international accredi-
tation organizations such as the Foundation for the Accreditation of Cellular 
Therapies (FACT) and the Joint Accreditation for the International Society of 
Cellular Therapy and European Society for Blood and Marrow Transplantation 
(JACIE) provide minimum standards for a high-quality HCT program [13].
It needs to be recognized that in setting up an HCT program, investment in per-
sonnel and infrastructure is also needed for ancillary services that are critical to 
providing safe and high-quality care to HCT recipients. Some examples of these 
services include availability of blood bank support, specialized laboratory testing 
(e.g., for cytomegalovirus (CMV), infectious disease markers, pathology expertise), 
intensive care unit support, palliative care and hospice, and collaboration with 
experts in other specialties such as intensive care, nephrology etc. Patients also need 
a range of supportive care services, such as psychosocial and palliative care ser-
vices, and local lodging for the patient and caregiver.
 HCT Program Structure
Strong institutional commitment and support is needed before embarking on estab-
lishment of an HCT program, given the resources required and the expense involved. 
Planning for an HCT program requires a long-term vision and a phased approach, 
especially if the cancer center does not have experience with hematologic malignan-
cies. Initial efforts need to be focused towards establishing a robust hematologic 
malignancy program, since they comprise the majority of indications for transplant, 
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and many of the personnel competencies can be applied to the care of HCT recipi-
ents. As discussed below, establishment of ancillary support services should be 
planned in parallel to the plan for the HCT program. Prior to setting up a program for 
management of HCT recipients, it is prudent to dedicate resources and efforts to set 
up a robust hematologic malignancy program that gives clinicians and other staff the 
opportunity to obtain experience in managing patients with acute leukemia, lym-
phoma, and myeloma. Once the hematologic malignancy program has matured, a 
rational next step towards HCT is to begin with autologous transplantation, and then 
expand to human leukocyte antigen (HLA)-matched sibling donor allogeneic trans-
plantation. Once sufficient experience has been obtained with these approaches, the 
program can expand to allogeneic transplantation using matched unrelated donors, 
haploidentical donors, and other alternative donor sources such as umbilical cord 
blood. Additionally, a new program may initially consider transplanting patients who 
are younger, have less comorbidities, and at lower risk for transplant-related compli-
cations. This phased approach gives the transplant team an opportunity to gain 
expertise as they evolve into the management of patients of increasing complexity, 
given that center volume and experience have been shown to be associated with out-
comes [14, 15]. The availability of local resources that can collaborate or the ability 
to contract out certain services (e.g., apheresis through a local blood bank) may also 
be a factor in planning for the setup of a new program. Histocompatibility expertise 
is fundamental and may be available locally, but is also frequently contracted out.
This suggested approach can be modified based on local priorities and comfort 
level of the transplant team – for example, in an area with high prevalence of hemo-
globinopathies and/or aplastic anemia, an initial focus on allogeneic rather than 
autologous transplantation may be advisable, especially if key personnel have prior 
experience in managing allogeneic HCT recipients. Although this chapter will not 
go into the details of setting up a cellular therapy program, the infrastructure and 
personnel established for a HCT program can also serve the needs of cellular ther-
apy recipients. Overall, there is significant overlap in resources needed for autolo-
gous and allogeneic transplantation and cellular therapies.
Various models of care delivery can be pursued as an HCT program is being devel-
oped, and they can evolve as the program grows [16]. In this context, it is also impor-
tant to understand the flow of a patient who is referred for and comes through the 
transplantation process (Fig. 13.1). When a program is in early stages of inception and 
volumes are rather small, the team and resources focused towards HCT can be shared 
by other cancer services. However, as the program matures and volumes increase, there 
may be a need to have personnel and resources dedicated towards hematologic malig-
nancies and HCT, and ultimately in the setting of a high-volume program, HCT only.
In a report from the WBMT [7], the following elements were identified as high-
est priority and thus essential elements for development of an HCT program:
• Institution (or hospital leadership) support to develop a transplant program.
• Leadership by a hematologist, oncologist, or immunologist as a medical director.
• Nursing staff trained in handling chemotherapy and infection control.
• Availability of irradiated blood and platelets.
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• Laboratory services with blood cell counter, chemistry, microbiology testing for 
bacteria and fungus, pre-transplant infectious disease markers.
• Access to standard radiology and computed tomography.
• Availability of chemotherapy, antiemetics, and broad-spectrum antibiotics.
• Availability of interventional radiology expertise for insertion of indwelling cen-
tral venous catheters.
• Access to HLA typing laboratory (for allogeneic HCT).
• Monitoring levels of calcineurin inhibitors (for allogeneic HCT).
• Availability of antivirals and antifungal for treatment (for allogeneic HCT).
• Prophylaxis and agents to prevent and treat graft-versus-host disease (GVHD, 
for allogeneic HCT).
The WBMT report also outlines preferred and ideal elements for developing an 
HCT program. With this foundation, HCT programs can evolve as they gain experi-
ence and grow and can add on personnel and infrastructure as they care for increas-
ingly complex patients and perform more sophisticated transplantation procedures. 
Other guidelines are also available that can be used as a platform to define the 
required elements as a new HCT program is considered [17].
 HCT Program Infrastructure
A good starting point for considering infrastructure and personnel requirements for 
an HCT program are FACT/JACIE standards. Table 13.1 describes the minimum 
infrastructure requirements for setting up an HCT program. It is not necessary for 
all of these resources to be available within the institution that offers HCT, since 
some of these services can be contracted out (e.g., HLA typing, cell processing, 
apheresis, blood bank).
*Early post-transplant phase typically begins at initiation of conditioning regimen and lasts through 100 days post-transplantation and 
subsequently transitions to the late post-transplant phase
- Evaluation of indication
 and candidacy for HCT
- Evaluation for need for
 additional therapy
- Evaluation for
 appropriate timing of 
 HCT
- Recipient HLA typing 
 (allogeneic HCT)
- Donor search and HLA









 (e.g., local lodging,
 transportation)




 collection of HPCs
 (autologous HCT)
- Donor hematopoietic










 for recovery and
 complications post-
 engraftment 





 for recovery and late
 complications
- Monitoring for chronic
 graft-versus-host disease
- Surveillance, screening,
 and management of late
 complications
- Disease surveillance and
 maintenance therapy
- Management of disease
 relapse
- Care coordination with
 local clinicians
Late Post-Transplant*
Fig. 13.1 Typical flow of HCT recipient (HPC denotes hematopoietic progenitor cells)
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In general, an HCT program is best served by a dedicated outpatient and inpa-
tient area. FACT/JACIE standards for clinical programs require presence of desig-
nated areas that have adequate space and design that minimizes microbial 
contamination, and allows for patient isolation and administration of intravenous 
fluids, blood products, and medications. This approach has the benefit of consolidat-
ing personnel and enhancing their experience. Furthermore, there are some infra-
structural advantages to this approach. For example, HCT units will frequently have 
laminar flow rooms or rooms with high-efficiency particle air (HEPA) filtration sys-
tems, which are most economically installed in a concentrated area. Depending on 
the existing layout for an institution, there may be value to having dedicated areas 
for procedures within the outpatient area (e.g., for bone marrow biopsy). Quality 
assurance is a major component of a high-functioning HCT program, and a specific 
area for caring for transplant recipients helps ensure that processes and outcomes 
are monitored appropriately.
Table 13.1 Infrastructure requirements suggested for establishing an HCT program (examples 
below highlight requirements above what a typical resource may be structured for in a high- 
functional medical institution)
Service Examples of infrastructure requirements
Outpatient clinic Single patient examination rooms
Infusion chairs
Inpatient unit Private (single bed) rooms with isolation capability
Pharmacy Pharmacy equipped to handle chemotherapeutic agents
Access to specialized medications (e.g., immunosuppressants, 
antimicrobials)
Radiology CT scan and MRI




Setup and experience in providing total body irradiation (if radiation-based 
conditioning regimens are planned)
Blood bank Adequate red blood cell and platelet blood product support
Ability to irradiate and leukocyte reduced blood products





Ability to perform HCT-specific tests (e.g., drug levels)
Microbiology Ability to perform infectious disease markers
Monitoring for CMV (antigen or PCR)
Monitoring for other organisms (e.g., fungi, viruses)
Pathology Expertise in hematopathology
Flow cytometry
Cytogenetics and molecular pathology
Emergency 
medicine
Emergency department with experience in handling cancer patients
Other services Intensive care unit, including ventilator support
Nephrology services, including dialysis
Gastroenterology services, including endoscopy services
Operating room services if bone marrow harvests are planned
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Other hospital services are also critical for optimal care of HCT recipients. For 
example, specialized imaging services such as interventional radiology are neces-
sary for placement of central venous catheters and organ biopsies (e.g., for GVHD), 
gastroenterology and endoscopy services for evaluation and diagnosis of GVHD 
and alimentary tract infections, intensive care services for management of patients 
who have hemodynamic compromise or need ventilator support, and nephrology 
services for dialysis. The pharmacy services should be able to handle and dispense 
high-dose chemotherapy medications. Similarly, in addition to providing routine 
support for cancer patients, laboratory, pathology, microbiology, and transfusion 
medicine services need to evolve to support HCT recipients. For example, patients 
who are going through the transplantation process need monitoring for levels of 
calcineurin inhibitors and monitoring for CMV. If the center is planning to pursue 
allogeneic transplantation, the laboratory needs to be equipped to test (or send out 
to another lab) HLA typing and donor-specific antibodies and conduct chimerism 
testing post-transplantation. The blood bank should have a process for ensuring 
adequate blood product support for the HCT program, including ability to irradiate 
and leucocyte reduce blood products. Blood banks will often provide apheresis and 
hematopoietic progenitor cell (HPC) storage/cryopreservation services for HCT 
programs. Obtaining and maintaining accreditation from national organizations 
(e.g., American Association of Blood Banks (AABB), American Society for 
Histocompatibility and Immunogenetics (ASHI), European Federation for 
Immunogenetics (EFI), College of American Pathologists (CAP)) ensures that 
ancillary services have the required infrastructure, processes, and experience to sup-
port the HCT program.
 HCT Program Personnel
Similar to infrastructure requirements, FACT/JACIE standards can lay the founda-
tion for determining personnel required for an HCT program (Table  13.2). 
Ultimately, a high-functioning, experienced, and cohesive team is required to pro-
vide high-quality and interdisciplinary care to HCT recipients. Additional training 
and qualifications specifically in HCT are often preferred for many personnel who 
participate in the care of transplant patients.
FACT/JACIE standards require an HCT program to have a dedicated clinical 
program director with background training in hematology, medical oncology, or 
immunology with at least 2 years of experience in direct clinical management of 
transplant patients. This individual is responsible for clinical and administrative 
operations and oversees care provided by the whole program. In addition, at least 
one other attending physician is recommended with one or more years of experience 
in the management of HCT recipients. It is not uncommon for programs to have 
physician trainees participate in the care of transplant patients. Many programs, 
especially in the United States, use advanced practice providers (APPs) such as 
nurse practitioners and physician assistants to provide care for their patients.
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Nursing staff with experience in management of HCT patients are a critical com-
ponent of a successful HCT program. In the outpatient setting, nurses may be 
involved in patient and donor education, pretransplant testing, and posttransplant 
care coordination. On the inpatient side, they need to be experienced in the admin-
istration of high-dose preparative regimens, infusion of HPC and blood products, 
providing supportive care, and management of various transplant related 
complications.
Several other team members are critical for safe and optimal care of HCT recipi-
ents. Some examples of such personnel include pharmacists and social workers. 
Pharmacists with experience in transplantation and dedicated to HCT program are 
in fact required per FACT/JACIE standards. There is guidance available from the 
American Society for Transplantation and Cellular Therapy (ASTCT) on the role of 
pharmacists in an HCT program, which can serve as a foundation for defining their 
role in patient care, education, research, and quality improvement [18, 19]. Social 
workers or psychosocial clinicians can assist in pretransplant evaluation of donors 
and recipients, facilitate with lodging, transportation, financial grants, and other 
social needs of patients, and screen and triage psychological complications. 
Guidance that defines the role of social workers in facilitating and optimizing the 
care of HCT recipients has been published [20].
In addition to clinical staff, several other personnel play a key role in the func-
tioning of an HCT program. FACT/JACIE standards require a clinical program 
Table 13.2 Personnel requirements suggested for establishing an HCT program
Physician and related staff
  Clinical program director
  Additional attending physician
  Advanced practice provider
  Trainee physician
  Consulting specialists
  Palliative medicine specialists
Outpatient personnel
  Nurse/care coordinator
  Educator
  Financial navigator
  Social worker or psychosocial clinician
  Pharmacist
  Physical therapists or physiotherapist
Inpatient personnel
  Nurse
  Social worker
  Pharmacist
  Physical therapists or physiotherapist
Other personnel
  Program manager or administrator
  Data coordinator
  Quality manager
  Dietician
  Research nurses and coordinators
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quality manager whose role involves establishing standard operating procedures and 
maintaining systems and processes to ensure they are followed and the program is in 
compliance. These individuals often manage data operations, especially for smaller 
programs. Additional personnel for data management and research may be required, 
depending on whether there is the availability and interest in pursuing research. It is 
advantageous for centers to submit data to a central registry such as the Center for 
International Blood and Marrow Transplant Research (CIBMTR) or the European 
Society for Blood and Marrow Transplantation (EBMT) (see below), and additional 
personnel for data capture and reporting may be needed for this purpose.
Several physician specialists and other clinicians outside the HCT team are also 
required for the care of HCT recipients. Some examples of these specialties include 
surgery, pulmonary medicine, intensive care, gastroenterology, nephrology, infec-
tious diseases, cardiology, pathology, psychiatry, radiology, radiation oncology, 
ophthalmology, dentistry, dermatology, and palliative care.
The expertise of personnel may change and evolve as the HCT program grows. 
For example, the skillset for managing allogeneic HCT recipients may be different 
than autologous HCT recipients, since expertise in managing issues such as fungal 
and viral infections and GVHD is required. Similarly, the models of care and roles 
for specific personnel may change with the growth of the program – for instance, an 
outpatient nurse position may get further specialized as the number of patients 
transplanted increases, with separate nurses focusing on donor search and pretrans-
plant evaluation, patient education, and post-transplant care coordination. An insti-
tution has to recognize that there is no one standard model of care for a transplant 
program, and the roles, types, and number of personnel depends on local infrastruc-
ture, priorities, and existing resources.
 Quality Management
A successful HCT program requires a robust quality management program to moni-
tor its performance, ascertain consistency of established processes, identify areas 
for improvement, implement corrective action for deficiencies, establish a culture of 
continuous improvement, and demonstrate operational effectiveness to internal and 
external entities. Recognizing its importance, FACT/JACIE standards require that 
HCT programs identify an individual who serves as quality manager and that pro-
grams have a quality management plan. Given its complexity, use of healthy donors, 
and economic impact, transplantation tends to be highly regulated by many coun-
tries, and the quality program also supports compliance with requirements laid out 
by national regulatory authorities.
A successful quality program requires collaborative and interdisciplinary inter-
actions between all stakeholders who are involved in the care of HCT recipients 
(Fig.  13.2). The program director and the quality manager ultimately maintain 
responsibility for engaging these stakeholder groups and ensure cohesive interac-
tions that focus on continuous program improvement and high-quality patient care.
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The FACT/JACIE standards are a good starting point to define the scope of the 
quality program. How the quality program is structured and what aspects of trans-
plant recipient care are under its oversight can vary by program. The HCT program 
should also establish certain benchmarks where it can meaningfully review its per-
formance and use those data as the foundation for program review and improvement 
(Table 13.3). In general, examples of some areas that may be under the purview of 
a quality program include:
• Personnel onboarding, continuing education, and maintaining competency – the 
quality manager can ensure that HCT program personnel are assigned relevant 
educational modules and complete all requirements for maintaining educational 
and professional competency as it relates to transplantation.
• Facility compliance – to meet accreditation and other regulatory standards, facil-
ity and equipment routinely used for the care of HCT recipients often needs 
continuous monitoring (e.g., functioning and maintenance of apheresis machine 
and cryogenic storage).
• Documentation  – HCT programs are required to maintain standard operating 
procedures (SOPs) that describe their processes and clinical guidelines, and the 
quality manager’s responsibilities typically include their development and main-
tenance, and ensuring that the HCT program and its personnel are in compliance.
• Audits – One aspect of quality assurance is to review compliance with various 
HCT program data, processes and SOPs, and the quality manager typically con-
ducts these audits with help from other program personnel.
• Adverse event monitoring – The complexity of HCT procedure and processes 



























Fig. 13.2 Example of various stakeholders required for an interdisciplinary and effective qual-
ity program
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establish processes for monitoring and reporting of expected and unexpected 
adverse events along with their remediation.
• Continuous improvement – Another aspect of the quality program is to provide 
tools and data for improving processes and outcomes, and the quality manager 
can lead these efforts under guidance form the HCT program director.
The quality aspects for the HCT program along with the resources needed to 
manage them will typically evolve with program growth, with implementation of 
high-risk allogeneic transplant programs necessitating more complex quality- 
related processes and procedures. Newer cellular therapy modalities add to the com-
plexity, as exemplified by FDA-approved CAR T products which have somewhat 
different requirements depending on the company providing the cells.
 Data and Research
HCT and cellular therapy are highly innovative and rapidly evolving fields. An 
active HCT program can serve as a platform for academic development and knowl-
edge generation. In addition, data captured for research can be repurposed and sup-
port the program from quality and clinical management standpoints.
Table 13.3 Sample metrics to monitor as part of HCT Program quality plan
Clinical program outcome metrics
  Overall survival (100 days, 1 year)
  Non-relapse mortality (100 days, 1 year)
  Acute GVHD rate (100 days)
  Chronic GVHD rate (1 year)
  Length of stay for transplant hospitalization
  Readmission rate
  Engraftment and graft failure rates
Patient safety metrics
  Rate of center line-associated blood stream infection
  Rate of C. difficile infections
  Rate of chemotherapy safety error events
  Rate of other medication safety error events
  Rate of falls
  Rate of compliance with hand hygiene
  Rate of mislabeled specimen events
  Rate of infusion reactions
Apheresis collection facility metrics
  Days required for adequate PBSC collection
  Rate of positive culture for HPC product
  CD34 collection efficiency
  Rate of central line use (in healthy donors)
  Rate of exceptional releases from apheresis
  Rate of serious adverse events
N. S. Majhail and M. De Lima
131
To support these efforts, we do recommend one or more data managers be 
incorporated within the HCT program structure from the outset. For an early pro-
gram still in its establishment phase, the individual overseeing quality can per-
form many of the duties expected of a data manager. However, as the program 
grows and becomes busier, investment into a data capture and management soft-
ware solution along with personnel and resources to support them can be an excel-
lent investment. Some HCT programs use simple systems to capture and manage 
data, whereas more sophisticated systems can also integrate into the clinical work-
flow for programs and possibly connect with the institutions’ electronic medi-
cal record.
Data capture on patient demographics, disease status, transplant regimen, and 
posttransplant complications and outcomes can serve several purposes. Since HCT 
is a highly regulated field, these data can be used to provide aggregate information 
on transplant activity and outcomes to regulatory and accreditation organizations. 
Payers and policy makers may also request access to these aggregate data to evalu-
ate HCT program capabilities and performance. The data collected often support 
quality management aspects of the program. It is advantageous to report data to 
central registries such as the CIBMTR, the EBMT, or another national or interna-
tional registry, since it provides a foundation for meaningful data that a center needs 
to capture, provides opportunities for HCT program faculty to participate in col-
laborative research and discovery, and can help benchmark HCT program data and 
outcomes with other similar programs. Along with collection of data, there needs to 
exist robust mechanisms to ensure that the data are accurate. Besides having well-
trained and high- functioning data coordinators, regular audits can help in ascertain-
ing the quality of data collected.
 Cellular Therapy
Recently, there has been significant interest in the application of non-HCT cellular 
therapies such as CAR T-cell therapy. Several products are now approved and com-
mercially available for the treatment of lymphoma (axicabtagene ciloleucel, brexu-
cabtagene autoleucel, and tisagenlecleucel), acute lymphoblastic leukemia 
(tisagenlecleucel), and myeloma (idecabtagene vicleucel). Several CAR T-cell and 
other cellular therapy products are under clinical investigation for the treatment of a 
spectrum of hematologic malignancies and solid tumors, and for nonmalignant indi-
cations. In essence, the clinical management, infrastructural, resource, personnel, 
process, and quality components are very similar to HCT, and transplant programs 
are a natural fit for administering standard of care and investigational cellular ther-
apy products. FACT/JACIE standards are available for immune effector cell therapy 
and can serve as the foundation for setting up a cellular therapy program. An expe-
rienced transplant program should generally be able to offer these therapies within 
its existing infrastructure. As we look ahead, there will be an increasing use of 
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cellular therapy for cancer and noncancer indications, and availability of these ser-
vices within a cancer center will be necessary for provision on comprehensive can-
cer care services.
In conclusion, a successful HCT and cellular therapy program is a service line 
that indicates that a cancer center has the infrastructure and commitment to provide 
comprehensive cancer care services. It provides the opportunity to provide the com-
plete spectrum of care for patients with advanced hematologic malignancies and 
other diseases. A successful program requires leadership and presence of a high- 
functioning clinical team in order to optimize patient experience and outcomes.
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Chapter 14




In a landmark article in 1966 [1], Avedis Donabedian, one of the pioneers of quality 
improvement in medicine, proposed a structural framework for assessing quality in 
healthcare. According to this framework, quality in healthcare is evaluated on three 
different dimensions: structure, process, and outcome. This framework remains rel-
evant today and is still an extremely useful model for assessing quality in medicine.
Structure, in Donabedian’s model, is the context of where and how care is deliv-
ered and paid for. This includes facilities, equipment, people who provide the care, 
and the ways care is paid for. Process involves the interactions between patients and 
providers along the entire continuum of care—in other words, the processes by 
which providers and hospital systems can ensure the safety and well-being of 
patients. Outcome, the third dimension, is what most think about when they con-
sider quality in health care—that is, the end result or effect of the care on the health 
status of individuals and entire populations. Example would be unplanned hospital 
readmissions, or five-year survival rates in patients with breast cancer.
In later work, Donabedian expanded his quality framework into the “seven pil-
lars of quality”: efficacy, effectiveness, efficiency, optimality, acceptability, legiti-
macy, and equity [2, 3]. The three components and seven pillars have served as the 
backbone of quality improvement in subsequent decades. A useful summary of 
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Donabedian’s work was published in NEJM in 2016, on the fiftieth anniversary of 
his seminal article [4].
Reports from the Institute of Medicine (IOM) in the United States in 1990, 1999, 
and 2001 adopted Donabedian’s framework in their analyses and their recommen-
dations for implementation. The first of these reports, Medicare: A Strategy for 
Quality Assurance [5], called for the creation of a Medicare Program to Assure 
Quality (MPAQ) and largely employed Donabedian’s structure-process-outcome 
framework. The second report, Ensuring Quality Cancer Care [6], applied improve-
ment principles specifically to cancer care, creating a twenty-first century frame-
work for quality measurement in oncology, building on Donabedian’s original triad 
of structure, process, and outcome. The 2001 report, Crossing the Quality Chasm 
[7], meanwhile, highlighted six core aims (similar to Donabedian’s seven pillars) 
for quality in health care: safe, effective, patient-centered, timely, efficient, and 
equitable. Subsequent reports from IOM/NAM have continued to build on this 
work [8].
Quality improvement in cancer care is especially urgent today, given the rising 
global incidence of cancer and soaring drug costs. The annual cost of care for a 
cancer patient is four times that for a noncancer patient in the United States [9]. The 
cost of cancer care is rising, and one major study has predicted a U.S. cancer survi-
vorship expenditure growth rate of 1.99% over the period from 2015 to 2030 ($183 
billion to $246 billion, inclusive of care and drug costs) [10]. Globally, the burden 
of cancer is expected to rise. The World Health Organization’s (WHO) International 
Agency for Research on Cancer predicts a global increase in new cancer cases from 
18.1 to 29.5 million from 2018 to 2040 (2.25% yearly growth rate), if rates remain 
constant, due only to population growth and demographic trends [11]. The increase 
is heterogeneous with respect to location and cancer type. For example, from 2013 
to 2035, colorectal cancer cases are expected to increase in Australia by 59% and in 
the United States by 28%, while the number of deaths globally is expected to 
increase by 60% for colon cancer and 71% for rectal cancer [12].
The updated IOM report recognized the challenges faced by cancer care delivery. 
According to the IOM report, the number of adults older than 65 is rapidly increas-
ing. Because the majority of cancer diagnoses and deaths occur in this demographic, 
the incidence of cancer is expected to increase 45% by 2030. Taken together, the 
rapid increase in the geriatric population, steady increase in the incidence of age- 
related cancers, and rapidly evolving treatment landscape underscore the impor-
tance of multidisciplinary cancer care. Consequently, a cancer center model appears 
to be the best model for ensuring high-quality cancer care in a patient- centered manner.
High-quality cancer care is characterized by the following features [13]:
• Prioritizes the safety of patients, through creation of processes that minimize 
harm and medical errors.
• Creates a culture that promotes evidence-based care and continuous improve-
ment of current practices.
• Maintains a patient-centered focus, and factor in personal and cultural needs.
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• Practices time efficiency, and minimize any delays that would be harmful to the 
patient and/or the caregivers.
• Avoids any form of waste, including supplies, equipment, ideas, and human 
resources.
• Ensures fairness and equity among all patients without discrimination.
Toward this end, when thinking about how to build a high-quality cancer center, 
Donabedian’s model is particularly useful in considering these essential compo-
nents (Fig. 14.1).
 Structure
In Donabedian’s model, structure refers to the context of where the care is delivered. 
Cancer care is complex and multidisciplinary. Therefore, a structural feature of 
quality cancer care is to have all the necessary personnel and physical resources in 
close proximity. This proximity permits cancer patients to see multiple specialists 
on the same day, thereby reducing the time to treatment. Moreover, having multiple 
resources, such as radiation and infusion suites, in proximity permits patients to 
receive care without needing to travel long distances to a new facility. Proximity of 
providers also facilitates communication between specialists and helps to break 
down barriers between different departments (e.g., surgery and medical oncology) 
that serve as impediments to quality in medicine.
For these reasons, multidisciplinary clinics (MDC) are a hallmark of quality and 
patient-centered cancer care. Multidisciplinary clinics have been shown to reduce 
time to treatment, decrease number of visits, improve communication between 
teams, increase patient satisfaction, improve quality of life, and even improve sur-
vival [14].



















Fig. 14.1 Proposed quality of care model for cancer centers
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Patients, families, and caregivers are at the heart of high-quality cancer care. 
High-quality cancer care should, therefore, ensure that the needs of the patients and 
their caregivers are met, which should include support in making informed deci-
sions that are based on evidence-based medicine and, more importantly, align with 
patients’ values and expectations. Cancer centers must assist their patients and fam-
ilies to comprehend the overall prognosis, benefits of treatments, and possible harms 
fully; provide palliative care, social support, and psychological support; and esti-
mate cancer treatment costs accurately. In the setting of terminal cancer, resources 
that emphasize the importance of end-of-life care to maximize quality of life should 
be readily available.
Additionally, a structural hallmark of a high-quality cancer center are the profes-
sionals who provide care to patients. These include surgical, medical, and radiation 
oncologists, pathologists, palliative care physicians, oncology nurses, psychosocial 
workers, pharmacists, and other specialties that are routinely involved in providing 
cancer care. All providers should work together and effectively communicate, 
ensuring seamless transitions for patients and their families. All healthcare workers 
should also possess appropriate proficiencies and make appropriate treatment rec-
ommendations based on patients’ and families’ wishes. Roles should be clearly 
defined, and responsibilities assigned, with clear expectations from each member. 
There should be mutual trust between members, and communication should be 
effective. A cancer center should help continually improve communication skills 
among the staff with patients.
Health information technology systems also play an integral role in ensuring a 
high-quality cancer center. The electronic medical record (EMR) should be efficient 
and able to provide information to patients and healthcare providers in an effective 
manner, and it ideally should be structured to promote continuous improvement.
Finally, a cancer center needs a team of quality professionals—including a phy-
sician lead, a nursing lead, and a nonphysician with a quality improvement back-
ground—who structurally comprise the core team that is tasked to help drive quality 
throughout the entire cancer center.
 Process
Medical errors are common in medicine. A medical error is a preventable adverse 
effect of medical care, whether or not it is evident or harmful to the patient [15]. A 
2013 study estimated that medical errors were the third leading cause of death in the 
United States, after heart disease and cancer, accounted for approximately 210,000 
and 440,000 deaths annually [16]. The nine most common medical errors in the 
United States in 2014, in order of frequency, were adverse drug events, catheter-
associated urinary tract infection (CAUTI), central line–associated bloodstream 
infection (CLABSI), injury from falls and immobility, obstetrical adverse events, 
pressure ulcers, surgical site infections (SSI), venous thrombosis (blood clots), and 
ventilator- associated pneumonia (VAP) [17].
A. Babar and A. J. Montero
139
The high complexity of cancer care and the morbidity of many cancer treatments 
greatly increase the potential for medical error, unfavorable outcomes, and system 
failure. Therefore, it is imperative for cancer centers to create a culture of safety, 
where all providers are expected to report and disclose errors due to the complexity 
of narrow therapeutic index of many cancer treatments. To support a culture of 
reporting medical errors, cancer centers should have an electronic reporting system 
in place that facilitates the reporting of adverse events by all members of the health-
care team. There should be a dedicated team comprised of physicians, nurses, and 
administrative staff who deal with adverse event reporting and are trained in per-
forming root cause analyses. This electronic platform should help to identify trends 
over time, enabling quality improvement work.
Morbidity and mortality (M&M) conferences are another vital tool that cancer 
centers should routinely use to improve overall quality of care [18]. These confer-
ences provide a venue where errors and adverse events from individual cases can be 
discussed and process issues identified.
In addition to M&M conferences, multidisciplinary tumor boards (MDTB) are 
an integral part of cancer care management, where experts from various domains of 
oncology discuss and present newly diagnosed patients. Research has shown that 
MDTBs lead to more accurate diagnosis, more accurate staging, and more appropri-
ate treatments [19].
To ensure high-quality care, cancer centers must create a system of continuous 
improvement where key quality metrics are measured along the entire continuum of 
cancer care. An organization cannot consistently deliver quality products or services 
without creating a system that promotes continuous improvement as well as self- 
improvement of employees. An organization cannot mandate excellence simply by 
slogans and unrealistic decrees by management [20].
Therefore, in order to hardwire quality and excellence, cancer center leadership 
must create an environment where processes are continuously improved, and those 
closest to the work are empowered to make changes that will lead to care of the 
highest possible quality for all patients. Continuous improvement is impossible 
without identification and measurement of key quality metrics. It is essential that 
those closest to the work (nurses, physicians, pharmacists, etc.), who are the content 
experts, help with deciding what key metrics to focus on and how best to measure 
them. Leadership is responsible with providing the infrastructure to measure key 
metrics and provide resources to permit continuous improvement of all cancer cen-
ter processes with the goal of improving the quality of care for all patients.
Fortunately, American Society of Clinical Oncology (ASCO), National 
Comprehensive Cancer Network (NCCN), and international oncology organiza-
tions have developed a wealth of quality metrics for cancer centers to use, helping 
to simplify the work of selecting and defining metrics (Table 14.2). For example, 
NCCN advances its mission to improve and facilitate quality, effective, efficient, 
and accessible cancer care through creation and continuous update of clinical prac-
tice guideline, thereby facilitating creation of a reliable source for patients, clini-
cians, payers, and other healthcare decision-makers. Table  14.1 presents quality 
measures selected by NCCN’s Quality and Outcomes Committee (Table 14.2).
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 Outcome
In medicine, there is a much greater focus on outcomes than processes. This is 
understandable, since the overall goal of treating any cancer is ultimately cure. 
However, any outcome is the culmination of many processes, and improving an 
outcome is nearly impossible without a thorough understanding of all the processes 
involved that led to a specific outcome. Take, for example, the diagnosis and subse-
quent treatment of early stage breast cancer. This involves many processes, includ-
ing breast cancer screening, radiographic interpretation, biopsy of suspicious 
lesions, pathologic interpretation, surgical management, selection of appropriate 
chemo- and endocrine therapy, radiation oncology, management of treatment- 
related toxicities, and cancer survivorship. Five-year breast cancer survival is a cul-
mination of all of these processes, as well as others. To improve this outcome metric 
requires identification of key improvements in many or all of these processes.
This is not to say that outcome measures are not important. Indeed, they are 
extremely important. However, outcomes cannot be viewed as independent of pro-
cesses, since they are completely dependent on them. Additionally, survival out-
comes for a cancer center cannot be viewed in isolation of the populations that they 
serve. Population and socioeconomic factors can influence survival, independent of 
quality of medical care. For example, breast cancer mortality has been shown to 
correlate positively with socioeconomic factors that vary quite substantially across 
Table 14.1 Quality measures selected by the NCCN quality and outcomes committee [23]
Cancer Quality metrics
Breast Patients should receive breast/chest wall plus regional lymph node radiation if they 
have M0 disease or involvement of ≥4 axillary lymph nodes.
Breast Patients who have been cured of breast cancer should not have tumor markers 
performed during the follow-up surveillance period.
Colorectal Patients with rectal cancer should undergo staging CT chest, abdomen, pelvis and 
pelvic MRI with contrast or endorectal ultrasound before surgery.
Colorectal Carcinoembryonic antigen should be performed every 6 months for 5 years for 
patients with resected pathological stage II and III colorectal cancer.
Lung Patients with newly diagnosed metastatic non-small cell lung cancer should have a 
palliative medicine consult within 8 weeks of diagnosis.
Prostate All patients in high-risk prostate cancer group who undergo radiation should be 
treated with androgen deprivation therapy.
Prostate Patients who have undergone surgery or radiation for localized prostate cancer 
should be evaluated for sexual dysfunction and urinary incontinence.
Prostate Patients with prostate cancer should have prostate specific antigen measured every 
12 months to monitor recurrence of disease.
Cross- 
cancer
Cancer stage should be documented.
Performance status should be documented before starting systemic therapy.
Percentage of patients with cancer admitted to intensive care unit in the last 
30 days of life.
Patients who smoke should be offered smoking cessation counselling.
Number of patients undergoing chemotherapy in the last 14 days of life.
Number of patients dying from cancer in the acute care setting.
Chemotherapy given within 30 days of end of life.
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countries and that are associated with economic development and social/lifestyle 
factors [21].
In order to measure long-term cancer outcomes, cancer centers need to have a 
robust tumor registry that can track outcomes among the cancer patients that they 
serve. These long-term outcomes would need to be stratified to factor in medical 
comorbidities and socioeconomic factors. Ideally, these data should be bench-
marked to national data if available. This would require statistical and epidemio-
logic support that may not be readily available to all cancer centers but would be of 
great value, particularly when thinking about where the greatest opportunities are 
for improvement of cancer outcomes.
Patient satisfaction is also an important outcome that cancer centers must reli-
ably track. Validated patient questionnaires that are provided to patients and their 
families are a key way to capture the voice of the patient and to identify areas of 
strength and areas where improvements must be made. Creating a culture of patient- 
centered care requires honest feedback from patients.
Table 14.2 Selected resources on cancer care quality
Organization Description Link
American Academy of 
hospice and palliative 
medicine (AAHPM)
Resources and tools to address quality 




American Society of 
Clinical Oncology 
(ASCO)
Information on ASCO quality programs, 
guidelines, chemotherapy safety 
standards, and quality oncology practice 




American Society of 
Hematology (ASH)
Quality care resources specific to 




guidelines- and- quality- 
care
American Society for 
Radiation Oncology 
(ASTRO)





Commission on Cancer 
(CoC)
Information on CoC standards to facilitate 




Foundation for the 
Accreditation of cellular 
therapy (FACT)
Quality standards for hematopoietic cell 
transplantation and cellular therapies
http://www.factwebsite.
org/
American College of 
Surgeons (ACS)








List of high-priority and high-impact 





National Quality Forum 
(NQF)






ONS resources on quality cancer care https://www.ons.org/
make- difference/
quality- improvement
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Another important outcome measure is patient-reported outcomes (PROs). Symptoms 
are common among patients receiving treatment for advanced cancers yet are unde-
tected by clinicians up to half the time. There is growing interest in integrating electronic 
PROs into routine oncology practice for symptom monitoring. In a recent randomized 
trial, data integration of PROs into the routine care of patients with metastatic cancer was 
associated with a significant improvement in overall survival compared with usual care 
[22]. Earlier identification of emerging toxicities in patients enabled the oncology care 
team to intervene more rapidly before toxicities became more severe, enabling patients 
to stay on treatments longer and avoid unnecessary hospitalizations.
 Conclusions
Quality in healthcare has three primary domains: structure, process, and outcome. 
This is the three-legged stool upon which clinical excellence sits. To successfully 
build quality from the ground up in a cancer center, first you need the right people. A 
quality team of professionals that is responsible for promoting a culture of excellence 
and quality improvement is needed. This small team should be comprised of physi-
cians, nurses, pharmacists, data management, and quality improvement profession-
als. Responsibility should be delegated by executive leadership to this quality team 
to drive quality and foster a culture of quality improvement throughout the entire 
cancer center. High-quality care is synonymous with patient-centered care and is 
everyone’s responsibility. Those who are closest to the patient and, therefore, have 
the greatest control over treatment decisions must be given the proper tools, educa-
tion, and support to conduct quality improvement activities. Providers need access to 
timely data on relevant quality-related process and outcome measures, because 
improvement is practically impossible without formal longitudinal measurements. 
Fortunately, there are a wealth of validated oncology quality measures that have been 
created by ASCO, NCCN, and other organizations, which cancer centers can adapt.
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Chapter 15
Patient Resources in a Cancer Center
Farah Yassine and Mohamed A. Kharfan-Dabaja
 Introduction
Treatment of cancer is complex and requires clinical expertise, close surveillance, and 
supportive therapies, among others, to help manage untoward side effects resulting 
from antineoplastic regimens. These therapies expose patients to adverse conse-
quences such as increased organ toxicity that could adversely affect overall quality of 
life. For instance, childhood cancer survivors are at a higher risk of being unable to 
work or missing work because of poor health; they also report difficulties with obtain-
ing insurance coverage, hence posing a challenge to adherence to optimal care [1]. A 
childhood cancer survivorship study showed that, in fact, survivors of childhood can-
cer spend a higher percentage of their income on medical expenses, adversely influ-
encing their future health-seeking behavior and ultimately their treatment outcomes [2].
Novel targeted therapies with better toxicity profiles, vis-à-vis conventional che-
motherapies, have become an integral part of treatment algorithms for various solid 
organ neoplasms and hematologic malignancies; they are already changing the 
treatment paradigm of various cancers [3–9]. However, these new therapies are 
expensive, especially when required to be taken for a long time [10, 11]. 
Unfortunately, patients with cancer are at high risk for substantial treatment-related 
costs owing to the high cost of these novel therapies. Apart from the high cost of 
therapies, availability of high-resolution genomic analysis of tumors, and other 
technologies, which are being used for more accurate diagnosis and prognostication 
have further added to the already elevated cost of treating cancer [12–14].
A recently published longitudinal study aimed at evaluating the impact of cancer 
on patient’s debt in the United States found a substantial proportion incurring finan-
cial toxicity and asset depletion [15]. This is also the case for parents of children 
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receiving anticancer therapies [1]. Below, we describe resources that are generally 
available to cancer patients to help cope with stressors associated with cancer care 
and to address their medical, financial, and spiritual needs, among others.
 Available Resources
 Education
Patient education is an essential requirement when developing a plan of cancer care. 
Education represents a continuum which is provided by several members of the 
treatment team, namely, hematologists/oncologists, advanced practice providers, 
nurses, nutritionists, and pharmacists, among others. Below, we describe available 
educational sources for patients, whether related to disease-specific, antineoplastic 
drugs and supportive therapy education.
 Disease-Specific Education
Several cancer societies provide disease-specific education to patients with cancer. 
We summarize a small selected sample of societies and organizations:
 (a) AA·MDS International Foundation (www.aamds.org).
 (b) American Cancer Society (ACS) (www.cancer.org).
 (c) International Myeloma Foundation (www.myeloma.org).
 (d) Leukemia & Lymphoma Society (www.lls.org).
 (e) Melanoma Research Foundation (www.melanoma.org).
 (f) National Cancer Institute (NCI) (www.cancer.gov).
 (g) Susan G.  Komen, originally known as The Susan G.  Komen Breast Cancer 
Foundation (ww5.komen.org).
 Treatment Education
Below we summarize the most common types of antineoplastic therapies offered to 
patients apart from surgical tumor resection. We also highlight selected educational 
sources available to patients.
 Conventional Chemotherapy
Conventional chemotherapy, alone or in combination with targeted therapies, 
remains an important treatment for various hematologic malignancies such as acute 
myeloid leukemia, acute lymphoblastic leukemia, lymphomas, breast, lung and 
F. Yassine and M. A. Kharfan-Dabaja
147
colorectal cancer, among many others. Side effects associated with chemotherapy 
vary according to each agent, but generally result in bone marrow toxicity which 
manifests as pancytopenia and could increase risk of infections, and organ toxicity 
manifesting as alopecia, mucositis, enteritis, cardiomyopathy, hemorrhagic cystitis, 
and others. When severe toxicity ensues, it can result in death. Therefore, it is impor-
tant to empower the patient with the necessary knowledge about commonly occur-
ring side effects associated with specific chemotherapies to ensure more successful 
outcomes. This information is generally available in the package inserts that is found 
online for each specific antineoplastic agent. Others sources of information include 
the drug manufacturer, the ACS (www.cancer.org), and the NCI (www.cancer.gov).
 Targeted Antineoplastic Therapies
Treatment of cancer has evolved over the past three decades. Nowadays, the back-
bone of anticancer treatments relies more heavily on targeted therapies, also known 
as precision medicine. It is a type of cancer treatment characterized by a more spe-
cific mode of action than conventional chemotherapy, through targeting specific 
genes and proteins involved in the growth and survival of cancer cells. It can either 
affect the tissue environment of cancer cells, or disrupt other key mechanisms 
essential for cancer growth and proliferation. Targeted therapies may be used as 
monotherapy; for example, in chronic lymphocytic leukemia and chronic myeloid 
leukemia; or in combination with other cancer treatments, namely, chemotherapy, 
surgery, or radiation in the case of solid tumors like lung, breast, and colorectal 
cancer. Below, we summarize several available online sources, apart from drug 
manufacturers, to educate patients about targeted therapies:
 (a) The American College of Physicians (ACP) offers a library of patient educa-
tion materials accessible through the following hyperlink: https://www.acpon-
line.org/practice- resources/patient- and- interprofessional- education. ACP is 
currently replacing its online library with a new Patient and Interprofessional 
Partnership initiative, delivering high-quality, patient-centered, interprofes-
sional education resources for internists, patients, and their clinical teams.
 (b) UpToDate is another platform offering patient education through two levels 
of content: “The Basics,” which are short overviews in easy-to-understand 
language aimed at answering important questions a patient may have about a 
medical topic; and “Beyond the Basics”, which are extensive, more detailed 
reviews with some medical terminology. Information about targeted therapies 
is included within each type of cancer (https://www.uptodate.com/contents/
table- of- contents/patient- education/cancer).
Following is a list of other selected resources for patient education on cancer- 
targeted therapies:
 (a) The NCI: https://www.cancer.gov/about- cancer/treatment/types/targeted- 
therapies/targeted-therapies- fact- sheet
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 (b) My Cancer Genome: https://www.mycancergenome.org/content/page/overview- 
of- targeted- therapies- for- cancer/
 (c) The ACS: https://www.cancer.org/treatment/treatments- and- side- effects/
treatment- types/targeted- therapy.html
 (d) The National Comprehensive Cancer Network (NCCN): https://www.nccn.org/
patients/resources/life_with_cancer/treatment/targeted_therapy.aspx
 Radiation Therapy
Since its discovery in the nineteenth century, radiation has been used in medicine 
through several applications [16]. In the field of cancer therapeutics, radiation ther-
apy is one of the primary treatment modalities, exerting its action by directly killing 
cancer cells or causing DNA damage leading to tumor cell death [17]. Cancer 
patients also benefit from the option of radiation therapy in the palliative care set-
ting, for example, to relieve pain caused by bone metastasis or cytoreducing large 
tumor masses obstructing the airway in head and neck cancers [18]. Constant 
advancements in this area enhanced the accuracy and quality of radiation delivery, 
increasing the survival rates for many patients [19]. Damage to healthy tissue near 
the treatment area results in multiple side effects, commonly skin problems (dry-
ness, itching, blistering, or peeling), and fatigue [20]. Other side effects are site- 
specific: for instance, radiation therapy aimed at head and neck tumors causes dry 
mouth, difficulty swallowing, mouth sores, nausea, hair loss, and tooth decay [21]. 
Chest radiation may result in lung fibrosis, radiation pneumonitis, cough, fever, 
shortness of breath, and cardiovascular side effects [22]. Radiation therapy for solid 
malignancies is also associated with higher risk of acute leukemias and non- 
Hodgkin lymphomas [23].
Multiple educational resources for patients on radiation therapy benefits and side 
effects are available on the American Society for Radiation Oncology (ASTRO) 
website (https://www.astro.org/Patient- Care- and- Research/Patient- Education), 
including brief videos, patient brochures, and radiation therapy presentations. With 
the emergence of modern virtual environments, radiation therapy patient education 
has witnessed the rise of two recent educational tools, namely, the Virtual 
Environment for Radiotherapy Training (VERT) and the Patient Education And 
Radiotherapy Learning (PEARL). The VERT system relies on a three-dimensional 
interactive radiotherapy treatment room that replicates realistic movements, sounds 
and even a visible radiation beam, suitable for both patient education and residency 
training [24]. Similarly, the PEARL system uses common features including a vir-
tual patient and treatment room environment, but with limited functionality as it is 
was solely conceived for the purpose of patient education [25]. Such rich visual 
displays and virtual environments constitute an innovative approach in radiation 
therapy patient education; however, they should be tuned to every cancer center’s 
budget and capacity [26]. Their roles in supporting psychological and health-related 
patient outcomes are still under investigation.
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 Supportive Therapies
Availability of effective supportive therapies have facilitated timely administration 
of chemotherapy, chemoimmunotherapy, other targeted therapies, and radiation 
therapy. These supportive therapies include but are not limited to:
 (a) Antiemetics to prevent nausea and vomiting.
 (b) Antimicrobials (antibacterials, antifungals, and antivirals).
 (c) Bisphosphonates or equivalents.
 (d) Granulocyte-Colony stimulating factor (G-CSF) that stimulates the bone mar-
row to produce granulocytes.
 (e) Intravenous fluids and electrolytes.
 (f) Transfusion of blood products (red blood cell and platelets). In certain cases, 
patients may need infusions of fresh frozen plasma and cryoprecipitate.
Education about the side effects of these therapies are generally provided by 
treating hematologists/oncologists, nurses, and pharmacists. More detailed infor-
mation is available at the manufacturer website or online drug package insert.
 Supporting Services
 Financial
Receiving a diagnosis of cancer not only imposes health-related challenges on the 
patient, but also results in “financial toxicity,” a term coined to describe the financial 
hardships associated with the cost of cancer treatments. Patients experiencing finan-
cial burden elect to alter care to defray out-of-pocket expenses [27]. Moreover, high 
treatment expenditures have been associated with nonadherence and poor clinical 
outcomes in several studies [28–30] . Accordingly, the NCI recommends offering 
financial counselling services at cancer treatment centers to help patients and their 
families understand the scope of the problem and plan better on how to manage their 
anticipated expenses. In the absence of proper counselling, financial toxicity bears 
material and psychological consequences [31]. Material consequences are mainly 
monetary owing to reduction or loss of income, time away from work, depletion of 
savings, and ultimately bankruptcy [32]. Interestingly, cancer patients are twice 
more likely to file for bankruptcy as compared to people without cancer [33]. On the 
other hand, psychological consequences translate into increased stress, worry, and 
decreased quality of life [34]. As a result, cancer patients develop maladaptive cop-
ing behaviors to lower their cost of care, such as not showing up to scheduled visits, 
medication noncompliance, omitting doses, and neglecting refills [35].
Apart from financial counselling, patients are encouraged to seek financial help 
starting from oncology social workers, case managers, physicians, and oncology 
nurses who can provide referrals to financial resources and support services, in 
addition to contacts with national, regional, and local organizations for financial 
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support. The ACS website also offers a list of programs and resources dedicated to 
help with cancer-related expenses like housing, transportation, caregiver expenses 
and food costs, accessible through the following hyperlink: https://www.cancer.org/
treatment/finding- and- paying- for- treatment/understanding- financial- and- legal- 
matters/managing- costs/programs- and- resources- to- help- with- cancer- related- 
expenses.html.
 Palliative Care
Integration of palliative care into standard oncology management at the time of 
cancer diagnosis is essential for optimal quality care, based on evidence from clini-
cal trials [36]. Palliative care services focus on approaching the patient as whole, 
communicating about goals of care while accounting for patient preferences [37]. 
This comprehensive approach addresses the quality of life, physical, psychological, 
emotional, religious, spiritual, and family concerns, as well as future care plans 
[38]. As such, offering palliative care to the patient and family caregivers confers 
additional emotional and psychological benefits by lowering levels of depression, 
caregiving burden, and psychological distress and anxiety [36].
Current professional guidelines recommend the integration of palliative care 
early in the disease course, and all throughout the treatment [39–41]. Palliative care 
is provided by specialists who work as part of a multidisciplinary care team that 
may include nurses, registered dieticians, pharmacists, chaplains, psychologists, 
and social workers, in conjunction with the oncology treatment team [38]. The 
American Society of Clinical Oncology (ASCO) offers a palliative care booklet 
(https://www.cancer.net/sites/cancer.net/files/palliative_care.pdf) to help cancer 
patients, their families, and caregivers understand options, find support, and ease the 
disease challenges. The NCI website also offers a wide platform to explain all about 
palliative care for patients and their families (https://www.cancer.gov/about- cancer/
advanced- cancer/care- choices/palliative- care- fact- sheet). Resources for program 
managers include the palliative care guide published by the World Health 
Organization that suggests steps for planning and implementing palliative care ser-
vices at cancer treatment centers (https://apps.who.int/iris/bitstream/han
dle/10665/250584/9789241565417- eng.pdf;jsessionid=45331C2A5976BE588817
9C10E4737A95?sequence=1).
While palliative care is provided at every step of treatment and at any stage of 
cancer, hospice care is a specific facet of palliative care only given to patients with 
advanced stages of cancer with a life expectancy of 6 months or less [42]. It shifts 
the focus from direct anticancer treatment to symptomatic relief. Consequently, the 
patient elects to stop chemotherapy, for example, and receive additional support in 
all other areas. Hospice is associated with less hospital-based end-of-life medical 
care, better quality of life, and improved caregiver outcomes [43–46], as well as 
better symptom relief and patient-goal attainment [47]. Therefore, encouraging ear-
lier hospice enrollment may improve the end-of-life experiences for cancer patients 
and their families.
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 Social Workers
Social workers are essential members of the cancer care team. They help address a 
variety of issues which include, among others:
 (a) Counseling for anxiety, depression, and other emotional aspects of cancer care.
 (b) Identifying resources for financial assistance, compassionate drug assistance 
programs, disease support groups, or spiritual counseling, etc.
 (c) Helping address and resolve transportation challenges.
 (d) Education of caregivers about the disease.
 Case Managers
A case manager is a healthcare professional who has vast clinical disease knowledge 
and a good understanding of the healthcare industry and payers’ dynamics. A case man-
ager is usually a nurse or nurse specialist who oversees all aspects of cancer care and 
helps patients navigate complex health insurance coverage issues, whether related to 
specific prescribed drug(s) or supportive services such as rehabilitation and skilled nurs-
ing facilities or nursing home placement, if indicated. Their ultimate goal is to optimize 
quality and cost-effective care in both hospital and outpatient cancer care settings.
 Nutritional Therapists
Both the cancer and its treatment(s) contribute to cachexia. Cancer patients are at 
increased risk of malnutrition due to decreased food intake, adverse effects of can-
cer therapies, and increase in metabolic waste products. A wide range of negative 
sequelae result from malnutrition, including prolonged hospitalization, reduced 
response to cancer treatment, increased susceptibility to treatment toxicity, 
decreased activity, and impaired quality of life, culminating in a worse overall prog-
nosis [48]. Therefore, proper diet plans and clinical nutrition are paramount. 
Nutritional therapists are registered dietitians that constitute another component of 
a cancer patient’s care team. They work closely with patients and their families to 
develop realistic and appropriate diet plans during and after cancer treatment. It is 
widely agreed that early consultation with a nutritional therapist is beneficial for 
cancer patients [49, 50], even in advanced stages of the disease [51]. Nutritional 
support prevents malnutrition, thus improving treatment tolerance and prognosis, 
while maintaining the patient’s functional activity and quality of life [52, 53]. As 
such, cancer centers provide consultation services with nutritional therapists and 
registered dieticians who help patients manage their nutritional concerns through 
personalized diet plans, safe food handling practices, weight management, multivi-
tamin supplements, among others. Patients who fail to achieve adequate energy 
intake with oral nutritional supplements are offered enteral nutrition options, or tube 
feeding, provided they have normal gut function. In the absence of proper gut 
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function or in case of patient refusal or intolerance due to nausea, vomiting or diar-
rhea, nutritional support is delivered through parenteral nutrition [52, 54–56].
 Religious and Spiritual
In the context of patient-centered care, the holistic view of the patient should be 
addressed all along the cancer care continuum [57]. As such, support services must 
account for the patients religious and cultural beliefs, among others. Several tools 
have been developed to assess the religious and spiritual needs of cancer patients, 
among which are the Faith, Importance and Influence, Community, and Address 
(FICA) spiritual history tool [58, 59] and the Spiritual Needs Assessment for Patients 
(SNAP) questionnaire [60]. Once the specific needs are assessed, several interven-
tions could be implemented. For instance, with the permission of the patient, a mem-
ber of the patient’s religious or spiritual community could be contacted [61]. The 
patient could be referred to hospital chaplaincy or psychosocial oncology providers, 
including oncology social workers, psychologists, or psychiatrists [61]. In other cases, 
members of the care team can intervene to address the religious and spiritual needs by 
offering narratives and psychotherapeutic interventions at bedside or during clinic 
visits [62]. Those interventions consist of a discussion of a short- term life review [63] 
and dignity talks [64] that enhance familial relationships with the patient and find 
purpose in the illness experience. Religious and spiritual support realizes particular 
prominence during end-of-life care, or once the patient resorts to hospice care.
 Discussion
The field of cancer therapeutics has evolved dramatically over the past three decades 
bringing smarter therapies from the bench to the bedside. While novel therapies 
have revolutionized cancer care from the mechanistic standpoint, treatment remains 
complex requiring multiple players beyond hematologists/oncologists and nurses. 
Pharmacists, social workers, and case managers play an essential role in patient 
education about drugs and treatment complications, support needs, and financial 
aspects associated with care. The ultimate goal is to provide all needed support to 
help cancer patients with their fight against the disease.
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Chapter 16
Data Unit, Translational Research, 
and Registries
Fazal Hussain, Saud Alhayli, and Mahmoud Aljurf
Research is the core competency and the third most crucial pillar of any major can-
cer center, followed by patient care and teaching. Research and development is a 
dynamic process with a myriad of dimensions, applications, and deliverables as the 
backbone of evidence-based medicine. If planned and executed correctly, it can 
yield huge dividends as per the center’s mission, vision, and lines of effort. 
Establishing a center of excellence to deliver world-class medicine is the patients’ 
right and the state’s obligation. Collaborative research with locoregional and inter-
national partners to offer the most advanced cancer care with dignity, respect, and 
the best possible QOL is noble. Challenging the existing standards of care and con-
tinuously improving cancer care is the silver lining of research. Cancer research has 
morphed into a tremendously relevant role for more comprehensive and long-term 
approaches. Shifting the paradigm, achieving new pinnacles by administering most 
innovative and novel therapies, devices, interventions, and techniques remain the 
primary objective of research for improving survival outcomes. Clinical research 
has witnessed unprecedented growth in recent years and has emerged as an area of 
high priority. Health improvement and optimization is directly linked to global 
security. The robust leadership, culture of research, continuous quality improve-
ment, and research infrastructure are the cornerstones of the most efficient cancer 
care for measurable and quantifiable outcomes [1].
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 Research Data Unit
The research unit serves as an institutional hub for initiation and registration of 
clinical trials by the clinicians/investigators, monitoring accrual to each protocol, 
budget negotiation, clinical trial agreements for research trials, and developing 
SOPS to facilitate centralized management of clinical studies. The research unit 
aims at providing the best possible quality care and a wide array of investigational 
therapeutic options to patients with highly advanced cancers, which would not be 
available otherwise. A well-structured research unit can be of immense help in 
streamlining and increasing efficiency for quantifiable and measurable outcomes. It 
is well-positioned for patient safety, higher recruitment and retention rates, quality 
data, and reduced study timelines and costs. The most commonly used staffing 
models in the research unit are team-based model (individual PIs head separate 
research team) and a more traditional centralized model (research supervisors 
assign research and support staff from pooled department resources to individual PI 
for each project). Research unit manages the design, conduct, approval, and analy-
sis of research by providing comprehensive data management support to research-
ers as per the IPPs for efficient, quality, and statistically sound research outcomes 
as follows:
• Staffing: Qualified and trained research staff with adequate process knowledge 
are pivotal for data management, multidisciplinary coordination, biological 
specimen processing/handling, and managing regulatory issues. Research staff is 
responsible for designing Case Report Forms (CRFs), documentation, database 
designing, data entry, data validation, discrepancy management, adverse events 
reporting, and data extraction. Research staff provides the support and conducive 
environment for the investigators and clinicians to conduct for locoregional and 
international clinical trials/registries/databases (from proposal inception to pub-
lication) as per the local and international standards (ICH-GCP, CIOMS, NIH 
OHRP, Declaration of Helsinki).
• Data management: Research unit supports the researchers during the entire life 
cycle of a clinical trial by determining patients’ eligibility, screening, workup, 
informed consent process, randomization, follow-up, protocol-specific proce-
dure as per the timelines, data entry, regulatory compliance, pharmacy coordina-
tion, quality assurance, risk communication/reporting, document submission, 
and management for enrolled patients of research protocols. Data accuracy, reli-
ability, and consistency are the minimum essential requirements for quality 
research programs. A wide variety of data management e-tools are being used to 
efficiently capture, store, and process tremendous amounts of data from multiple 
sources in one central platform for high-quality output. The most used commer-
cial software are RAVE, ORACLE CLINICAL, CLINTRIAL, MACRO, and 
eClinical Suite as per the Code of Federal Regulations (CFR), 21 CFR Part 11. 
Some of the open-source software are TrialDB, openCDMS, OpenClinica, and 
PhOSCo. SOPs and control measures of the research unit ensure the integrity, 
confidentiality, and authenticity of research data.
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• Regulatory compliance: The roles and responsibilities of the research unit 
include the development and implementation of research protocols, administra-
tive support, regulatory support, monitoring subject accrual, and providing sup-
port for institutional leadership. Supporting clinical/translational review 
committees, data and safety monitoring committee, and QA committees in addi-
tion to continuing education and training for research staff are done by the 
research unit. Regulatory compliance is pivotal for generating high-quality data 
for an accurate trial outcome.
• Investigational drug management/pharmacovigilance: Research unit provides 
effective stakeholder coordination for study-specific drug shipment, dispensing, 
and administration as per protocol. Adverse drug reaction reporting, pharmaco-
vigilance, risk management, and patient safety are critical elements of clinical 
research and are addressed, monitored, coordinated by the research unit through 
effective communication and robust teamwork. Patient safety monitoring during 
research studies is a critical component throughout the conduct of the study and 
requires effective and timely communication among all the stakeholders.
• Quality assurance: It is the fundamental process for generating high-quality, 
accurate, reliable, complete, and suitable data for statistical analysis as per pro-
tocol parameters and requirements. QA is the best way to determine protocol 
deviations and noncompliance. Quality data have minimal unknown or missing 
variables and acceptable level of protocol deviations in accordance with regula-
tory requirements specified for data quality. Periodic QA site visits and audits are 
conducted by the sponsors for protocol compliance. Institutions also have built-
 in internal and external audit programs for continuous quality improvement.
 Translational Research (TR)
TR encompasses multidisciplinary and multidirectional coordination of laboratory 
and clinical research to enhance disease control and improve survival. The purpose 
of this bench to bedside approach is to facilitate the application of newly acquired 
knowledge to the patient, effectively and expeditiously, to maximize the benefit, 
minimum adverse events, and optimize the treatment outcomes. Translational 
research is the application of laboratory research innovations through preclinical 
studies to the patients in the clinic through clinical trials with agility to improve 
health outcomes. Translational research can be divided into three domains: From 
bench to bedside; from bench to public health; and industrialization of medical 
research processes. TR requires very close collaboration between the clinicians and 
the scientists through effective teamwork and communication. Continuous funding 
helps maintain the infrastructure and the minimum essential manning for the 
research facilities. Quality management is a pivotal part of the translational research.
Paradigmatically contextualized within the emerging purview of oncology 
research, translational research has become a vital tenet of accelerating research 
into complex cancer treatments that conflate a balance between costs of 
16 Data Unit, Translational Research, and Registries
160
administration, primary effectiveness, and adverse implications on patient well- 
being. Axiomatic translational research entails the creation of an unimpeded con-
tinuum of clinical dynamics which encapsulate both clinical and basic research. The 
purview of collaboration rectifies the capacity for clinicians to accelerate the transi-
tion from bench to bedside. The insidious implications of ineffective collaboration 
are amplified amongst singular basic research institutions whose activity is contin-
gent on the clinical care conducted by surrounding institutions, ensuring a stream-
lined approach to collecting adequate data samples measuring drug efficacy. Further 
establishment of lines of communication between all constituent actors involved 
across the research continuum facilitates the rigorous testing required to ensure the 
viability of potential cancer medications, cultivating long-term prospects for the 
most effective remedial practices. Stagnated collaboration has the potential to insti-
gate debilitating parameters for further innovative oncological research not condu-
cive to the rapid conditions required to venture into all ostensible treatments. 
Collaboration, however, entails robust leadership with an emphasis on the creation 
of standardized quality guidelines across all disciplines embedded within the mech-
anism of translational research. Standardized guidelines, pertaining to clinical 
follow- ups and procedural methods, would ensure mitigation of potential disconti-
nuities arising across the interdisciplinary, diverse translational research team. 
Furthermore, standardized guidelines for translational research would essentially 
streamline all subsequent trials, preventing the need to pursue trial and error strate-
gies for clinical implementation of research practices.
The equitable dissemination of research-related expertise, resources, and techni-
cal knowledge would ameliorate more efficient research processes, thus potentially 
facilitating an increased capacity for diverse research activity simultaneously. 
Concurrent mechanisms, notably the demand for a streamlined accessibility of 
foundational resources to facilitate the unimpeded transition from bench to bedside, 
is elemental in reconciling the gap along the continuum of research and preventing 
the stagnation of novel research. Funding allocated towards the fields of data trans-
fer for the dissemination of information characterizes the remainder of clinical test-
ing subsequent to embracing its transition from the bedside, shifting crucial 
information from clinical results to the preclinical investigator who seeks to discern 
any potential adverse outcomes from the experimental treatment.
 Registry
One of the most efficient instruments of data management is disease-specific regis-
tries to generate high-quality, reliable, and statistically sound data. These registries, 
frequently referred to as outcomes registries, are “organized systems” that use 
observational study methods to collect uniform data. Specified outcomes are evalu-
ated by the disease-specific registries for predetermined clinical, scientific, and 
administrative end state. Currently, myriads of local, national, regional, and interna-
tional registries exist to collect information about cancer outcomes. These registries 
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have played a pivotal role in determining trends, patterns, treatment practices, tox-
icities, patterns of failures, and survival outcomes.
Wide array of registries exist, globally, each with a well-defined and specific 
aims and objectives. These registries are managed by academic institutions, coop-
erative groups, professional organizations, third parties, public and private authori-
ties, or researchers. Registries vary in the type, depth, timeline, and outcome 
variables. Overtime registries are evolving to complement and collaborate with each 
other to provide even larger pool of data to expand future joint research activities. A 
critical development in the last few years has been the recommendations by the 
World Health Organization (WHO) that data capturing and outcome analysis needs 
to be essential element of treatment and mandatory instead of an option for trans-
plant centers. This chapter will focus on establishing an effective prospective insti-
tutional database with a silver lining in ensuring data quality and functions of HSCT 
registries by highlighting the processes involved and tools and standards adopted 
along with the roles and responsibilities of the team members. It will further high-
light the challenges faced in reporting to international outcome registries, including 
CIBMTR, EBMT, and others.
Registry Fundamentals Observational data is highly valuable research tool in 
assessing utilization and patterns of medical care as well as facilitating outcomes 
analysis to fill evidence gaps regarding safety and effectiveness. Patient registries, 
typically referred to as outcomes registries, are the “organized systems” that utilize 
observational study methods to collect uniform data to assess predetermined out-
comes for a particular exposure or disease. Highly valuable registry output serves as 
the rationale for future scientific and clinical trials or policy purposes [2]. Registries 
can be classified according to how their populations are defined and their objectives. 
Populations may be defined according to disease or conditions, exposures such dis-
ease managements, interventions, or side effects, or other variables like socio- 
economic status. Registries are most used to capture demographics, exposures, or 
natural history of disease, treatment efficacy, safety, complications, adverse events, 
quality of life, and changing patterns of disease in an organized manner.
Registries facilitate research by addressing questions difficult to answer by clini-
cal trials [3] or complementing clinical trial findings [4]. If data collection is suffi-
ciently comprehensive, outcome analysis from registries could be broadly 
generalizable. Registries can be pivotal in continuous quality improvement, maxi-
mizing patient care, and reducing complications by reporting loops and data 
feedback.
Registries based upon international ethical and quality standards are considered 
of high scientific value for outcome analysis. Easy accessibility, credibility, accu-
racy, integrity, and confidentiality are the essential ingredients of a quality registry. 
Registries can promote research in the region, identify locoregional trends and prac-
tices, standards, and interventions, and may also be helpful in benchmarking disease 
outcomes. Comparison with European Group for Blood and Marrow Transplantation 
(EBMT) registry has shown that national registries can be used to benchmark out-
come using the EBMT registry as reference [5]. The Center for International Blood 
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and Marrow Transplantation (CIBMTR) assesses yearly survival after allogeneic 
HSCTs in each of the US transplant centers for participating centers and the public 
[6, 7]. Globalization of HSCT donor and patient registration is a realistic goal and 
could lead to donor safety, better treatments, and outcomes [8, 9]. Registry data 
have provided important insights into international differences in indications for 
HSCT, and access to HSCT [10]. Data from outcome registries is helpful for com-
parative analysis to further refine therapeutic intervention and improve outcomes. 
Outcome registries face a myriad of challenges and are summarized as follows:
Research Personnel Adequately qualified and properly trained research profession-
als with sound medical background and experience with multidisciplinary approach 
are essential. Critical experts in the operation of the registry include clinical/scientific, 
project management, biostatistics and epidemiology, data managers, database admin-
istrators, regulatory compliance, and expertise in quality assurance. Staff familiariza-
tion with basic principles of cancer epidemiology, terminology, therapeutic 
interventions, and outcomes can substantially increase the value of registry. Cohesive 
teamwork is the key for optimizing the value of the registry throughout the registry 
life cycle by data capturing, analysis, dissemination, reporting, and publications.
Regulations – Managing Ethical, Privacy, and Legal Considerations Maintaining 
privacy and confidentiality, protection of human subjects and legal issues in data 
management (ownership, collection, and data exchange) are the major tenets of 
registry. Robust security mechanisms are crucial to safeguards the rights of registry 
participants, especially for the registry involving international collaboration. The 
bylaws, data transfer agreements, accreditation for standardization are pivotal in 
streamlining regulatory trepidations. However, wide-ranging variations in IRB reg-
ulations and cultural sensitivities can be challenging, especially for multinational 
registries. However, because outcomes registries are observational, they are often 
considered “low risk” with regard to the potential for harm to human subjects. The 
registry must address consent for the use of data for research obtained from research 
subjects by outcomes registries; however, registry functions for public health or 
government program purposes may not require specific consent for research [11].
Data Management Scope and quality of data determines the usefulness of a regis-
try. The scope of the data collected is framed by purpose and objectives and is 
influenced by myriad factors (geographic location, setting of data collection, cost). 
The size of the registry can vary depending upon the number of observations 
required to achieve the desired end states.
Registries have well-defined core dataset of essential data elements and patient 
outcomes as per the purpose and objectives. Core data sets and CRFs are reviewed 
and revised periodically to align with evolving diagnostic, therapeutic and prognos-
tic markers. Accuracy, integrity, and data completeness are the most critical ele-
ments in the quality and value of a registry. Most data collection for HSCT outcomes 
registries is conducted using electronic applications. Sound quality information sys-
tems are needed for effective data collection to support the registry.
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Cultural Sensitivities and Communication Issues Particularly, international reg-
istries are managed by continuous education and training in a unified manner to 
overcome tremendous cultural, social, and economic heterogeneity. Culturally sen-
sitive tools (QOL form, etc.) can help enhance registry compliance.
Performance/Quality Management Registry (e.g., HSCT) can be a crucial compo-
nent of a center’s quality management/performance improvement programs. The 
accreditation bodies for HSCT in the US and Europe (FACT, ISCT, EBMT-JACIE, 
etc.) mandate that transplant centers collect and utilize standard core dataset defined by 
the field to analyze and understand their program quality [12]. Accreditation helps in 
implementing basic unified standards for good clinical practice among all participating 
centers for accuracy, integrity, and transparency of registry data. Outcomes registries 
can also provide a quality context or benchmark for HSCT centers when evaluating 
their program’s performance. Quality management research can also be facilitated by 
outcome registries, which can lead to better survival outcomes by improving transplant 
practices. Registries facilitates uniformity in lab standards, toxicity criteria (Bearman) 
[13],GVHD definitions (National Institutes of Health [NIH] [14], and performance 
status (Karnofsky Performance Status [KPS], Eastern Cooperative Oncology Group 
[ECOG]/Zubrod, etc.). High-quality registry encompasses advanced methodology, 
operational excellence, enhanced validity, and discernible outcomes.
Data Utilization and Publications Observational research findings yield in sig-
nificant clinical improvement and clinical trial planning [15]. Data sharing and col-
laborative research for optimizing patient outcomes is the key to a useful registry 
[16–17]. Many cancer centers report their data to comprehensive global registries 
(CIBMTR, EBMT, etc.). Interoperability, interfacing, and integration can maximize 
outcome and utility of these registries. Well-outlined and clear authorship guide-
lines are followed and unanimously approved by the participating centers based 
upon the number of patients, intellectual contributions, and center participation. 
Registry enhances the understanding of disease outcomes by addressing key ques-
tions like intervention results in specific patient groups, prognostic factors, new 
therapeutic regimens, comparison of therapies, inter-center practice, and outcome 
variability, capturing delayed adverse events and novel analytic approaches [18].
Registry can help in determining the efficacy of innovative and novel therapeutic 
strategies, assess outcomes, accrual patterns, generalizability, and patient selection 
practices. Registries can provide valuable data for well-designed retrospective obser-
vational studies to improve clinical practice [19–21]and plan future clinical trials [22].
Funding and Sustainability Registry operations to collect complete, high-quality 
data are resource-intense and funding-dependent. Sponsors include government 
agencies, scientific grant organizations, research collaborators, pharmaceutical 
manufacturers, accreditation bodies, philanthropic organizations, and others. 
Funding could be for the overall operations of the registry or a specific research 
project. Some sponsors may have vested interest, and partially fund the registry, for 
capturing the utilization data of a particular product, device, or intervention. 
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Outcomes registries must remain vigilant for an innovation or collaborative oppor-
tunities to use or expand the registry to seize new funding opportunities.
 Conclusion
There is a growing need to develop high-quality research infrastructure in newly 
developing cancer centers. Existing international models are a great resource for 
adopting best practices in establishing the research unit with advanced capabilities 
and procedures for data capturing, data quality monitoring, data analysis, strategic 
communication, and publications. Well-positioned, fully operational and optimally 
functional research unit should be able to provide highly valuable information and 
data that would not be available otherwise. The data quality standardization is vital 
to determine the scientific credibility and reliability of a research entity. A critical 
development in the last few years has been the recommendation of the World Health 
Organization (WHO) to make the data collection and analysis an integral part of the 
therapy rather than a choice for cancer programs.
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One of the main missions of any comprehensive cancer center is to provide oppor-
tunities for training and education to improve prevention and treatment outcomes of 
cancer patients. Management of cancer in today’s era is multidisciplinary, with 
patient care teams comprised of multispecialty physicians, advanced practice pro-
viders (APPs), nurses, therapists, and other health-care staff across different fields. 
Each team member holds a specific role in cancer care and has a different approach 
to the management of patients ultimately leading to more comprehensive care.
Given the many components and specialties that comprise a comprehensive can-
cer center, the educational programs are often specialized and tailored to multiple 
disciplines. The ultimate goal of establishing education and training programs 
within a comprehensive cancer center is not only to have them available to their 
staff, but rather to garner the ability to disseminate education to health-care provid-
ers, cancer patients, and the public at large.
 Training of Health-Care Professionals
Within a cancer center, there is a variety of specialties which provide expertise in 
oncology. These specialties possess their own individual training programs that help 
train and develop future physicians, scientists, APPs, and nurses specialized within 
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oncology. Training programs may include but are not limited to biomedical and 
basic science research, postdoctoral programs, clinical residency and/or fellowship 
programs, all geared towards research and treatment of cancer.
 Hematology/Medical Oncology
Hematologists and medical oncologists comprise the largest block of cancer spe-
cialists in a comprehensive cancer center. Their standard training is called 
“Hematology/Oncology fellowship”, which in the USA follows completion of 
3 years of internal medicine residency, but that is not always the case in other coun-
tries. A hematology/oncology fellowship typically requires 3 years, although some 
programs offer the opportunity for a 2-year fellowship in either hematology or med-
ical oncology. The goal of fellowship training programs is to enable trainees to gain 
a broad knowledge of clinical and research cancer sciences, and to develop the 
needed clinical skills and expertise to become competent and proficient hematolo-
gists and/or oncologists. At least half of the fellowship curriculum is spent in clini-
cal training with a combination of inpatient and outpatient experiences, focusing on 
different malignancies including solid tumors, benign hematology, malignant hema-
tology, and hematopoietic cell transplantation (HCT) or other cellular therapies. 
Many programs offer dedicated research time that can be spent in basic science or 
in clinical/observational investigation, depending on the trainees’ interest and it is 
usually under the guidance and tutelage of a research mentor. Trainees present their 
research projects at national scientific meetings and ultimately publish the findings 
in peer-reviewed journals.
Apart from clinical training and research, another major component of a fellow-
ship program is the didactic and experiential learning lectures and activities, which 
are embedded within the context of health-care delivery system. It also provides 
trainees with access to comprehensive education resources provided by major 
national hematology and oncology societies, namely, the American Society of 
Clinical Oncology (ASCO), the American Society of Hematology (ASH), and oth-
ers. Some centers offer an additional 1 year of subspecialty cancer training after 
completion of the 3 years fellowship, like fellowships in leukemia, blood and mar-
row transplantation, thoracic malignancies and others, or in drug development and 
early cancer therapeutics trials.
 Pediatric Hematology/Medical Oncology
A pediatric hematology/oncology fellowship curriculum also requires 3 years and 
mirrors that of the medical oncology/hematology fellowship.
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 Radiation Oncology
One field that differs slightly in this training model is radiation oncology. In the 
USA, radiation oncology is a 5 year residency program for which candidates may 
apply for and join directly out of medical school. The first year is generally a tran-
sitional year of a medical internship followed by 4 years of radiation oncology train-
ing. Radiation oncology residency training prepares for treatment of both adult and 
pediatric populations and most of the training occurs in the outpatient setting. Time 
for research is also embedded in many radiation oncology programs.
 Other Oncology Specialties
Oncology specialty training also includes surgical oncology and gynecology oncol-
ogy. Similar to medical and pediatric oncology programs, eligible trainees must 
have completed residencies in their respective fields before pursuing oncology spe-
cialty training. The length of residency and fellowship training may vary. We refer 
the reader to the Accreditation Council of Graduate Medical Education oncology 
specialty training programs for additional details (https://www.acgme.org).
 Pharmacy
Pharmacists with specific expertise in oncology often go through additional train-
ing, including attaining board certification in oncology pharmacy (BCOP) [1]. 
BCOP is a credential for pharmacists whose practice involve understanding the 
complexity of drug therapies use for preventing and treating cancer, manage cancer- 
related and drug-related adverse events, or clinical situations not encountered in 
other diseases. To obtain BCOP, they are required to graduate from an accredited 
pharmacy program, followed by completion of a 2 year pharmacy residency pro-
gram, which includes 1 year dedicated to oncology pharmacy training followed by 
passing score on standardized board certification examination.
 Basic Science/Laboratory Researcher
The Cancer Biology Training Consortium (CABTRAC) was created in 2005 in order 
to help develop and facilitate training recommendations for future cancer researchers, 
especially graduate and postgraduate researchers [2]. The goal of CABTRAC was to 
establish guidelines for trainees focused on education in the experimental science of 
cancer biology, research training in the experimental science of cancer biology, and 
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career development of trainees towards independent cancer biologists [3]. Trainees 
are expected to be exposed to topics including basic science of cancer biology: dys-
regulation of signal transduction pathways, oncogenes and tumor suppressor genes, 
control of cell proliferation, cell cycle, and cell death, carcinogenesis, DNA damage, 
and repair, tumor angiogenesis, invasion, and metastases, tumor microenvironment, 
cancer genetics and epigenetics, cancer immunology, translational science (molecular 
diagnosis and prognosis, molecular imaging, systems biology and bioinformatics, 
therapeutic strategies including targeted and cytotoxic therapies, immunotherapy, 
hormone therapy, small molecules), and chemoprevention. Educational exposure to 
biostatistics, informatics, data interpretation, cancer disparities, and basic experimen-
tal design is also deemed essential to the training of cancer biology scientists.
 Continued Medical Education (CME)
Training and education in a comprehensive cancer center are not restricted to train-
ees within a structured training program. Continued education of all cancer care 
team members is essential, given the always changing understanding of cancer biol-
ogy and emergence of new therapies, technologies, and innovations. The goals of 
CME as it pertains to members of a cancer center are twofold: to enhance their 
knowledge and skills pertaining to their own individual practices and specialties and 
acquiring knowledge from other specialties (also known as cross-training). Some 
examples of cross-training include incorporating novel concepts that can be investi-
gated across multiple diseases, or awareness of clinical scenarios that may allow lab 
or translational researchers to gain better insight into the cancer.
 Grand Rounds
Cancer center grand rounds are regularly scheduled seminar series through which 
invited speakers present insights and expertise on cancer treatment and/or new innova-
tions in cancer research. Speakers typically include cancer center members or outside 
invited speakers. Grand rounds can serve multiple purposes within a cancer center. It 
can provide members with updates in patient care and management and could be a 
CME source. Additionally, grand rounds, through presentation of new innovations and 
research findings, can also spawn collaboration and promote cross- training among spe-
cialists from different disciplines within oncology, potentially stimulating new research.
 Board Certification
Many oncology specialties have board certification requirements as dictated by 
their respective specialty organizations. In addition, certification is often contingent 
on passing specialty board examinations. Maintaining board certification also 
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requires maintaining standards including participation in educational programs, 
continued professional development, and satisfactorily passing board examinations. 
Maintenance of such standards by cancer center members is important to ensure 
continued training and education, remaining current with advances in oncology, and 
ultimately improving delivery of care to cancer patients.
 Development of New Cancer-Specific Programs
Continued advancement in oncology therapeutics can sometimes be limited by 
expansion of these therapies to centers with limited resources. New programs are 
developed in order to provide education on emerging or complex therapies such as 
phase 1 clinical research units, HCT, and other cellular therapies.
Building specialized cancer-specific programs may be burdensome, particularly 
in low- to middle-income countries. Accordingly, partnering with more established 
cancer institutions with requisite expertise can prove beneficial. One successful 
example of this was the partnership of the Global BMT program of the University 
of Illinois at Chicago (UIC) [4] and its partnership with developing a bone marrow 
transplant program in Kathmandu, Nepal [5]. The steps involved included training 
relevant staff in Nepal and allowing for Nepalese providers to receive training at 
UIC, exchange of standard operating procedures, overseeing construction of HCT 
unit in a Nepalese hospital, and continued teleconferences between UIC and Nepal. 
Another example includes enhancing cancer care in low-income limited resource 
countries such as Guatemala, Vietnam, and Rwanda [6]. Through partnership with 
established cancer centers and with significant investment, improvements, and 
development of infrastructure, training of relevant professionals, implementing new 
cancer screening programs, and developing cancer-specific health policy have 
improved cancer care in these regions. These serve as examples of the benefits of 
partnering with established cancer centers with requisite experience to facilitate the 
development of new cancer-specific programs.
 Discussion
Cancer is a major public health problem worldwide. Recent advances in the under-
standing of the biologic and molecular aspect of cancer, and emergence of new and 
more effective targeted therapies highlight the importance of continuous education 
of health-care providers and supporting staff. The ultimate goal is to deliver effec-
tive treatment in a safe manner. Unfortunately, there is a gap in the ability to make 
these therapies and new technologies available to all cancer patients worldwide. 
Education and training addresses one major aspect of this problem by developing 
partnerships between cancer centers in the developing world and established centers 
in developing countries to facilitate exchange of knowledge. Regrettably, the high 
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cost of these therapies and technologies is a serious limitation to deliver these treat-
ments to cancer patients in the developing world.
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Chapter 18
Cancer Management at Sites with Limited 
Resources: Challenges and Potential 
Solutions
Shahrukh K. Hashmi, Fady Geara, Asem Mansour, and Mahmoud Aljurf
The World Bank defines low-income economies ($1005 or less GNI per capita) or 
lower middle-income economies ($1006 to $3955 GNI per capita) as Low- and 
Middle-Income Countries (LMIC) which comprise of approximately two-thirds of 
the world’s 197 countries recognized by the United Nations.
In the LMICs, population pyramids are changing dynamically towards a con-
strictive pattern from an expansive pattern as the lifetime expectancy is increasing 
due to an ageing population [1]. As age is the greatest risk factor for cancers [2, 3], 
expectedly the incidence of cancer continues to increase dramatically in LMIC, 
which is also partly due to advancements in diagnostic techniques [4]. The majority 
of cancer cases globally now occur in LMIC, and 65% of cancer deaths worldwide 
occur in these countries [5].
Apart from economic factors, there are considerable differences in the geopoliti-
cal arenas of LMIC compared to many developed nations [6, 7]; therefore the 
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challenges of providing comprehensive cancer care in the LMIC are different. Here, 
we will briefly summarize the current challenges that many LMICs face with respect 
to oncologic care, focusing on both prevention and therapeutics, with the caveat that 
these are general issues which may not apply to all LMICs.
 Medical Services, Data, and Infrastructure
 Need for Effective cancer Registries
A database or a registry of the cancer cases encompassing the type of tumor, stage, 
genomics, and other parameters is essential for overall cancer care for any country. 
This database could be a hospital-based or a population-based registry. Concept of 
population-based cancer registries is at least half a century old, as in 1950s, the 
American College of Surgeons (ACoS) implemented policies for development of 
hospital-based cancer registries. Sweden was the first country globally to establish 
a formal cancer registry for all cases diagnosed and linked the data with personal 
information (Swedish PIN and other variables). In 1973, The National Cancer 
Institute of the United States (US), through its Surveillance, Epidemiology and End 
Results (SEER) program established the first national cancer registry program 
which currently produces a variety of data (and analytics) on various aspects of 
cancer epidemiology [8].
Some LMICs have established cancer registries at federal level; however, the 
quality control mechanisms of these registries are extremely variable, and quite 
often data is either missing, or lags current data entry mechanisms which leads to 
consider delays in updating the data. Moreover, lack of long-term outcomes data 
would preclude accurate mortality or morbidity analysis. The need of accurate data 
of cancer cases in a country is imperative to develop cancer control programs and 
screening guidelines. Unless the burden of each cancer type and subtype is known, 
it is hard to allocate appropriate resources for prevention or treatment of the specific 
types of cancer. Additionally, there are a number of international grants or programs 
specifically for cancer-associated activities in LMICs; however, one needs to know 
the exact burden of the disease in order to apply for most of these grants. Therefore, 
the need for a cancer registry at national level should be a top priority of a country’s 
healthcare policy. A state-of-the-art cancer center’s hospital-based registry is insuf-
ficient to formulate future planning for cancer control, since it is limited to the 
patients coming to that center, and also due to the known phenomenon of patient 
shopping at various institutions (and second opinions), which may be more pro-
nounced in the LMICs.
Given the importance of a nationwide cancer registry covering both urban and 
rural areas, as a solution, we would encourage both the governmental agencies and 
the institutional leadership to work together to develop policies for a mandatory 
cancer reporting mechanism and a national registry that would capture important 
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variables (including outcomes data) and have resources to functionally sustain the 
registry in long run (technologic tools, data managers, statisticians etc.). The World 
Health Assembly in conjunction with World Health Organization (WHO) has passed 
the resolution Cancer Prevention and Control and has urged the governments to 
accelerate action to achieve the targets specified in the Global Action Plan and the 
“2030 United Nations Agenda for Sustainable Development”. Establishment of 
effective cancer registries is an integral part of the proposed agenda by WHO.
Moreover, The World Bank’s Regional Program of Cancer Registries (P163187) 
has proposed help in establishing population-based cancer registries to collect, ana-
lyze, and publish a regional compilation of cancer statistics. This is another avenue 
which can be evaluated for establishment of cancer registry at regional level.
 Lack of Connectivity
Quite often, patients care is fragmented across the institutions. Some patients would 
receive initial consult at one institution, then laboratory work at another, and then 
radiology at a third institution. Not only the care is fragmented which can result in 
delay in both diagnosis and treatment, but also the information technology (IT) 
systems are not interfaced with each other thereby care is further affected. Having a 
unified IT system, or electronic medical record (EMR) systems that can interface 
with each other would make care better, and also would allow for a smooth transi-
tion of care between institutions. Another layer of approvals required for sharing 
information is the lack of clear cybersecurity laws for exchanging EMRs. Thus a 
conscious effort has to be made to clarify pathways for information exchange 
between institutions so that patient care is not affected.
 Research Infrastructure
The improvement in the cancer survival is mainly due to tremendous investment in 
preclinical and clinical research by institutions (e.g., tertiary care hospitals), gov-
ernmental agencies (e.g., National Institutes of Health), and the pharmaceutical 
industry. However, most of the innovation and discovery in oncology (including 
genomics and drug development) has come from investigators from the developed 
countries. A robust research infrastructure is required to assimilate all three phases 
of research, that is, basic science, translational, and clinical trials.
Basic science: The investment in preclinical research requires considerable 
resources that include laboratory and equipment as well as expertise [9]. Scientific 
collaborations with global experts is necessary at least in initial phases of setup of 
basic science laboratories, which require expensive equipment (and reagents) and 
human resources (PhD, and advanced technicians, besides postdoctoral trainees).
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Clinical trials: For clinical research, the institutional leadership and the govern-
mental agencies must invest both in infrastructure (e.g., clinical trials unit) and in 
human resources [10]. The phase I, II, and III clinical trials require funding as 
expertise, and once the infrastructure is available (including CRCs, clinical trialists, 
and biostatisticians), then physician-scientists would be able to produce (write up 
protocols and successfully accrue the projected number of subjects) results from 
clinical research, and moreover attract cutting-edge clinical trials from pharmaceu-
tical and biotech industry. Typically, randomized trials (mostly phase III) change the 
clinical practice, and over the past few decades, successful completion of random-
ized trials initiated by principal investigators from developing countries has been 
extremely rare [11, 12]. Most common pathway of executing clinical trials in LMICs 
is facilitation by pharmaceutical industry, and occurrence of phase I clinical trials is 
hardly existent in most of the LMICs [13]. Having physician-scientists who are 
appreciated and given ample time and resources for research is a necessary factor 
for the successful execution of a clinical trial.
Translational research: Some LMICs have advanced facilities for basic science 
research and excellent tertiary care hospitals as well both producing some degree of 
scientific output. To translate the preclinical models into medical field requires 
direct collaboration between institutions. Unless this happens, cutting-edge innova-
tion may not occur.
A comprehensive research infrastructure would require (apart from HR, space, 
and equipment), effective Institutional Review Board (IRB), Data Safety Monitoring 
Board (DSMB), and extensive collaborations with the regulatory agencies (e.g., a 
country’s federal drug authority or equivalent agency). How to operationalize such 
an infrastructure requires a huge setup which has four essential aspects – human 
resources (scientists, physicians, nurses, clinical research coordinators, biostatisti-
cian, clinical nurses, pharmacists, phlebotomists) physical space (including nega-
tive pressure and positive pressure rooms), equipment (laboratory and office), and 
software (REDCap or other databases). This requires direct interaction with local 
health authorities.
 Tumor Boards and Multispecialty Care
Recent data has indicated that multidisciplinary care and decisions improve out-
comes of cancer patients [14]. A multidisciplinary tumor board may require exper-
tise from radiologists, medical oncologists, radiation oncologists, surgeons, 
pathologists, and other specialties. This pertains more to solid cancers; however, in 
hematologic malignancies, molecular hematology boards have become routine to 
discuss the cases and diagnostic dilemmas at large cancer centers in developed 
countries. Emphasis should be laid in assimilation of such tumor boards for cancer 
subtypes in developing countries, which can also foster holistic care to a patient 
apart from increasing research collaborations between various clinical specialties. If 
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multispecialty tumor boards cannot be established due to limited resources or lack 
of expertise, then efforts could be concentrated on scheduling regular tumor board 
meetings at a partner institution with a large cancer center (maybe within the same 
country or internationally).
Building a homogeneous multidisciplinary tumor board can indeed be very chal-
lenging at the beginning. Apart from utilizing technology to have virtual boards, one 
must continue to organize a team to eventually establish functional tumor boards – 
this would require at least a medical oncologist, radiation oncologist, surgical 
oncologist, radiologist, pathologist, oncology nurses, coordinators, and ideally also 
palliative care team as well.
 Human Resources
 Unavailability of Specialized, but Essential Cancer Services 
and Human Power Radiotherapy and Stem Cell Transplantation
There are many services that are necessary for both curative and palliative manage-
ment in cancers; however, due to expertise required, technology transfer issues, 
equipment infrastructure, and costs, they may be unavailable in LMICs. On the top 
of these essential services are stem cell transplantation (SCT) [15, 16] and radio-
therapy [17–19]. These two services are necessary for many cancers and may be the 
only potential cure, and in order to achieve this cure, many patients from LMIC may 
travel outside their home country for the receipt of these services. One essential ele-
ment of these services is that efforts must be concentrated to start with bare mini-
mum requirements in order to establish at least one specialized unit, for example, 
for radiation therapy unit in a country, it is not essential to wait for funding and 
expertise for carbon-ion therapy or proton beam therapy, but can start with the 
cobalt therapy or with traditional linear accelerators. Similarly, for SCT, it is not 
imperative to have a huge infrastructure for allogeneic SCTs, when a center can start 
with the relatively low-risk autologous SCTs. Apart from getting expertise from 
outside the country for a new specialized program, one has to consider capacity 
building and skills training for physicians and nurses within a country.
 Education Infrastructure
Efforts to train physicians, nurses, and technicians for specialized care is essential. 
This applies directly to the fields of cancer in general, but more so to the very spe-
cialized fields, for example, radiation oncology and bone marrow transplantation. 
There should be concentrated effort by the institutional leadership and also by the 
governmental agencies who regulate the medical training programs.
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 Quality Management and Access to Care
 Sustainability and Consistency
Sustainability and consistency in quality of cancer care is a challenge in unpredict-
able geopolitical circumstances and, therefore, a great degree of disparity exists in 
the quality level among various providers (and/or institutions). Given there is a lack 
of effective reporting and measurement of outcomes, we propose to have simplified 
metrics for objective evaluation of quality of care so that the results can be shared to 
identify gaps and acquire best practices.
 Access to cancer Care
In many countries, access to cancer care is extremely hard due to many factors par-
ticularly due to the shortage of comprehensive services, lack of expertise, and due 
to economic hardships due to a lack of comprehensive national coverage. Even if 
there is a well-established cancer center, populations may not have the resources to 
reach to the specialized centers due to social and financial barriers.
A study from Cameroon indicated a 6 month delay between appearance of the 
first sign of cancer and seeing a healthcare provider [20]. Access to a cancer special-
ist is significantly delayed due to a variety of reasons in LMIC, which include (but 
not limited to), cultural preferences (e.g., taboo in some communities) and trust 
issues with medical providers or allopathic physicians (with a greater emphasis on 
complementary and alternative medicine therapies), financial reasons, or due to a 
deficiency of oncologists. This must be addressed at both institutional level and 
national health policy level. The governmental structure should be able to cope up 
with the increasing demand for treating oncologists in LMICs. Moreover, dispari-
ties in access to cancer specialists and cancer-related services (e.g., PET scans, 
radiation oncology facility, etc.) should be addressed. Some methods could poten-
tially be applied to improve access, for example, targeted fundraising and donations, 
support group initiation, negotiating with government sponsoring of cancer pro-
grams and services, and revenue sharing programs with industry.
 Influence of Political Activities: Refugee Crises 
and Internal Displacement
According to the UN Refugee Agency (UNHCR), at least 79.5 million people 
around the world have been forced to flee their homes which includes nearly 26 mil-
lion refugees and 47 million internally displaced people (IDP) by 2019 [21]. This 
leads to additional burdens for social and healthcare-related expenditures to the 
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countries. Not only delayed diagnosis of the refugees and IDPs can lead to increased 
mortality, the psychosocial issues in these people can lead to considerably increased 
morbidity.
There has to be a concentrated effort by the governmental agencies to evaluate 
the exact oncologic needs of the refugees and IDPs. Mechanisms must be estab-
lished to provide both urgent care and long-term planning if the refugees and IDPs 
are diagnosed with cancer or received initial treatment at their home country or local 
city before being displaced. Many hospitals may not accept refugees for cancer 
care, but it is the government’s responsibility to provide at least emergency oncol-
ogy care to the refugees and IDPs, and these include but are not limited to spinal 
cord compression, hypercalcemia of malignancy, superior-vena-cava syndrome, 
acute leukemias (ALL, APL, AML), and high-grade lymphomas (particularly 
Burkitt lymphoma and large cell lymphomas).
It is critical that the international or local governmental support provided by the 
stakeholders focus on noncommunicable diseases as hematologic and oncologic 
emergencies are almost always fatal if not treated urgently.
 Successful Models of Cancer Care: Sharing Best Practices
Given a multitude of differences between LMIC and developed world with respect 
to cancer care, especially in regard to socioeconomic status (SES) of patients, regu-
latory agency policies, and political climates, a potential solution to successfully 
implement oncologic care so that outcomes in the end users improve is to partner 
with countries in which successful execution of the cancer programs has already 
occurred. This would ideally be a concept of twinning which has prevailed in devel-
oping countries to many projects both in healthcare and other sectors. A classic 
example is the twinning program for the establishment of a stem cell transplant 
program in Bangladesh with the help of expertise at every level (architecture/design, 
laboratory issues, transplant physician expertise, nursing training, and others), with 
a hospital in Boston, Massachusetts, which has resulted in successful example of 
technology transfer from a developed country to LMIC.
For sharing best practices, it is not essential to have physical presence of large 
teams in a LMIC institution or governmental agency, and a virtual contract for tele-
health could also be of help for smaller projects, for example, for tumor boards.
Nonetheless, a unified standard approach is essential for a country’s success so 
that most successful practices which have proven to improve clinical outcomes can 
be shared. In this instance, it is imperative that there is one professional organization 
which dictates not only national guidelines but also sets up research priorities. 
Although this seems trivial, however, in real-world practice, there are critical chal-
lenges with respect to establishing or sustaining professional organizations. For 
example, in some LMIC there may be two or even three professional hematology or 
oncology societies, all claiming national statuses in clinical and research matters. 
This practice of egoistic approach based on institutional or personal prides must 
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end, and a unified organization representing the entire nation should be established. 
In the USA, for instance, there is one national organization for each subspecialty, 
for example, ASCO for medical oncology, ASTRO for radiation oncology, and ASH 
for hematology. To have some control to either mandate or at least encourage one 
national society will lead to less dispersion of knowledge and best practices.
An ideal model to cover cancer care in all LMICs does not exist; however, vari-
ous models fit into the geopolitical and economic infrastructure of a country, for 
example, matrix cancer centers or stand-alone centers may fit into the management 
paradigm of different countries.
 Drug Approvals and Shortages
Drug approval processes in the LMIC vary considerably and quite often is a con-
stantly changing process with layers of bureaucratic and political interventions. 
Each LMIC, like the developed countries, has a drug regulatory authority or agency; 
however, efficiency differs tremendously and is influenced not only by intervening 
individuals with authority but also by pharmaceutical industry. Given immunother-
apy especially with checkpoint inhibitors is being increasingly used for treatments 
of various cancers; its regulation and importation poses a constant challenge to 
developing countries. It is predicted that immunotherapies will replace majority of 
the cytotoxic chemotherapies in the near future for most of the cancers. Thereby, 
regulatory agencies of LMIC need to have dedicated staff for establishment of 
effective policies for rapid approval of essential cancer drugs.
Essential cancer drugs are often not available, not accessible, or not used appro-
priately in LMICs which is one of the greatest dilemmas of oncologic care [22]. 
Drug shortages are typically more common in LMICs and can lead to devastating 
outcomes in cancer patients [23]. This aspect of drug shortages is a critical, yet rela-
tively neglected issue within the cancer management paradigm, and downstream the 
cost of cancer care can potentially increase tremendously. For example, if vincris-
tine deficiency is sustained for few weeks or months, then it could result in a domino 
effect as this drug is the backbone of treatment of pediatric ALL, and if unavailable, 
can lead to multiple relapses, the treatment of which may be extremely complicated 
(including perhaps an allogeneic stem cell transplant) and expensive.
In 2011, the Council of International Pharmaceutical Federation called on “all 
stakeholders, including governments, pharmaceutical manufacturers, pharmacy 
wholesalers, pharmaceutical purchasing agencies, medicine insurance plans, phar-
maceutical regulators and the pharmacy profession to urgently evaluate these issues 
and work to ensure continuity of medication supply so that the appropriate treat-
ment of patients can be initiated and maintained”. One of the solutions is to ensure 
smooth network of supply chain between the institutions that carry cancer drugs so 
that transfer can be ensued where the greatest need is apparent. Moreover, techno-
logic advancements including machine learning algorithms (described below) can 
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augment a smooth drug supply chain by not only prompting exchanges but also 
providing predictions for shortage of essential medications.
Pricing models that apply to the North American and European countries do not 
apply to the LMICs. Models where cost-sharing or cost-containment policies that 
can be enacted should be sought, and if not possible, then innovative strategies that 
can derive delivery of medications to the end users must happen. In India and Brazil, 
for some chemotherapy drugs, the pharmaceutical industry and the government 
have negotiated contracts to ensure cheaper drug availability to the cancer patients 
(subsidized cost versus on a governmental plan), and this includes local manufac-
turing for certain specialized medications. This is not an easy task, and would need 
to conform to the international patency laws; however, it is achievable as experi-
enced by the abovementioned LMICs. Applications of generic medications and bio-
similars should increase once equivalence in safety and efficacy is established.
 Essential Need for a Safe and Effective Institutional Blood Bank
In many developing countries, it can be challenging to secure matched platelets and 
packed red blood cells in a timely fashion. This issue is complicated by the fact that 
some federal authorities in some countries restrict the blood banking and donor 
procedures to a central blood bank supervised by the government officials, and thus 
distribution can be at risk. This issue must be tackled before establishing a compre-
hensive cancer center, as many patients undergoing chemotherapy or stem cell 
transplantation require massive amounts of transfusion.
 Applying Technologic Advancements in Oncology: Artificial 
Intelligence and Internet-of-Things
The technologic advancements are revolutionizing the cancer care especially with 
respect to diagnostics particularly in pathology and radiology [24]. The availability 
of big data has provided ample opportunity to evaluate and analyze predictive mod-
els in hematology [25, 26], medical oncology [27–29], and radiation oncology [30–
32] via machine learning algorithms [33]. Apart from software development, the 
Internet-of-Things which runs on 5G network [34] is well posed to direct many 
aspects of healthcare including telehealth [35]. Some LMICs have already adapted 
these technology-based tools to improve the management of hematologic and onco-
logic management; though it requires initial investment in hardware/software tech-
nology and human resources, in long run, these technologies are predicted to lower 
cost of care and improve efficiencies. Thereby, we strongly propose to consider 
incorporation of technologic advancements in the current cancer framework going 
forward if possible and resources allow.
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 Unavailability of Specialized, but Essential Cancer Services: 
Radiotherapy and Stem Cell Transplantation
There are many services that are necessary for both curative and palliative man-
agement in cancers; however, due to expertise required, technology transfer 
issues, equipment infrastructure, and costs, they may be unavailable in LMICs. 
On the top of these essential services are stem cell transplantation (SCT) [15, 16] 
and radiotherapy [17–19]. These two services are necessary for many cancers and 
may be the only potential cure, and in order to achieve this cure, many patients 
from LMIC may travel outside their home country for the receipt of these ser-
vices. One essential element of these services is that efforts must be concentrated 
to start with bare minimum requirements in order to establish at least one special-
ized unit, for example, for radiation therapy unit in a country, it is not essential to 
wait for funding and expertise for carbon-ion therapy or proton beam therapy, but 
can start with the cobalt therapy or with traditional linear accelerators. Similarly, 
for SCT, it is not imperative to have a huge infrastructure for allogeneic SCTs, 
when a center can start with the relatively low-risk autologous SCTs. Apart from 
getting expertise from outside the country for a new specialized program, one has 
to consider capacity building and skills training for physicians and nurses within 
a country.
Above, we mention some of the challenges and propose potential solutions for 
these issues pertaining to LMICs with respect to cancer care. It is apparent that one- 
size- fits-all solution is impractical and an approach tailored towards individualizing 
the priorities within a country given its resources is the most practical way of suc-
cessfully implementing comprehensive cancer care.
 Public Health Crises
 Carcinogen Prevention
The tobacco epidemic due to a high prevalence of smoking has led to a much 
higher incidence of smoking-related cancers in the developing countries [36, 37]. 
While in the United States, the prevalence of smoking has decreased over the past 
few decades, in the developing countries, this trend has not been observed, and 
therefore, it is very likely that for the next few years there is a predictable increase 
in the incidence rates of cancers. Apart from cigarette smoking, certain behavioral 
practices are much more prevalent in the developing countries that also contribute 
to the increase in certain cancers in these populations which include betel nut 
(especially when mixed with slate lime) [38], herbal cigarettes [39], and shisha 
(pot smoking) [40].
S. K. Hashmi et al.
183
 Late Diagnosis
Due to either a lack of public health mandate for screening or non-implementation 
of policies of the screening programs, majority of the cancers are seen at a later- 
stage diagnosis.
Significant investment in the infrastructure for the above is needed. In the current 
era of media, the message also needs to get across to the public as well, and the 
media tools, for example, WhatsApp, Twitter, television, and direct-to-consumer 
messages could be tremendously helpful. Moreover, getting support by interna-
tional organizations that have established programs for prevention and management 
of cancers should ideally be undertaken. Union for International Cancer Control 
(UICC) is one such nongovernmental organization that opens to membership to all 
developing and developed countries.
 Conclusions
Above, we mention some of the challenges and propose potential solutions for these 
issues pertaining to LMICs with respect to cancer care. Some of the solutions are 
covered after each issue mentioned above. Some umbrella solutions include seeking 
funding by collaboration with charity and philanthropic organizations for financial 
and also in-kind support (patient transportation, housing, food, etc.). Holding fund-
raising events in collaboration with other government or private agencies could also 
be tremendously helpful.
It is apparent that one-size-fits-all solution is impractical and an approach tai-
lored towards individualizing the priorities within a country given its resources is 
the most practical way of successfully implementing comprehensive cancer care.
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